% Exported from Psilocybin Research Publication Tracker
% Tracker site: https://psilocybin-research.com
% Publication tracker: https://psilocybin-research.com/
\documentclass[11pt]{article}
\usepackage[T1]{fontenc}
\usepackage[utf8]{inputenc}
\usepackage{enumitem}
\usepackage[hidelinks]{hyperref}
\usepackage[margin=1in]{geometry}
\title{Psilocybin and Psilocin Research Export}
\author{Psilocybin Research Publication Tracker}
\date{2026-07-12}
\begin{document}
\maketitle
\noindent Exported from \href{https://psilocybin-research.com}{psilocybin-research.com}. Records: 1135.

\begin{enumerate}[leftmargin=*]
\item Bruyère Health Research Institute. (2026). \textit{PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07063862}{source link}.
\item Ottawa Hospital Research Institute (2026). \textit{PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04754061}{source link}.
\item Gagnon F, Philibert A, Carignan B, Labonté E, Dufresne Y. (2026). \textit{Psychedelics stores, their regulation and public health: knowledge, perceptions, attitudes and opinions of Canadians.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2026.105427}{doi:10.1016/j.drugpo.2026.105427}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06341426}{source link}.
\item Douglass HM, Spriggs MJ, Godfrey K, Danby JL, de Magalhaes FJC, Macdonald L, Alderton KL, Archer S, Ahmad K, Martell J, Frias JT, Sawicka G, Read T, Blemings A, Lafrance A, Nicholls D, Erritzoe D, Park RJ, Nutt DJ, Carhart-Harris RL. (2026). \textit{Psilocybin therapy for adult females with anorexia nervosa: pilot study.}. The British Journal of Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1192/bjp.2026.10687}{doi:10.1192/bjp.2026.10687}.
\item University of Wisconsin, Madison (2026). \textit{Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04161066}{source link}.
\item University of Colorado, Denver (2026). \textit{A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07516405}{source link}.
\item Enriquez-Geppert Stefanie, Bevers Lisa, Rosander Arvid, Fodran Peter, Polito Vince (2026). \textit{Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development}. Biomolecules. [published; Crossref]. \href{https://doi.org/10.3390/biom16070983}{doi:10.3390/biom16070983}.
\item Matthew A. Boehm, Oriana Mayorga (2026). \textit{Policy Considerations for Psychedelics in Research and Medicine - What’s Next on the Schedule?}. Journal of Science Policy \& Governance. [published; OpenAlex]. \href{https://doi.org/10.38126/jspg280103}{doi:10.38126/jspg280103}.
\item Koning E, Richard J, Keshen A. (2026). \textit{Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.}. International Journal of Eating Disorders. [published; Europe PMC]. \href{https://doi.org/10.1002/eat.70164}{doi:10.1002/eat.70164}.
\item Centre Hospitalier Universitaire de Nīmes (2026). \textit{Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07638553}{source link}.
\item Sunstone Medical (2026). \textit{A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06902974}{source link}.
\item Plourde L, Chang SL, Nguyen O, Garel N, Farzin H, Stephan JF, Fallu JS, Dorval M, P3A Research Group (2026). \textit{Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders.}. Palliative medicine. [published; PubMed]. \href{https://doi.org/10.1177/02692163261446141}{doi:10.1177/02692163261446141}.
\item Artna E, Sandhu G, Chisamore N, Lipsitz O, Kaczmarek ES, Johnson DE, Rosenblat JD, Sediqzadah S (2026). \textit{Psychedelics as a potential treatment for borderline personality disorder: A narrative review.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2026.117152}{doi:10.1016/j.psychres.2026.117152}.
\item Sjöström D, Schau Rybäck O, Claesdotter Knutsson E, Kajonius P, Jensen Sondén O, Carlbring P, Björkstrand J, Movahed Rad P. (2026). \textit{Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults".}. PLoS ONE. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0352246}{doi:10.1371/journal.pone.0352246}.
\item Stefanie Enriquez Geppert, Lisa Bevers, Arvid Rosander, Peter Fodran, Vince Polito (2026). \textit{Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical Development}. University of Groningen research database (University of Groningen / Centre for Information Technology). [published; OpenAlex]. \href{https://research.rug.nl/en/publications/370a82bd-d8db-4a02-b644-bf0c9131680b}{source link}.
\item Yale University (2026). \textit{The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07610369}{source link}.
\item Özaydın Y, Canlan Özaydın B. (2026). \textit{Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811261456196}{doi:10.1177/02698811261456196}.
\item Unity Health Toronto (2026). \textit{Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06386003}{source link}.
\item University of California, San Diego (2026). \textit{Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)]}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06814522}{source link}.
\item University Hospital, Basel, Switzerland (2026). \textit{Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06884514}{source link}.
\item Brar PS, Price RB, Ross S, Tofighi B, Sarpal DK (2026). \textit{The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261456191}{doi:10.1177/02698811261456191}.
\item M.D. Anderson Cancer Center (2026). \textit{TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06200155}{source link}.
\item M.D. Anderson Cancer Center (2026). \textit{TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06801041}{source link}.
\item Júlio César Claudino dos Santos, Sofia Januário Bolan, Guilherme Lodetti da Silva, Germano Lapa Viana, Eduardo Pacheco Rico, Cinara Ludvig Gonçalves (2026). \textit{Psychedelics and autism spectrum disorder: Mechanistic insights, translational evidence and ethical challenges}. Journal of Psychiatric Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jpsychires.2026.06.035}{doi:10.1016/j.jpsychires.2026.06.035}.
\item Yale University (2026). \textit{Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07449351}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07048743}{source link}.
\item van den Busken WJ, Dines AM, Eyer F, Heyerdahl F, Hovda KE, Liechti ME, Miró Ò, Vallersnes OM, Wood DM, Yates C, Dargan PI, (on behalf of the Euro-DEN Plus Research Group), Gresnigt FMJ, Euro-DEN Plus Research Group (2026). \textit{Cardiovascular effects associated with acute recreational drug toxicity presentations to the emergency department: a European drug emergencies network (Euro-DEN plus) study.}. Clinical toxicology (Philadelphia, Pa.). [published; PubMed]. \href{https://doi.org/10.1080/15563650.2026.2669671}{doi:10.1080/15563650.2026.2669671}.
\item Bray E, Glatfelter GC, Maitland AD, Gonzalez NR, Walther D, Yacoub J, Baumann MH, von Salm JL. (2026). \textit{Synthesis and Biological Evaluation of 4-Bromo-N,N-dimethyltryptamine (4-Br-DMT): A Synthetic Building Block for Future Analog Development.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsomega.6c02996}{doi:10.1021/acsomega.6c02996}.
\item Roswell Park Cancer Institute (2026). \textit{Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06827054}{source link}.
\item Johns Hopkins University (2026). \textit{Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06407635}{source link}.
\item University Health Network, Toronto (2026). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06416085}{source link}.
\item Camille Racca, Cécilie Cordier (2026). \textit{Psychedelics and related compounds in cluster headache and migraine: a systematic review and meta-analysis v1}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.17504/protocols.io.j8nlk7ey6g5r/v1}{doi:10.17504/protocols.io.j8nlk7ey6g5r/v1}.
\item Eric P. Rubenstein (2026). \textit{Beyond Psychedelic Microdosing: Therapeutic Potential, Neuropharmacology, and Safety Considerations in Low-Dose Psychoactive Use}. Journal of Advances in Developmental Research. [published; OpenAlex]. \href{https://doi.org/10.71097/ijaidr.v17.i1.1997}{doi:10.71097/ijaidr.v17.i1.1997}.
\item Astrit Sabani, Adnan Khatak (2026). \textit{Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidence}. Annals of Medicine and Surgery. [published; OpenAlex]. \href{https://doi.org/10.1097/ms9.0000000000005244}{doi:10.1097/ms9.0000000000005244}.
\item Mengxuan Dong, Yi Zhang, Manzhu Cao, Tong Shi, Liqin Li, Xingxing Zong, Chen Wang (2026). \textit{DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in Zebrafish}. Molecules. [published; OpenAlex]. \href{https://doi.org/10.3390/molecules31122143}{doi:10.3390/molecules31122143}.
\item Michał Wanke, Paweł Matuszewski, Piotr Siuda (2026). \textit{“I even saw four deer grazing”: online-offline entanglements in the psilocybin pluriverse}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.31235/osf.io/tk4bv\_v1}{doi:10.31235/osf.io/tk4bv\_v1}.
\item Lawrence Leeman, Maya Armstrong, Dara Menashi, Hanifa Nayo-Washington, Elliot Marseille, Janus Herrera, Crystal Romero, Janet Page-Reeves (2026). \textit{Community engagement as a foundation for implementation research for group psilocybin assisted therapy in New Mexico}. Frontiers in Public Health. [published; OpenAlex]. \href{https://doi.org/10.3389/fpubh.2026.1845943}{doi:10.3389/fpubh.2026.1845943}.
\item Edward P. Hackett, Aditi Chaudhri -, Linda Hasman, Rajbala Thakur, Michael Scott, Robert H. Dworkin (2026). \textit{Dextromethorphan Beyond the Cough: Exploring Its Psychedelic Potential: A Systematic Review}. CNS Drugs. [published; OpenAlex]. \href{https://doi.org/10.1007/s40263-026-01305-9}{doi:10.1007/s40263-026-01305-9}.
\item Brigham and Women's Hospital (2026). \textit{Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296094}{source link}.
\item SAIMSARA (2026). \textit{Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARA}. SAIMSARA Journal. [published; OpenAlex]. \href{https://doi.org/10.62487/saimsara7a54f680}{doi:10.62487/saimsara7a54f680}.
\item Angel Labra-Lorenzana, Dania Nimbe Lima Sanchez, Christian Alejandro Delaflor-Wagner, Diana Martínez-Hernández, Christian Ramos-Jiménez, Christian Gabriel Toledo-Lozano (2026). \textit{Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-Analysis}. Psychiatry International. [published; OpenAlex]. \href{https://doi.org/10.3390/psychiatryint7030137}{doi:10.3390/psychiatryint7030137}.
\item Katherine Cheung, Caleigh Propes, David B. Yaden (2026). \textit{Balancing safety and access in Oregon’s psilocybin services}. International Journal of Drug Policy. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugpo.2026.105384}{doi:10.1016/j.drugpo.2026.105384}.
\item Guimarães AL, Beserra FR, Cruz L, Bienemmann B, Freind JMK, Guinle V, Rodrigues RS, Regalado JA, Mograbi DC (2026). \textit{Barriers and Facilitators for Psychedelic Research and Regulation in Brazil: Insights From Diverse Stakeholders.}. Clinical therapeutics. [published; PubMed]. \href{https://doi.org/10.1016/j.clinthera.2026.05.012}{doi:10.1016/j.clinthera.2026.05.012}.
\item Zuzana Postránecká, Matyáš Lucký, Viktor Mravčík, Tomáš Páleníček (2026). \textit{Integrating psychedelic-assisted psychotherapy into addiction care in the Czech Republic: Clinical evidence, safety, and regulatory developments}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00514}{doi:10.1556/2054.2026.00514}.
\item Unknown authors (2026). \textit{Altered States, Enhanced Potential: Psychedelics and Physical Performance}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/txgq2\_v2}{source link}.
\item Yale University (2026). \textit{Psilocybin as a Treatment for Chronic Pain in Smokers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07118332}{source link}.
\item Alexander Bryson, Chiranth Bhagavan, O. Carter, Glenn Nielsen, David Berlowitz, Sara Issak, Zachary Attard, Dina Eleftheriadis, Gina Oliver, Deanne Mayne, Greg Roebuck, James Rucker, Matthew Butler, Richard Kanaan (2026). \textit{Psilocybin-assisted Physiotherapy for Refractory Motor Functional Neurological Disorder: A Randomized Dose-comparison Pilot Study (P7-17.001)}. Neurology. [published; OpenAlex]. \href{https://doi.org/10.1212/wnl.0000000000212934}{doi:10.1212/wnl.0000000000212934}.
\item Jennifer Mitchell (2026). \textit{A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07386730}{source link}.
\item VA Office of Research and Development (2026). \textit{A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07226232}{source link}.
\item Samaneh Ahmadian-Moghadam, Shiva Roshan-Milani, Ehsan Saboory (2026). \textit{Prenatal stress, excitatory-inhibitory imbalance, and ADHD risk: a hypothesis-driven perspective on psilocybin-induced neuroplasticity}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-026-04151-x}{doi:10.1038/s41398-026-04151-x}.
\item Myfanwy Graham, Yimin Ge, Rosalie Liccardo Pacula, Seema Choksy Pessar, Chris Wilkins, Wayne Hall, David Hammond (2026). \textit{A cross-national comparison of nonmedical and medical use of psychedelic drugs in the international cannabis policy study}. International Journal of Drug Policy. [published; OpenAlex]. \href{https://doi.org/10.1016/j.drugpo.2026.105348}{doi:10.1016/j.drugpo.2026.105348}.
\item Kevin F. Boehnke, Niloufar Pouyan, Jacob S. Aday (2026). \textit{Classic Psychedelics for Chronic Pain: A Critical Review of the Literature and Practical Advice for Clinicians}. Drugs. [published; OpenAlex]. \href{https://doi.org/10.1007/s40265-026-02339-5}{doi:10.1007/s40265-026-02339-5}.
\item Carter D, Reardon I, Swain J, Vando L. (2026). \textit{Prolonged Grief Symptom Outcomes During At-Home Ketamine-Assisted Therapy: A Real-World Retrospective Analysis of 503 Adults}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9839240/v1}{doi:10.21203/rs.3.rs-9839240/v1}.
\item Usona Institute (2026). \textit{A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06308653}{source link}.
\item Li EJ, Mosharraf B, Ali H, Noyes M, Doshi P, Wallace C, Petranker R, Adili A, Khan M, Busse JW, MacKillop J, Madden K. (2026). \textit{Patient perceptions towards psychedelics for musculoskeletal pain: A cross-sectional survey}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.05.29.26354422}{doi:10.64898/2026.05.29.26354422}.
\item Josh Allen, Bianca Jupp, Tamara L. Baker, Mohammad B. Haskali, Robert Brkljača, Zoe Plummer, Mujun Sun, Justin Brand, Brian R. Christie, Chantel T. Debert, Stuart J. McDonald, Terence J. O’Brien, Pablo M. Casillas-Espinosa, Sandy R. Shultz (2026). \textit{Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in rats}. Cell Reports Medicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.xcrm.2026.102867}{doi:10.1016/j.xcrm.2026.102867}.
\item Michelle Priest, Beau Kilmer, Ben Senator, Claude Messan Setodji (2026). \textit{U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.}. PubMed. [published; OpenAlex]. \href{https://pubmed.ncbi.nlm.nih.gov/42368324}{source link}.
\item University of Washington (2026). \textit{A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07336238}{source link}.
\item Eskinazi M, Nasserdine R, Cusin RM, Baniotoupoulos P, Saccaro LF, De Pieri M, Corino T, Seragnoli F, Briefer JF, Aboulafia Brakha T, Richard-Lepouriel H, Penzenstadler L, Böge K, Kirchner M, Zullino D, Højlund M, Sapienza J, Bosia M, Catalan A, Vieta E, Solmi M, Sabé M. (2026). \textit{Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-026-03657-6}{doi:10.1038/s41380-026-03657-6}.
\item Mazen A. Atiq, Eli Weisman, Rodrigo B. Guerra, Luis Luna Martinez, David B. Yaden, Frederick S. Barrett, Sandeep Nayak, Ceyda Sayalı (2026). \textit{Psilocybin-induced neurocardiogenic syncope: a case report}. Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1007/s00213-026-07079-8}{doi:10.1007/s00213-026-07079-8}.
\item Emory University (2026). \textit{The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07332143}{source link}.
\item Berg CJ, LoParco CR, Rossheim ME, McCready DM, Langan L, Platt E, Romm KF, Johnson M, Speer MB, Burris S, Cavazos-Rehg PA. (2026). \textit{Mystery shopper assessments of cannabis retailer practices and regulatory compliance in five U.S. states, 2025.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugalcdep.2026.113218}{doi:10.1016/j.drugalcdep.2026.113218}.
\item Zhang T, Lin C, Wang X. (2026). \textit{Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.6c00146}{doi:10.1021/acsptsci.6c00146}.
\item Dallas T Mason (2026). \textit{Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic Potential}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/dmscjournal/vol8/iss1/6}{source link}.
\item Rachel N Clark (2026). \textit{The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising Approach}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3694\&context=dmscjournal}{source link}.
\item Caleb Lemus (2026). \textit{Psilocybin-Assisted Therapy in the Management of Anxiety and Depression Among Cancer Patients}. Digital Showcase Research, Scholarship, \& Creative Works (University of Lynchburg). [published; OpenAlex]. \href{https://digitalshowcase.lynchburg.edu/cgi/viewcontent.cgi?article=3713\&context=dmscjournal}{source link}.
\item University of New Mexico (2026). \textit{Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07506395}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06299319}{source link}.
\item Unknown authors (2026). \textit{Corrigendum to: “Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape”}. Australian \& New Zealand Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/00048674261450797}{doi:10.1177/00048674261450797}.
\item Alan Davis (2026). \textit{Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07216404}{source link}.
\item Unknown authors (2026). \textit{Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/3b9fx\_v1}{source link}.
\item Jamarie Geller, Rachel Pacilio, Amanda E. Downey, Anya Ragnhildstveit, Marissa Raymond-Flesch, Stephanie Knatz-Peck, Natalie Gukasyan (2026). \textit{Psilocybin-Assisted Therapy for Adolescent Anorexia Nervosa: Clinical Considerations and Emerging Models of Care}. Current Psychiatry Reports. [published; OpenAlex]. \href{https://doi.org/10.1007/s11920-026-01679-z}{doi:10.1007/s11920-026-01679-z}.
\item Christina Chwyl, Alissa Bazinet, Adrianne R. Wilson-Poe, Kim Hoffman, Kellie Pertl, R. Cameron Wolf, P. Todd Korthuis, Jason B. Luoma (2026). \textit{Ethical Complexities and Best Practices in Informed Consent Processes for Psilocybin Services: A Qualitative Study}. Neuroethics. [published; OpenAlex]. \href{https://doi.org/10.1007/s12152-026-09645-5}{doi:10.1007/s12152-026-09645-5}.
\item Feliciano Yu, Joe Tafur, Francisco Moreno, Stephen Dahmer (2026). \textit{Inaugural year of regulated psilocybin services in Oregon: safety, motivations, and utilization}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2026.1777387}{doi:10.3389/fpsyt.2026.1777387}.
\item Francisco A Moreno (2026). \textit{A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07347405}{source link}.
\item University of Wisconsin, Madison (2026). \textit{Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05322954}{source link}.
\item COMPASS Pathways (2026). \textit{A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07570654}{source link}.
\item Bartłomiej Kosiarski, Anna Skrzypek, Patrycja Markowicz, Mikołaj Zbrożek, Krzysztof Biłyk, Maciej Hutkowski, Zuzanna Chwostek, Hanna Maruchniak, Wiktoria Marzec, Paulina Biedroń (2026). \textit{Rapid-acting interventions in treatment-resistant depression - a comparative review of esketamine and psilocybin}. Journal of Pre-Clinical and Clinical Research. [published; OpenAlex]. \href{https://doi.org/10.26444/jpccr/221219}{doi:10.26444/jpccr/221219}.
\item Andrew van der Vaart, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm, Scott T. Aaronson (2026). \textit{Efficacy and Safety of a Single Dose of Psilocybin for Chronic Suicidal Ideation}. The Journal of Clinical Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.4088/jcp.26m16338}{doi:10.4088/jcp.26m16338}.
\item Walters CK, Chetty S, Rants’o TA, Gossayn S, Lerotholi LJ. (2026). \textit{Safety and Efficacy of Psilocybin in the Management of Treatment-Resistant Depression: A Systematic Review}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9283280/v1}{doi:10.21203/rs.3.rs-9283280/v1}.
\item Jessie Kim, Liam Lochhead, Cory R. Weissman (2026). \textit{From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical Practice}. Pharmacology Research \& Perspectives. [published; OpenAlex]. \href{https://doi.org/10.1002/prp2.70262}{doi:10.1002/prp2.70262}.
\item University Medical Center Groningen (2026). \textit{The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06782724}{source link}.
\item Ioanna Artemis Vamvakopoulou, D. P. Nicholls, David J. Nutt, M. Di Simplicio (2026). \textit{Exploring new avenues: Psychedelic-assisted therapy for young people}. British Journal of Clinical Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1002/bcp.70579}{doi:10.1002/bcp.70579}.
\item Centre for Addiction and Mental Health (2026). \textit{Does Psilocybin Require Psychedelic Effects to Treat Depression? A4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05710237}{source link}.
\item Kinga Zachar, Maksymilian Sito, Filip Jurkowski, Łukasz Wójcik, Natalia Gawron, Hubert Tomasz Bojanowski, Aleksandra Dobracka, Zuzanna Marczak, Monika Jarowicz, Jędrzej Czmyr (2026). \textit{Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative Review}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2026.91.70672}{doi:10.12775/jehs.2026.91.70672}.
\item Peter S. Hendricks, Sara Lappan, Richard C. Shelton, Adrienne C. Lahti, Karen L. Cropsey, Matthew W. Johnson, Melissa Bradley, Otto Simonsson, Lori L. Davis, Daniel H. Grossman, Cynthia E. Ortiz (2026). \textit{Psilocybin in the Treatment of Cocaine Use Disorder}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2026.11029}{doi:10.1001/jamanetworkopen.2026.11029}.
\item Dayna Forsyth, Nicoletta Faraone, Simon G. Lamarre, Suzanne Currie (2026). \textit{The magic of mushrooms: psilocybin influences behavior in the mangrove rivulus fish, Kryptolebias marmoratus}. Frontiers in Behavioral Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnbeh.2026.1767175}{doi:10.3389/fnbeh.2026.1767175}.
\item Bart A. Ellenbroek, Gernot Riedel (2026). \textit{Announcement of special issue: ‘Behavioural pharmacology of ketamine and psychedelic drugs’}. Behavioural Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1097/fbp.0000000000000878}{doi:10.1097/fbp.0000000000000878}.
\item Sunstone Medical (2026). \textit{A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05947383}{source link}.
\item Stanford University (2026). \textit{A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07479550}{source link}.
\item University of Washington (2026). \textit{A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07565909}{source link}.
\item James J. Peters Veterans Affairs Medical Center (2026). \textit{Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07251491}{source link}.
\item Lakshmi N Yatham (2026). \textit{Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06943573}{source link}.
\item R Andrew Yockey, Amber Amis, Elise Devier, Aminul Apu, Rachel Hoopsick (2026). \textit{Prevalence and Correlates of Past-Year Psilocybin Use in the U.S., 2024, USA}. AJPM Focus. [published; OpenAlex]. \href{https://doi.org/10.1016/j.focus.2026.100518}{doi:10.1016/j.focus.2026.100518}.
\item O'Mahony B, Harrington C, Harkin A, Lally N (2026). \textit{Trip killers: Addressing a critical knowledge gap in psychedelic research.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811261431056}{doi:10.1177/02698811261431056}.
\item Marilyn H. Silva (2026). \textit{New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants}. Birth Defects Research. [published; OpenAlex]. \href{https://doi.org/10.1002/bdr2.70048}{doi:10.1002/bdr2.70048}.
\item Nayak SM, Sepeda ND, Dick MN, Tiwari P, Zahid Z, Sayalı C, Weiss BM, Yaden DB, Garcia-Romeu A, Barnett BS, Barrett FS. (2026). \textit{Acute Cardiovascular Effects of Psilocybin: A Pooled Analysis of 14 Studies with Safety Recommendations}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2026.04.28.26351625}{doi:10.64898/2026.04.28.26351625}.
\item Marini S, De Berardis D. (2026). \textit{The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202604.1998.v1}{doi:10.20944/preprints202604.1998.v1}.
\item Broc Pagni, Stephen Ross, Yuna Kim, Michael Bogenschutz (2026). \textit{6. Open-Label Extension of Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Continued Safety and Short-Term Efficacy Signal for Drinking, Craving, and Self-Efficacy}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2026.03.240}{doi:10.1016/j.biopsych.2026.03.240}.
\item Salinsky LM, Fox JL, Diaz KC, Timmons BC, Ferguson SM. (2026). \textit{Methamphetamine-Fentanyl Polysubstance Administration Produces Social Deficits and Corticolimbic Stress-Reward Circuit Adaptations}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9306429/v1}{doi:10.21203/rs.3.rs-9306429/v1}.
\item Low ZXB. (2026). \textit{Serotonergic psychedelics for Autism spectrum disorder: Neurobiological mechanisms and translational prospects.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2026.111717}{doi:10.1016/j.pnpbp.2026.111717}.
\item Portland VA Research Foundation, Inc (2026). \textit{Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04982796}{source link}.
\item Usona Institute (2026). \textit{A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03866174}{source link}.
\item Kyle Greenway (2026). \textit{Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07373535}{source link}.
\item Deivid Antonio Cahuasqui-Mendoza (2026). \textit{Psilocybin as an alternative to conventional treatments: A systematic review}. Gaceta Médica de Caracas. [published; OpenAlex]. \href{https://doi.org/10.47307/gmc.2026.134.s2.32}{doi:10.47307/gmc.2026.134.s2.32}.
\item Mohsen Khosravi, Domenico De Berardis, Massimo Tusconi (2026). \textit{The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes}. Mental Wellness. [published; OpenAlex]. \href{https://doi.org/10.4081/mw.2026.40}{doi:10.4081/mw.2026.40}.
\item Siti Nashria Rusdhy, Andrian Fajar Kusumadewi, Carla Raymondalexas Marchira, Mustika Suci Mahardikaningrum, Teresa Lalita Wiryarini, Devira Ayu Wulandari (2026). \textit{Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials}. Open Access Indonesian Journal of Medical Reviews. [published; OpenAlex]. \href{https://doi.org/10.37275/oaijmr.v6i2.883}{doi:10.37275/oaijmr.v6i2.883}.
\item Cassidy R. LoParco, Carlton Bone, Annalynn M. Galvin, Matthew E. Rossheim, Carla Berg (2026). \textit{Oregon’s Psilocybin Services: A summary and public health commentary}. New Prairie Press (Kansas State University). [published; OpenAlex]. \href{https://newprairiepress.org/hbr/vol9/iss1/20}{source link}.
\item Klintefors P, Bhagavan C, Kanaan R, Bryson A, Berlowitz D, Attard Z, Carter O. (2026). \textit{Psilocybin’s Kinematic Effect on Manual Dexterity}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9291780/v1}{doi:10.21203/rs.3.rs-9291780/v1}.
\item Jóźwiak-Bębenista M, Stasiak A, Sienkiewicz M, Kwiatkowski P, Kowalczyk E. (2026). \textit{Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging-From Depression to Neurodegeneration}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202604.1125.v1}{doi:10.20944/preprints202604.1125.v1}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie L. Thorn, Kalin Harvey, Dianna Blom, George Callan, John Guy, Sameet Kumar, Rob Hershberg, Melissa Layer, Jackie Levin, Susanna Myers, Juliana Perez, Kathy Salmonson, Peter Thompson, Joseph Whinney (2026). \textit{A phase 1 study of a second experience with Group Retreat Psilocybin Therapy for partial responders after a first experience}. Frontiers in Public Health. [published; OpenAlex]. \href{https://doi.org/10.3389/fpubh.2026.1810904}{doi:10.3389/fpubh.2026.1810904}.
\item J. Morgan Penberthy, Fatma Wise, Nicholas P. Cherup, Evaline Mitchell, Madeline Burns, Oluwafunmilayo Akinlade, David Chung, Harshit Parmar, Jonathan Singer (2026). \textit{Psilocybin for Treatment of Prolonged Grief Disorder: An Open-Label Feasibility Study Protocol}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives5020012}{doi:10.3390/psychoactives5020012}.
\item Rumph JT, Winquist A, Troeschel AN, Pulver S, Schnall AH, Ebersole J, Yeh M, Burt B, Federman SL, Klontz K, Dasenbrock C, Leahy HL, Brady S, Stuteville H, Patel K, Daniel J, Chang A (2026). \textit{Severe Illness Associated with Eating Mushroom-Containing Chocolate Products - United States, January-October 2024.}. MMWR. Morbidity and mortality weekly report. [published; PubMed]. \href{https://doi.org/10.15585/mmwr.mm7513a2}{doi:10.15585/mmwr.mm7513a2}.
\item University of California, Los Angeles (2026). \textit{Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06102434}{source link}.
\item University of Wisconsin, Madison (2026). \textit{Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05866471}{source link}.
\item Johns Hopkins University (2026). \textit{Effects of Psilocybin in Obsessive Compulsive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05546658}{source link}.
\item Shakila Meshkat, Manish K. Jha, Venkat Bhat (2026). \textit{Therapeutic Potential of Psilocybin in Psychiatric Disorders: Mechanisms, Efficacy, and Clinical Implications}. FOCUS The Journal of Lifelong Learning in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.focus.20250043}{doi:10.1176/appi.focus.20250043}.
\item Kush V. Bhatt, Joseph Friedman, Lindsay Benster, Rekha Narasimhan, Ke Yang, Jyoti Mishra, Cory R. Weissman, Dhakshin Ramanathan (2026). \textit{Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use}. Community Mental Health Journal. [published; OpenAlex]. \href{https://doi.org/10.1007/s10597-026-01620-x}{doi:10.1007/s10597-026-01620-x}.
\item Kamil Jurowski, Damian Kobylarz, Maciej Noga (2026). \textit{In-silico toxicity study of tryptamine, psilocin, psilocybin, N,N-dimethyltryptamine, 5’-methoxy-N,N-dimethyltryptamine and O-acetylpsilocin}. Archives of Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1007/s00204-026-04365-4}{doi:10.1007/s00204-026-04365-4}.
\item Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin (2026). \textit{Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.65801/pcp.3512}{doi:10.65801/pcp.3512}.
\item Indiana University (2026). \textit{Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07499583}{source link}.
\item Federal University of Latin American Integration (2026). \textit{Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06898606}{source link}.
\item Aly Shah Aziz (2026). \textit{Classic psychedelic medicines for adolescent refractory mental health disease}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2026.00452}{doi:10.1556/2054.2026.00452}.
\item Unknown authors (2026). \textit{Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/7xfek\_v1}{source link}.
\item Donatella Marazziti, Matteo Gambini, Riccardo Gurrieri, Gerardo Russomanno, Giorgia Sità, Elena Pescini, FRANCESCA RITA DIGIUSEPPE, Federico Mucci (2026). \textit{Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations}. Expert Opinion on Pharmacotherapy. [published; OpenAlex]. \href{https://doi.org/10.1080/14656566.2026.2654682}{doi:10.1080/14656566.2026.2654682}.
\item Gillet A, Geron C, Vitello MM, Lejeune N. (2026). \textit{Pharmacotherapy in Disorders of Consciousness: A Mechanism-Based Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40263-026-01274-z}{doi:10.1007/s40263-026-01274-z}.
\item Alexandra Hopkins, Cassandra A. Bailey, Emily Rybak, Mia M. Ricardo (2026). \textit{Psychedelic-Assisted Psychotherapy: Attitudes of Law Enforcement and Military Personnel}. Journal of Police and Criminal Psychology. [published; OpenAlex]. \href{https://doi.org/10.1007/s11896-026-09807-4}{doi:10.1007/s11896-026-09807-4}.
\item Malkanthi Evans, Andrew Charrette (2026). \textit{Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility}. Frontiers in Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnins.2026.1816932}{doi:10.3389/fnins.2026.1816932}.
\item Jordan J. Negrine, Stephen Bright, Monica J. Barratt, Matthew Pennell, Anthony Barnett, James Bennett-Levy, Timothy Piatkowski (2026). \textit{“You can only take your clients as far as you’ve been yourself”: examining the intersections between psychedelic-assisted therapy, lived-living experience, and clinical practice}. Drugs Education Prevention and Policy. [published; OpenAlex]. \href{https://doi.org/10.1080/09687637.2026.2645025}{doi:10.1080/09687637.2026.2645025}.
\item University of New Mexico (2026). \textit{Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07484906}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731621}{source link}.
\item Bonnie Brusky, Katia M’Baïlara, François Alla, M. Barrault (2026). \textit{Psychological support in psychedelic-assisted therapy clinical trials: A systematic review}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811261424204}{doi:10.1177/02698811261424204}.
\item Mingyu Sun, Xiaoyu Zhao, Fandi Kong, Jinsong Wang, Yunchang Lu, Liang Tong (2026). \textit{Raman Activity Investigation and Utilization of Psilocybin}. Journal of Raman Spectroscopy. [published; OpenAlex]. \href{https://doi.org/10.1002/jrs.70133}{doi:10.1002/jrs.70133}.
\item Anna Komarczewska, Michał Kociński, Patryk Iglewski, Michał Pietrasz, Jakub Idziński, Anna Lubomska (2026). \textit{PSILOCYBIN AS AN ADJUNCTIVE TREATMENT FOR DEPRESSION AND PSYCHOLOGICAL DISTRESS IN ONCOLOGY: CURRENT EVIDENCE AND CLINICAL IMPLICATIONS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.5034}{doi:10.31435/ijitss.1(49).2026.5034}.
\item Gustavo Vazquez (2026). \textit{Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06818994}{source link}.
\item Lea J. Mertens, Michael Koslowski, Felix Betzler, Manuela Brand, Ricarda Evens, Laura Kärtner, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Christian N. Schmitz, Andreas Ströhle, Dennis Scharf, Moritz Spangemacher, Max Wolff, Zahra Assadi, Scharif Bahri, Lilith Becher, Luca V. Färber, Niklas Kirchen, Eugenia Kulakova, Linda C. Kunz, Andy Meijer, Barbara Rohrmoser, Stefan Wellek, Moritz Berger, Gerhard Gründer (2026). \textit{Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2026.0132}{doi:10.1001/jamapsychiatry.2026.0132}.
\item Akey Sungheetha, R. Rajesh Sharma, Oluwasegun Julius Aroba, Sheila Mahapatra, P. D. Mahendhiran (2026). \textit{Explainable AI framework for psilocybin depression treatment optimization}. Frontiers in Computer Science. [published; OpenAlex]. \href{https://doi.org/10.3389/fcomp.2025.1652190}{doi:10.3389/fcomp.2025.1652190}.
\item Marc-Antoine Crocq, Philippe Auby (2026). \textit{The renaissance of research on psychedelics in child and adolescent psychopharmacology}. Child and Adolescent Psychiatry and Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1186/s13034-026-01069-6}{doi:10.1186/s13034-026-01069-6}.
\item Francisco A. Moreno, Katja Ehrmann Allen, Christopher B. Wiegand, Rajan Dunne, James I. Prickett, Brian Bayze, John J. B. Allen (2026). \textit{A randomized clinical trial of repeated doses of psilocybin for the treatment of obsessive-compulsive disorder}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811261424214}{doi:10.1177/02698811261424214}.
\item Michel Sabé, Paul Grof, Nathan Sackett, Sara Tai, Pamela Kryskow, Anya K. Bershad, Douglas Turkington, Matteo Buonarroti, Marco De Pieri, Pantelis Baniotopoulos, Mickael Eskinazi, Kerem Böge, Stefan Leucht, Federico Seragnoli, Leonice Furtado, Tatiana Aboulafia Brakha, Logos Curtis, Matthias Kirschner, Stefan Kaiser, Louise Penzenstadler, Daniele Zullino, Mikkel Højlund, Jade Gallo, Marco Solmi, Jacopo Sapienza, Marta Bosia, Joseph La Torre (2026). \textit{Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review}. Schizophrenia Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.schres.2026.03.003}{doi:10.1016/j.schres.2026.03.003}.
\item University of Alabama at Birmingham (2026). \textit{Psilocybin-facilitated Treatment for Chronic Pain}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05068791}{source link}.
\item Yale University (2026). \textit{Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06442423}{source link}.
\item Shikha Baghel Chauhan, Naziya Akhtar, chirag Jain, Indu Singh (2026). \textit{Strategic Neurodelivery of Psychedelic Compounds: Bridging MolecularPharmacology with Therapeutic Innovation in CNS Disorders}. CNS \& Neurological Disorders - Drug Targets. [published; OpenAlex]. \href{https://doi.org/10.2174/0118715273434237251212095005}{doi:10.2174/0118715273434237251212095005}.
\item Gregorio GD, Basset S, Manmohan H, Nixon WC, Pogaku A, Zhou J, Sanderson DJ, Lengieza ML, Bocchio M. (2026). \textit{Age moderates the relationship between psychedelics use and mental health in naturalistic settings}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-9022170/v1}{doi:10.21203/rs.3.rs-9022170/v1}.
\item Floris G, Jefferson SJ, Rondeau J, Yu AL, Menniti FS, Kwan AC, De Aquino JP, Krystal JH, Pittenger C, Kaye AP. (2026). \textit{Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.64898/2026.03.06.710108}{doi:10.64898/2026.03.06.710108}.
\item Suzanne "Sue" Sisley MD (2026). \textit{An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07275970}{source link}.
\item Shore Ronald, Dobson Kat, Thomson Nina, Barnim Nigel, Bergman Hailey, Rideout Katie, McKeown Sandra, Olmstead Mary C., Goldie Craig, Dumont Eric (2026). \textit{Behavioural investigations of psilocybin in non-human animals 1962-2021: A scoping review}. Journal of Psychedelic Studies. [published; Crossref]. \href{https://doi.org/10.1556/2054.2025.00364}{doi:10.1556/2054.2025.00364}.
\item Shah S, Morrin H. (2026). \textit{Substance-induced manic psychosis in which delusions were corroborated by a chatbot - case report}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8919841/v1}{doi:10.21203/rs.3.rs-8919841/v1}.
\item Fabiano N, Stubbs B, Lawrence DW, Rosenblat JD, Teixeira PJ, Wong S, Zhou C, Carhart-Harris R (2026). \textit{The combination of exercise and psychedelics for the treatment of major depressive disorder.}. Discover mental health. [published; PubMed]. \href{https://doi.org/10.1007/s44192-026-00408-5}{doi:10.1007/s44192-026-00408-5}.
\item Region Skane (2026). \textit{The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07169747}{source link}.
\item Ohio State University (2026). \textit{Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05554094}{source link}.
\item Jennifer E. Thomas, Anna Dellarole, Joshua Caballero (2026). \textit{Efficacy and risks of psychedelics in the treatment of posttraumatic stress disorder: A systematic review}. American Journal of Health-System Pharmacy. [published; OpenAlex]. \href{https://doi.org/10.1093/ajhp/zxag062}{doi:10.1093/ajhp/zxag062}.
\item Psyence Australia Pty Ltd (2026). \textit{A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07072728}{source link}.
\item Alexander WB, Hansen ED, Anderson BT, Zarrabi AJ, Rogers AH, Loewen G, Ficarro ZR, Alexander MH, Schaefer D, Case AA (2026). \textit{Meaning and Psychedelics in Palliative Care: A Narrative Review.}. Journal of pain and symptom management. [published; PubMed]. \href{https://doi.org/10.1016/j.jpainsymman.2025.10.015}{doi:10.1016/j.jpainsymman.2025.10.015}.
\item Ovie Martin Albert, Alexander Arthur (2026). \textit{Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling}. Therapeutic Advances in Drug Safety. [published; OpenAlex]. \href{https://doi.org/10.1177/20420986261436104}{doi:10.1177/20420986261436104}.
\item C Faria, Diana Dias da Silva, João José Sousa (2026). \textit{Psilocybin-assisted therapy for major depressive disorder: implications for clinical effectiveness, health economics, and regulatory decision-making}. Instituto Politécnico do Porto. [published; OpenAlex]. \href{https://doi.org/10.26537/prpaeh.v4i3.7173}{doi:10.26537/prpaeh.v4i3.7173}.
\item Shokr MM, Fawzy MN, Abdelaziz AM. (2026). \textit{Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.mcn.2026.104076}{doi:10.1016/j.mcn.2026.104076}.
\item Kengo Yonezawa, M. Hirata, Hiroaki Takano, Keisuke Kusudo, Sota Tomiyama, Lisa Harada, Kota Suzuki, DJ Nutt, H. Uchida, Hideaki Tani (2026). \textit{Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations}. Psychiatry and Clinical Neurosciences. [published; OpenAlex]. \href{https://doi.org/10.1111/pcn.70042}{doi:10.1111/pcn.70042}.
\item Diana Silva, Andreia Machado Brito-da-Costa, Mariana Carvalho, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Sérgio F. Sousa (2026). \textit{Psilocin as a Broad Inhibitor of CYP450 Enzymes: Integrated In Vitro and In Silico Evidence}. Instituto Politécnico do Porto. [published; OpenAlex]. \href{https://doi.org/10.26537/prpaeh.v4i3.7159}{doi:10.26537/prpaeh.v4i3.7159}.
\item van der Meer PB, Schukking N, Dik M, van Reemst A, Fuentes JJ, Kaptein AA, Schoones JW, Verboeket S, de Waal MM, Goudriaan AE, Kramers C, Schellekens A, Bossong MG, Somers M, Batalla A. (2026). \textit{Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/28314425251364182}{doi:10.1177/28314425251364182}.
\item Johns Hopkins University (2026). \textit{Safety for Home Administration of Microdose Psilocybin Use}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06450210}{source link}.
\item Petranker R, Farb N, Syed O, Li E, Shore D, Anderson T, Blackman A. (2026). \textit{Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8319478/v1}{doi:10.21203/rs.3.rs-8319478/v1}.
\item Unknown authors (2026). \textit{Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/mdz73\_v2}{source link}.
\item Yvan Beaussant, MD, MSci (2026). \textit{Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04950608}{source link}.
\item Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily C. Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Magdalena Jaglinska, Tatiana Son, Norman Farb, Rotem Petranker (2026). \textit{Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10968}{doi:10.1192/bjo.2025.10968}.
\item MycoMedica Life Sciences PBC (2026). \textit{A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07050368}{source link}.
\item Johns Hopkins University (2026). \textit{Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07053917}{source link}.
\item Trent Emerick (2026). \textit{Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07406828}{source link}.
\item Centre for Addiction and Mental Health (2026). \textit{Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07405606}{source link}.
\item Ziping He, Yijie Wang, Jie Chen, Junzhe Cheng, Yuxin Feng, Shuliang Niu, J. Yan (2026). \textit{Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects}. European Archives of Psychiatry and Clinical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1007/s00406-025-02165-y}{doi:10.1007/s00406-025-02165-y}.
\item Chiranth Bhagavan, Olivia P. Carter, Alexander Bryson, Orwa Dandash, Richard Kanaan (2026). \textit{Psychedelics in functional disorders: A scoping review}. Progress in Neuro-Psychopharmacology and Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.pnpbp.2026.111642}{doi:10.1016/j.pnpbp.2026.111642}.
\item Hadassah Medical Organization (2026). \textit{Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07079930}{source link}.
\item TRYP Therapeutics (2026). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06206265}{source link}.
\item Nantes University Hospital (2026). \textit{Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07391332}{source link}.
\item Tianyi Xu, Sabrina Wong, Gia Han Le, Christine E. Dri, Kayla M. Teopiz, Andy Lu, Serene M. L. Lee, Taeho Greg Rhee, Liyang Yin, Stavroula I. Bargiota, Roger Ho, Roger S. McIntyre (2026). \textit{Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease}. Pharmacopsychiatry. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2794-6487}{doi:10.1055/a-2794-6487}.
\item Benjamin R. Lewis, M. Carrington Reid, Andrew M. Novick, Kevin Byrne, Mark J. Niciu, Gregory A. Fonzo, Thomas D. Meyer, David Feifel, Rif S. El-Mallakh, Jair Soares, Trisha Suppes, Frederick S. Barrett (2026). \textit{Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compounds}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251413490}{doi:10.1177/02698811251413490}.
\item Ben-Zion Z, Simon G, Lazebnik T. (2026). \textit{Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8682370/v1}{doi:10.21203/rs.3.rs-8682370/v1}.
\item Olofsson M, Osika W, Goldberg SB, Hendricks PS, Petrovic P, White T, Stenfors CUD, Chaturvedi S, Simonsson O (2026). \textit{Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2025.105105}{doi:10.1016/j.drugpo.2025.105105}.
\item Rachel Ham, John Gardner, Adrian Carter, Paul Liknaitzky (2026). \textit{Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy}. Brain and Behavior. [published; OpenAlex]. \href{https://doi.org/10.1002/brb3.71262}{doi:10.1002/brb3.71262}.
\item Aditi Kanwar, Nitin Jeengar, Pramod Kumar Ashaiya (2026). \textit{Protecting patient autonomy in psychedelic-assisted psychotherapy: a nursing ethics perspective}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18425838}{doi:10.5281/zenodo.18425838}.
\item Łukasz Deska, Cezary Kosmecki, Dawid Głaz, Natalia Kamińska, Wojciech Sołtys, Magdalena Stolarczyk, Maksymilian Głaz, Mateusz Stronczyński, Aleksandra Jagura-Sukiennik, Julia Wawerska (2026). \textit{PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4711}{doi:10.31435/ijitss.1(49).2026.4711}.
\item Adam Wolski, Ewa Szplit, Mikołaj Franciszek Patalong, Roman Cemaga, Mateusz Kubicki, Przemysław Kołodziej, Natalia Bruska, Bartłomiej Błaszkowski, Andrii Bilyk, Katarzyna Więckowska (2026). \textit{Psychedelics in psychiatric treatment: a literature review}. Quality in Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/qs.2026.50.68013}{doi:10.12775/qs.2026.50.68013}.
\item Fernando Mora López, Johynny Solís Solís, Ekaterina Daniela Hernández Baker, Olger Herrera Barboza, David Diaz Polo, Daniela Consumi Cordero (2026). \textit{The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18375715}{doi:10.5281/zenodo.18375715}.
\item S Shiju, Rohan P. Tirumala, Elliot Marseille (2026). \textit{Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence}. Exploratory Research in Clinical and Social Pharmacy. [published; OpenAlex]. \href{https://doi.org/10.1016/j.rcsop.2026.100709}{doi:10.1016/j.rcsop.2026.100709}.
\item Rishika Scott, James Smith (2026). \textit{The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression}. Emerging Minds Journal for Student Research. [published; OpenAlex]. \href{https://doi.org/10.59973/emjsr.317}{doi:10.59973/emjsr.317}.
\item NYU Langone Health (2026). \textit{A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06796062}{source link}.
\item Jakub Klepacz, Radosław Swędrak, Marzena Swojnóg, Zuzanna Dobrakowska (2026). \textit{THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS}. International Journal of Innovative Technologies in Social Science. [published; OpenAlex]. \href{https://doi.org/10.31435/ijitss.1(49).2026.4582}{doi:10.31435/ijitss.1(49).2026.4582}.
\item Marija Franka Žuljević, Antonija Mijatović, Renata Orhanović, Glenn Goasdoué, Diana Gujinović (2026). \textit{Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin}. Journal of Clinical Epidemiology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jclinepi.2026.112170}{doi:10.1016/j.jclinepi.2026.112170}.
\item Tripdatabase (2026). \textit{Does psilocybin help with mental health conditions?}. Zenodo (CERN European Organization for Nuclear Research). [published; OpenAlex]. \href{https://doi.org/10.5281/zenodo.18339283}{doi:10.5281/zenodo.18339283}.
\item Baylor College of Medicine (2026). \textit{The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06888128}{source link}.
\item Florineth, Gianluca Andri, Klima, Isabell, Boeker, Anna Laura, Catzeflis, Polina, Wopfner, Alexander, Denier, Niklaus, Bracht, Tobias, Adorjan, Kristina, Pfammatter, Mario, Müller, Felix, Soravia, Leila Maria (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.}. Open Access CRIS of the University of Bern. [published; OpenAlex]. \href{https://doi.org/10.48620/94398}{doi:10.48620/94398}.
\item Gianluca Andri Florineth, Isabell Klima, Anna Laura Boeker, Polina Catzeflis, Alexander Wopfner, Niklaus Denier, Tobias Bracht, Kristina Adorjan, Mario Pfammatter, Felix Müller, Leila Maria Soravia (2026). \textit{Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2025.54843}{doi:10.1001/jamanetworkopen.2025.54843}.
\item Laura Mills, Susan L. Rossell, Sean Carruthers (2026). \textit{Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts}. Journal of Affective Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.jad.2026.121220}{doi:10.1016/j.jad.2026.121220}.
\item Anthony L. Back, Bonnie A. McGregor, Leslie Lazar Thorn, Kelsey K. Baker, T. Gooley, Mendel Kaelen, Kalin Harvey, John M. Guy, Susanna Myers, Juliana Pérez, Peter Thompson, Lindsay Billingsley, Cheryl Sesnon (2026). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251413856}{doi:10.1177/28314425251413856}.
\item Unknown authors (2026). \textit{Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/atfum\_v1}{source link}.
\item Celia Faye Jacobsen, Dea Siggaard Stenbæk, Stig Poulsen, Sophia Armand (2026). \textit{The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise?}. Psychiatric Research and Clinical Practice. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.prcp.20250113}{doi:10.1176/appi.prcp.20250113}.
\item COMPASS Pathways (2026). \textit{A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05711940}{source link}.
\item AL McGuire, Logan Neitzke-Spruill, Jill O. Robinson, Caroline Beit, Nikita Singh, David S. Mathai, Lynnette A. Averill (2026). \textit{Reported Safety Practices of Publicly Advertised Psychedelic Retreats}. JAMA Network Open. [published; OpenAlex]. \href{https://doi.org/10.1001/jamanetworkopen.2025.52505}{doi:10.1001/jamanetworkopen.2025.52505}.
\item Jesse Dallery, Jennifer L. Miller, Jeff Boissoneault, Lauren Harvey, Lindsey Ives, Alexandra Knerr, Shelby Blaes, Morgan N. Ransom, Melissa S. Munson, James P. Gilligan, Michael H. Silverman, Peter R. Guzzo, Beverlee Loeser (2026). \textit{An open-label pilot study of psilocybin-assisted therapy for binge eating disorder}. Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1186/s40337-025-01508-3}{doi:10.1186/s40337-025-01508-3}.
\item Frederick D. Sancilio, Maghsoud Dariani, Purvi Chavda, Harsha Mysore Rajagopal, Lyl Tomlinson (2026). \textit{Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2607726}{doi:10.1080/02791072.2025.2607726}.
\item Reza Moshfeghinia, Sara Mostafavi, Kimia Jazi, Amir Reza Ghasemi, Yasamin Khosravaninezhad, Santhosshi Narayanan, Jamshid Ahmadi, Mehdi Pasalar (2026). \textit{The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis}. BMC Psychology. [published; OpenAlex]. \href{https://doi.org/10.1186/s40359-025-03935-y}{doi:10.1186/s40359-025-03935-y}.
\item Marta Gómez Álvarez, Javier Calleja-Conde, Víctor Echeverry-Alzate (2025). \textit{Psychedelics and Mental Health: Psilocybin and Depression. A Sistematic Review}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/yu3n9}{doi:10.17605/osf.io/yu3n9}.
\item Unknown authors (2025). \textit{Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken}. Fortschritte der Neurologie · Psychiatrie. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2700-8978}{doi:10.1055/a-2700-8978}.
\item Maurice Lam, C. Khor, S. Hultin, J. J. Cheung, N. A. Shah (2025). \textit{‘Shroom’ for concern: a case of psychedelic mushroom-induced acute kidney injury}. Internal Medicine Journal. [published; OpenAlex]. \href{https://doi.org/10.1111/imj.70313}{doi:10.1111/imj.70313}.
\item L.J. Mertens, M. Koslowski, F. Betzler, M. Brand, R. Evens, L. Krätner, A. Jungaberle, H. Jungaberle, T. Majić, C.N. Schmitz, A. Ströhle, D. Scharf, M. Spangemacher, M. Wolff, Z. Assadi, B. Scharif, L. Becher, L.V. Färber, N. Kirchen, E. Kulakova, L. Kunz, A. Meijer, B. Rohrmoser, S. Wellek, M. Berger, G. Gründer (2025). \textit{Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE): Results of a randomized active placebo-controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.105779}{doi:10.1016/j.nsa.2025.105779}.
\item N. Mcgowan, J. Rucker, R. Yehuda, M. Agrawal, H. Simmons, S. Das, G. Goodwin (2025). \textit{An open-label study of single-dose COMP360 psilocybin for post-traumatic stress disorder: safety, tolerability, and secondary efficacy outcomes}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2025.106821}{doi:10.1016/j.nsa.2025.106821}.
\item Jensen, Hailey A (2025). \textit{Psilocybin Treatment for Refractory Depression: A Clinical Review}. Digital Commons - Gardner-Webb University (Gardner-Webb University). [published; OpenAlex]. \href{https://digitalcommons.gardner-webb.edu/pa-department-journal-of-medical-science/63}{source link}.
\item Holze F, Liechti ME, Müller F. (2025). \textit{Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2024\_510}{doi:10.1007/7854\_2024\_510}.
\item Viljoen G, Betzler F (2025). \textit{Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.}. Current topics in behavioral neurosciences. [published; PubMed]. \href{https://doi.org/10.1007/7854\_2024\_534}{doi:10.1007/7854\_2024\_534}.
\item Bradberry MM, Appelbaum PS, Gukasyan N. (2025). \textit{Informed Consent in Psychedelic-Assisted Therapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2024\_559}{doi:10.1007/7854\_2024\_559}.
\item Chwyl C, Wilson-Poe AR, Hoffman KA, Bazinet A, Pertl K, Luoma JB, des Jarlais D, Bielavitz S, Korthuis PT (2025). \textit{Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability.}. The International journal on drug policy. [published; PubMed]. \href{https://doi.org/10.1016/j.drugpo.2025.104938}{doi:10.1016/j.drugpo.2025.104938}.
\item Hirschfeld T, Blei F, Stegemann L, van der Gouwe D, Smit-Rigter L. (2025). \textit{Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2025\_606}{doi:10.1007/7854\_2025\_606}.
\item Brunno Freitas da Costa, Paula Hartmann, Daniel Pagnin (2025). \textit{Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin}. Human Psychopharmacology Clinical and Experimental. [published; OpenAlex]. \href{https://doi.org/10.1002/hup.70032}{doi:10.1002/hup.70032}.
\item Magar, Marlena Robbins, Óscar Martín López Fernández (Lobo Blanco), Ismail Lourido Ali, Brian Anderson, Charlie Grob, Jack E. Henningfield, Pamela Kryskow, Heather Kuiper, Anja Loizaga-Velder, Brian Rush, Miriam Volat, Sandor Iron Rope (2025). \textit{Indigenous Knowledge Systems \& Psychedelic Science: Towards Ethical and Reciprocal Collaboration}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251387104}{doi:10.1177/02698811251387104}.
\item Majić T, Gouzoulis-Mayfrank E, Evens R. (2025). \textit{Classifying Psychedelic-Related Complications.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2026\_614}{doi:10.1007/7854\_2026\_614}.
\item Tyler Durns, Greg Iannuzzi (2025). \textit{Contextualizing Violence Risk Associated With Hallucinogens}. FOCUS The Journal of Lifelong Learning in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.focus.20250027}{doi:10.1176/appi.focus.20250027}.
\item Spiti A, Caldirola D, Perna G. (2025). \textit{New Antidepressant Development in the Treatment of Depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/978-981-95-6872-7\_23}{doi:10.1007/978-981-95-6872-7\_23}.
\item Xia K, Gao T. (2025). \textit{[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.12122/j.issn.1673-4254.2026.01.01}{doi:10.12122/j.issn.1673-4254.2026.01.01}.
\item Thuery G, Crossen F, Mc Loone D, Hinds C, Duffy R, Jairaj C, Harkin A, Kelly JR (2025). \textit{Psychedelic therapy and postpartum depression: priorities and prospects.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/20451253251408280}{doi:10.1177/20451253251408280}.
\item University of Calgary (2025). \textit{A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06615908}{source link}.
\item Rotem Petranker (2025). \textit{Microdosing Psychedelics to Improve Mood}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05259943}{source link}.
\item Miguel Benjamín Cervera-Sánchez, Daniel San-Juan, Roberto Díaz-Peregrino, Evelin Zulema Camacho-Castillo, Sthefany Anahi Bringas-Ortiz, Christian Padilla-Cabezutd (2025). \textit{Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.22541/au.176701186.65064859/v1}{doi:10.22541/au.176701186.65064859/v1}.
\item Monika Dominiak, Adam Gędek, Szymon Modrzejewski, Agnieszka Permoda-Osip, Anna Zofia Antosik (2025). \textit{Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials}. Journal of Clinical Medicine. [published; OpenAlex]. \href{https://doi.org/10.3390/jcm15010253}{doi:10.3390/jcm15010253}.
\item Omer A. Syed, Sean M. Nestor, Muhammad Ishrat Husain, Mark Sinyor, Fahad Alam, Peter Giacobbe (2025). \textit{Adverse events associated with classic psychedelics and MDMA: a real-world population-based study using the WHO pharmacovigilance database (VigiBase)}. Psychiatry Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psychres.2025.116929}{doi:10.1016/j.psychres.2025.116929}.
\item Emmanuelle A. D. Schindler, Christopher Gottschalk, Brian Pittman, Deepak D'Souza (2025). \textit{Comparing single- and repeat-dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.70024}{doi:10.1111/head.70024}.
\item Manasicha Wongpaiboon, Jackson L. Shelton, Eric Delgado Rendon, Maddison Vail (2025). \textit{A Systematic Review of the efficacy, safety, and Tolerability of Psychedelics in the Treatment of post-traumatic Stress Disorder}. Current Treatment Options in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1007/s40501-025-00373-w}{doi:10.1007/s40501-025-00373-w}.
\item Sahba Afsharnia, Vivian Liang, Yona Lunsky, A Orsini, Ami Tint, Hsiang-yuan Lin (2025). \textit{Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey}. PLOS mental health.. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmen.0000514}{doi:10.1371/journal.pmen.0000514}.
\item Sheppard Pratt Health System (2025). \textit{The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05220410}{source link}.
\item University of Chicago (2025). \textit{An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05399498}{source link}.
\item Bhagavan C, Carter O, Nielsen G, Berlowitz D, Issak S, Braat S, Zaloumis S, Attard Z, Oliver G, Mayne D, Rucker J, Butler M, Dandash O, Bryson A, Kanaan RA. (2025). \textit{A Randomised, Triple-Blind, Dose-Finding Study of the Impact of Psilocybin on Motor Function in Healthy Participants}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.64898/2025.12.22.25342874}{doi:10.64898/2025.12.22.25342874}.
\item Anthony L. Back, Bonnie A. McGregor, Lindsay Billingsley, Dianna Blom, George Callan, Susanna Myers, John Guy, Sameet Kumar, Melissa Layer, Jackie Levin, Juliana Pérez, Peter Thompson, Kathy Salmonson, Joseph Whinney, Leslie Lazar Thorn (2025). \textit{Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251404460}{doi:10.1177/28314425251404460}.
\item Paweł Liszka, Agata Ogórek, Klaudia M Olejnik-Chlewicka, Konrad Puchalski, Marta Zasiadła, Klaudia M Patrzykąt, Jakub Perediatkiewicz, Wojciech Urbański, Paweł M Łuczak, Jakub Brodowski (2025). \textit{Psychedelics as a Therapeutic Opportunity or Threat: A Narrative Review}. Cureus. [published; OpenAlex]. \href{https://doi.org/10.7759/cureus.99942}{doi:10.7759/cureus.99942}.
\item NYU Langone Health (2025). \textit{Effects of Psilocybin on Speech Fluency, Struggle, and Brain Activity in People Who Stutter}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07296328}{source link}.
\item Amanda Husein, Madalynn Traylor, M. Frances Vest, Bo Jarrett Wood, Madison Brogan, Alfred Thomas, Shawn E. McNeil, M Alfrad Nobel Bhuiyan, Peter S. Hendricks, John R. Kelly, Andrew Gribben, Sultan Alqahtani, Kelsea Keys, Amber N. Edinoff, J C Patterson, Kevin S. Murnane (2025). \textit{Assessing The Readiness of Psychiatrists in Louisiana to Incorporate Psilocybin into Clinical Practice-Lessons Learned from a State Underrepresented in Clinical Psychedelic Research}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251381806}{doi:10.1177/28314425251381806}.
\item Koning E, Gamberg S, Keshen A. (2025). \textit{Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale \& Considerations for Protocol Development}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202512.1705.v1}{doi:10.20944/preprints202512.1705.v1}.
\item COMPASS Pathways (2025). \textit{A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05624268}{source link}.
\item Gurjot Brar, T. R. JUN. BURKE, Andrew Gribben, Colm Harrington, Guillaume Thuery, John R. Kelly (2025). \textit{Psilocybin reporting in media (PRiMe) for the treatment of depression}. Irish Journal of Psychological Medicine. [published; OpenAlex]. \href{https://doi.org/10.1017/ipm.2025.10142}{doi:10.1017/ipm.2025.10142}.
\item Matos ARS, Silva AC, Rego L, Fernandes R, Gonçalves S. (2025). \textit{Psilocybin-assisted therapy for individuals with palliative care needs: A systematic review of safety and efficacy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02692163251383335}{doi:10.1177/02692163251383335}.
\item Unknown authors (2025). \textit{Exploring Psilocybin-Assisted Schema Therapy: A Conceptual Framework for Potential Therapeutic Synergies in Personality Disorders}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.47626/2237-6089-2025-1273}{doi:10.47626/2237-6089-2025-1273}.
\item Juuso Kähönen (2025). \textit{Subjective Effects of Psychedelics Are the Plausible Mechanism of Psychedelic Moral Enhancement Rather than a Risk. Comment on Tang, B.L. Psychedelics for Moral Bioenhancement in Healthy Individuals-A Violation of the Non-Maleficence Principle? Psychoactives 2025, 4, 5}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4040043}{doi:10.3390/psychoactives4040043}.
\item Megan Dutton, Paul Schwenn, Jules Mitchell, Per Hoffmann, Neil W. Bailey, Paul B. Fitzgerald, Jim Lagopoulos, Adem Can (2025). \textit{Psilocybin in the real world: Regulatory, ethical, and operational challenges in Australia’s clinical landscape}. Australian \& New Zealand Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/00048674251398677}{doi:10.1177/00048674251398677}.
\item M. H. M. Wickramasekara, G. D. M. C. Gonapaladeniya (2025). \textit{Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment}. The journal of desk research review and analysis.. [published; OpenAlex]. \href{https://doi.org/10.4038/jdrra.v3i2.87}{doi:10.4038/jdrra.v3i2.87}.
\item Yvan Beaussant, MD, MSci (2025). \textit{Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06001749}{source link}.
\item Nicole Ledwos, Jenna Baer, Muhammad Ishrat Husain, Daniel M. Blumberger, Rachel Patterson, Elizabeth Hollingdrake, Ezmond S.L. Cheung, Colin Hawco, Christoph Zrenner, Brigitte Zrenner, Jamie D. Feusner, Susan L. Rossell, David Castle, Gwyneth Zai (2025). \textit{Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10895}{doi:10.1192/bjo.2025.10895}.
\item Jungwirth J, Westenhöfer S, Aicher H, Provaznikova B, Kronenberg G, Seifritz E, Prinz S, Olbrich S. (2025). \textit{Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-8079137/v1}{doi:10.21203/rs.3.rs-8079137/v1}.
\item Gerasimos Konstantinou, Joshua D. Rosenblat, Sarah Hales, Muhammad Ishrat Husain, Daniel M. Blumberger (2025). \textit{Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2025.12.005}{doi:10.1016/j.genhosppsych.2025.12.005}.
\item Imperial College London (2025). \textit{Investigating the Effects of a Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm Behaviour: an Experimental Medicine Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06798636}{source link}.
\item Taslim Uddin, Suma Akter, Kanak Yadab Ghosh (2025). \textit{Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges}. Advanced Neurology. [published; OpenAlex]. \href{https://doi.org/10.36922/an025410095}{doi:10.36922/an025410095}.
\item University of British Columbia (2025). \textit{Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication in Patients With Chronic Pain: an Open-label Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05585229}{source link}.
\item NYU Langone Health (2025). \textit{A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Effects of Psilocybin-assisted Psychotherapy on Psychiatric and Existential Distress in Advanced Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05398484}{source link}.
\item Spohn, Kyle (2025). \textit{Magic Mushrooms as Medicine: What the United States Can Learn from Jamaica’s Unregulated Psilocybin Industry as FDA Approval Nears}. eYLS (Yale Law School). [published; OpenAlex]. \href{https://repository.law.miami.edu/umialr/vol57/iss1/7}{source link}.
\item Morris Lintong Barimbing, Dian Pritasari Jeger, Made Edwin Sridana (2025). \textit{Efficacy of psilocybin on death anxiety in terminal patients: a narrative review}. Progress in Palliative Care. [published; OpenAlex]. \href{https://doi.org/10.1080/09699260.2026.2657096}{doi:10.1080/09699260.2026.2657096}.
\item Bukovsky D, Amaev A, Song J, Torres-Carmona E, Kyte S, Ueno F, Deluca V, Bowie C, Flint A, Husain I, Graff-Guerrero A, Gerretsen P. (2025). \textit{Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12740486}{source link}.
\item Aboulafia-Brakha T, Buchard A, Mabilais C, Alaux S, Amberger C, Furtado L, Seragnoli F, Briefer J, Thorens G, Sabé M, Szczesniak L, Iuga R, Zullino D, Penzenstadler L. (2025). \textit{Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.12.01.25341335}{doi:10.1101/2025.12.01.25341335}.
\item Nadav Liam Modlin, Victoria Williamson, Guy M. Goodwin, Ekaterina Malievskaia, Merve Atli, Zsofia Elek, Alice Gaillard, Don Koelpin, Anthony J. Cleare, Manish Agrawal, Rachel Yehuda, Namik Kirlić, James Rucker (2025). \textit{Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2025.103692}{doi:10.1016/j.eclinm.2025.103692}.
\item Joseph G. Lorenz, Scott A. Hawkins, Bryan C. McCarthy (2025). \textit{Griffiths et al.’s Study of Psilocybin with Religious Professionals: A Theological Response from a Christian Perspective}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251406251}{doi:10.1177/28314425251406251}.
\item University of Texas at Austin (2025). \textit{Assessing the Safety, Tolerability, and Efficacy of Psilocybin Therapy Followed by Accelerated Intermittent Theta Burst (aiTBS) Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment-Resistant Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06132178}{source link}.
\item Charles S. Grob, M.D. (2025). \textit{Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05403086}{source link}.
\item Daniel J. Kruger, Gina Mersereau, Ashley F. Sullivan, Julie Barron, Moss Herberholz, Niloufar Pouyan, Jacob S. Aday, Kevin F. Boehnke (2025). \textit{Best practices for first psychedelic experiences: harm reduction advice from the psychedelic community}. Harm Reduction Journal. [published; OpenAlex]. \href{https://doi.org/10.1186/s12954-025-01337-2}{doi:10.1186/s12954-025-01337-2}.
\item Sana Rasheed, Rida Arif, Ahmed Asad Raza, Abedin Samadi (2025). \textit{Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder}. Annals of Medicine and Surgery. [published; OpenAlex]. \href{https://doi.org/10.1097/ms9.0000000000004349}{doi:10.1097/ms9.0000000000004349}.
\item Silvia Natoli, Arturo Cuomo, Maurizio Marchesini, Livio Luongo, Giuliano Lo Bianco, Vittorio Guardamagna, Shigeki Yamaguchi (2025). \textit{Psilocybin and Chronic Pain: A New Perspective for Future Pain Therapists?}. Medical Sciences. [published; OpenAlex]. \href{https://doi.org/10.3390/medsci13040277}{doi:10.3390/medsci13040277}.
\item Beersheva Mental Health Center (2025). \textit{A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07183748}{source link}.
\item Beersheva Mental Health Center (2025). \textit{Open Label, Phase 2 Study for Evaluating the Feasibility, Safety and Efficacy of Psychotherapy Assisted Psilocybin for Treatment of Severe Obsessive Compulsive Disorder (OCD) in Drug and/or Psychotherapy Resistant Patients.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04882839}{source link}.
\item Ioakimidis-MacDougall G, Gardner J, Liknaitzky P. (2025). \textit{Psilocybin Experiential Therapist Training: Insights from a World-First Study}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.11.15.25340324}{doi:10.1101/2025.11.15.25340324}.
\item Unknown authors (2025). \textit{Microdosing Psilocybin for Major Depressive Disorder: Study Protocol for a Phase II Double-Blind Placebo-Controlled Randomized Partial Crossover Trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/hmnsw\_v1}{source link}.
\item Nicky J. Mehtani, Maha N. Mian, Gabrielle Agin-Liebes, Allison R. Coker, Christopher Huebner, B. Anderson, Jennifer Mitchell (2025). \textit{Psychedelic Augmentation of 12-Step Engagement: A Novel, Accessible Approach to Enhance Community-Based Recovery from Substance Use Disorders}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2583960}{doi:10.1080/02791072.2025.2583960}.
\item Zech JM, Richard J, Jones GM (2025). \textit{The Relationship Between Psychedelic Use and Alcohol Use Disorder in a Nationally Representative Sample.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2025.2583967}{doi:10.1080/02791072.2025.2583967}.
\item Højlund M, Kafali HY, Kırmızı B, Fusar-Poli P, Correll CU, Cortese S, Sabé M, Fiedorowicz J, Saraf G, Zein J, Berk M, Husain MI, Rosenblat JD, Rubaiyat R, Corace K, Wong S, Hatcher S, Kaluzienski M, Yatham LN, Cipriani A, Gosling CJ, Carhart-Harris R, Tanuseputro P, Myran DT, Fabiano N, Moher D, Mayo LM, Nicholls SG, White T, Prisco M, Radua J, Vieta E, Ladha KS, Katz J, Veroniki AA, Solmi M. (2025). \textit{Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2025.09.011}{doi:10.1016/j.euroneuro.2025.09.011}.
\item University of Washington (2025). \textit{A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05847686}{source link}.
\item Jevotovsky DS, Chopra H, Pak DJ, Durbhakula S, Shustorovich A, Juneja T, Broachwala MY, AlFarra T, Silver C, Kreitzer G, Oreoluwa P, Weissman BB, AlFarra A, Mayrsohn BG, Orhurhu V, Emerick T, Furnish T, Castellanos JP. (2025). \textit{Psilocybin and chronic neuropathic pain: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1136/rapm-2024-105532}{doi:10.1136/rapm-2024-105532}.
\item Kent E. Hutchison, Jake F. Hooper, Hollis C. Karoly (2025). \textit{Psilocybin Outside the Clinic}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2025.3038}{doi:10.1001/jamapsychiatry.2025.3038}.
\item Chiranth Bhagavan, Alexander Bryson, Olivia Carter, Glenn Nielsen, David J. Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Dina Eleftheriadis, Georgina Oliver, Deanne Mayne, Greg Roebuck, James Rucker, Matthew Butler, Richard Kanaan (2025). \textit{Psilocybin-assisted physiotherapy for refractory motor functional neurological disorder: protocol for a randomised dose-comparison pilot study}. Acta Neuropsychiatrica. [published; OpenAlex]. \href{https://doi.org/10.1017/neu.2025.10042}{doi:10.1017/neu.2025.10042}.
\item Yvan Beaussant, Zachary Sager, Caitlin W. Brennan, Isabel Kristan, Michael Ljuslin, Emanuele Mazzola, David R. Macdonald, M. Murphy, Kabir Nigam, Alden Doerner Rinaldi, Justin J. Sanders, Kristen G. Schaefer, Roxanne Sholevar, Lisa Summer, Alifia Waliji-Banglawala, Sandra Yudilevich-Espinoza, James A. Tulsky (2025). \textit{Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy}. BMJ Supportive \& Palliative Care. [published; OpenAlex]. \href{https://doi.org/10.1136/spcare-2025-005773}{doi:10.1136/spcare-2025-005773}.
\item Unknown authors (2025). \textit{Lifetime Psychedelic Use and Opioid Use Disorder Severity: Substance-Use Pattern Specific and Mental Health-Dependent Associations in a National Survey}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1016/j.addbeh.2026.108652}{doi:10.1016/j.addbeh.2026.108652}.
\item Thomas Zandonai, Sofia Venturini, Ornella Corazza (2025). \textit{Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope?}. Performance Enhancement \& Health. [published; OpenAlex]. \href{https://doi.org/10.1016/j.peh.2025.100386}{doi:10.1016/j.peh.2025.100386}.
\item Rahmani S, Crupi R, Riley AL, Davidson T (2025). \textit{The therapeutic use of psychedelic drugs: Legal, policy, and neuroscientific perspectives.}. Pharmacology, biochemistry, and behavior. [published; PubMed]. \href{https://doi.org/10.1016/j.pbb.2025.174087}{doi:10.1016/j.pbb.2025.174087}.
\item Jonathon Marinis, Sarah Clarke, Alexandre A. Guerin, Adam J. Guastella, Gillinder Bedi (2025). \textit{Reporting of side-effects in clinical trials of psilocybin-assisted psychotherapy for psychiatric conditions: systematic review}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2025.10847}{doi:10.1192/bjo.2025.10847}.
\item André Leão Dantas, Lara Moreira Jalles Milani, Saulo Gabriel Moreira Falci, João Américo da Silveira, Cristina Pereira Isolan, Lia Dietrich (2025). \textit{Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications}. Caderno Pedagógico. [published; OpenAlex]. \href{https://doi.org/10.54033/cadpedv22n12-345}{doi:10.54033/cadpedv22n12-345}.
\item Do A, Cloutier L, Hébert-Tremblay L, Thauvin C. (2025). \textit{Psilocybin use in bipolar disorder: A comprehensive review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2025.120485}{doi:10.1016/j.jad.2025.120485}.
\item Anna Rose Childress, Ph.D. (2025). \textit{A Wellcome Leap for the Opioid Crisis: Can the 5HT2A Agonist Psilocybin Improve Brain, Behavioral, and Clinical Outcomes in Opioid Use Disorder (OUD)?}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06786325}{source link}.
\item Candice Richardson, Cindy Chan, Emily Macgregor, Crystal Hare, Breffni Hannon, SarahRose Black, Evan E. Schneider, Daniel Z. Buchman, Stella Wang, Valeria E. Rac, Lusine Abrahamyan, Ella Huszti, Rinat Nissim, Madeline Li, Camilla Zimmermann, Emma Hapke, Daniel M. Rosenbaum, Sarah Hales (2025). \textit{Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) therapy for patients with advanced cancer: protocol for a multi-method feasibility trial}. Pilot and Feasibility Studies. [published; OpenAlex]. \href{https://doi.org/10.1186/s40814-025-01706-5}{doi:10.1186/s40814-025-01706-5}.
\item Bukovsky D, Amaev A, Song J, Kyte S, Carmona-Torres E, Ueno F, Deluca V, Strafella AP, Husain MI, Graff-Guerrero A, Gerretsen P. (2025). \textit{Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111541}{doi:10.1016/j.pnpbp.2025.111541}.
\item David J. Heal, Jane Gosden, Sharon L. Smith (2025). \textit{Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251382147}{doi:10.1177/02698811251382147}.
\item Gerard J. Marek, Soma Makai-Bölöni, Daniel Umbricht, Edward P. Christian, Jason Winters, Dino Dvořák, Shane Raines, Zoë A. Hughes, Eric W. Austin, Adam K. Klein, William Leong, Fas J. Krol, Anne J. van der Graaf, Maria J. Juachon, Marije E. Otto, Laura Borghans, Gabriël E. Jacobs, Andrew C. Kruegel, Jonathan Sporn (2025). \textit{A novel psychedelic 5-HT2A receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251378512}{doi:10.1177/02698811251378512}.
\item University of Washington (2025). \textit{A Phase 1 Study of a Second Psilocybin Group Retreat for Partial Responders With Anxiety Associated With Metastatic Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06644170}{source link}.
\item Johns Hopkins University (2025). \textit{Psilocybin and Affective Function in Chronic Lower Back Pain Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06355414}{source link}.
\item Rajiv Agrawal, Daniel J. Gillie, Alison E. Mungenast, Milan Chytil, Sharon Engel, Michael C. Wu, Kurt Rasmussen, Eliseo Salinas, David E. Olson (2025). \textit{Zalsupindole is a Nondissociative, Nonhallucinogenic Neuroplastogen with Therapeutic Effects Comparable to Ketamine and Psychedelics}. ACS Chemical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.5c00667}{doi:10.1021/acschemneuro.5c00667}.
\item Renee Ireland (2025). \textit{Psychedelics in Practice: Science, Safety, and the Future of Healing}. The proceedings of sliit international conference on advancements in science and humanities. [published; OpenAlex]. \href{https://doi.org/10.54389/epsd8792}{doi:10.54389/epsd8792}.
\item Oregon Health and Science University (2025). \textit{Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06988319}{source link}.
\item Renner AC, Kargbo RB. (2025). \textit{Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsmedchemlett.5c00595}{doi:10.1021/acsmedchemlett.5c00595}.
\item Kevin Murnane (2025). \textit{A Pilot Study in North Louisiana to Assess the Tolerability of Psilocybin as Well as Its Capacity to Promote Abstinence From Methamphetamine}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06899594}{source link}.
\item Centre Hospitalier St Anne (2025). \textit{Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07210112}{source link}.
\item M Loganathan, A Saravanakumar, P. Parthiban, G Anandharaj, S Gobika, D Dharshana, Mohamed Safir Ali (2025). \textit{Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders}. Journal of Pharma Insights and Research.. [published; OpenAlex]. \href{https://doi.org/10.69613/thv1dn30}{doi:10.69613/thv1dn30}.
\item Dutton C, North E, Chun Tie Y, Oliva J, Skeffington P (2025). \textit{Harm reduction practises for users of psychedelic drugs: a scoping review.}. Harm reduction journal. [published; PubMed]. \href{https://doi.org/10.1186/s12954-025-01264-2}{doi:10.1186/s12954-025-01264-2}.
\item University Hospital, Geneva (2025). \textit{Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164287}{source link}.
\item Stephanie Marco (2025). \textit{B-302 Psychedelics and Dissociative Anesthetics: Concentrations in Suspected Impaired Driving Investigations, 2024}. Clinical Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1093/clinchem/hvaf086.689}{doi:10.1093/clinchem/hvaf086.689}.
\item Johns Hopkins University (2025). \textit{Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06989957}{source link}.
\item Rajwani K, Jacobs E, Bruce L, Hokanson J, Almonte MT, Feroz F, Waldman E, Cheung K, Levy N, Savulescu J, Singh I, Yaden DB, Earp BD. (2025). \textit{Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s2352-4642(25)00208-1}{doi:10.1016/s2352-4642(25)00208-1}.
\item Michel Sabé, Federico Seragnoli, Louise Penzenstadler, Gabriel Thorens (2025). \textit{[Role of psychedelics in psychiatry: a true therapeutic revolution or a trend?]}. PubMed. [published; OpenAlex]. \href{https://pubmed.ncbi.nlm.nih.gov/41575100}{source link}.
\item Cassandra J. Hatzipantelis, Min Liu, A. H. G. Love, Sadie J. Leventhal, Hero Maera, Srinidhi Viswanathan, Emily Avetisyan, Liana Belinsky, McKenna M. Rangel, Nina J. Jain, Max Kelly, C. Copeland, Yara A. Khatib, Oliver Fiehn, David E. Olson, Danielle S. Stolzenberg (2025). \textit{Psilocybin during the postpartum period induces long-lasting adverse effects in both mothers and offspring}. Nature Communications. [published; OpenAlex]. \href{https://doi.org/10.1038/s41467-025-64371-5}{doi:10.1038/s41467-025-64371-5}.
\item Caporuscio C, Poppe C, Gieselmann A, Repantis D. (2025). \textit{Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s0033291725101761}{doi:10.1017/s0033291725101761}.
\item University of Southern California (2025). \textit{An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06233344}{source link}.
\item Unknown authors (2025). \textit{“So many relationships in the room”: Participant perspectives on the affordances and challenges of co-therapy in psychedelic assisted therapy}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/4cn5r\_v1}{source link}.
\item Stefania Chiappini, Clara Cavallotto, Andrea Miuli, Giacomo d’Andrea, Alessio Mosca, Carlotta Marrangone, Rita Allegretti, Serena Panichella, Antonio d'Attilio, Giovanna Mammarella, Luca Persico, Alessia Santeusanio, Gianfranco Tamagnini, Mauro Pettorruso, Giovanni Martinotti (2025). \textit{Novel perspectives for glutamatergic strategies, psychedelics and antipsychotic augmentation in Treatment Resistant Depression: A narrative review}. Clinical Neuropsychopharmacology and Addiction. [published; OpenAlex]. \href{https://doi.org/10.53941/cna.2025.100006}{doi:10.53941/cna.2025.100006}.
\item Healing Advocacy Fund (2025). \textit{Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07189988}{source link}.
\item Matthew Halma, R. Levy, Joseph Varón (2025). \textit{With great power comes great responsibility: Promise and caution in the new psychedelic renaissance}. Brain Disorders. [published; OpenAlex]. \href{https://doi.org/10.1016/j.dscb.2025.100286}{doi:10.1016/j.dscb.2025.100286}.
\item Hosein MM, Reid MJ, Walser S, Charney S, Fonzo GA, Lewis BR, Yaden DB, Suppes T, Cordner ZA, Barrett FS. (2025). \textit{Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.eclinm.2025.103517}{doi:10.1016/j.eclinm.2025.103517}.
\item Elizabeth Knock, Krista J. Siefried, Gillinder Bedi, Steven M. Albert, Richard O. Day, Nadine Ezard, Margaret Ross, Paul Liknaitzky, Jonathan Brett (2025). \textit{Psilocybin-assisted psychotherapy for methamphetamine use disorder: A pilot open-label safety and feasibility study}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.70187}{doi:10.1111/add.70187}.
\item Beaglehole B, Manuel J. (2025). \textit{Reappraisal of the hype and hope offered by psilocybin treatment of depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.26635/6965.7138}{doi:10.26635/6965.7138}.
\item Benjamin R. Lewis, John Hendrick, Kevin Byrne, Madeleine Odette, Chaorong Wu, Eric L. Garland (2025). \textit{Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial}. PLoS Medicine. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pmed.1004519}{doi:10.1371/journal.pmed.1004519}.
\item Anastasia Calin, Ana Flavia Burlec, Cornelia Mircea, Irina Macovei, Monica Hăncianu, Andreia Corciovă (2025). \textit{Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US}. Journal of Clinical Medicine. [published; OpenAlex]. \href{https://doi.org/10.3390/jcm14186613}{doi:10.3390/jcm14186613}.
\item Ophir Netzer, Noa Magal, Yonatan Stern, Tzuk Polinsky, Raz Gross, Roee Admon, Roy Salomon (2025). \textit{Trauma under psychedelics: how psychoactive substances impact trauma processing}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21363}{doi:10.1002/wps.21363}.
\item Maastricht University (2025). \textit{The Impact of Psilocybin on Pain in Fibromyalgia Patients: a Multicentre Trial.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06368492}{source link}.
\item Taynah Pereira Galdino, Antônio Braz de Medeiros Bisneto, Marcelo da Silva Pedro, Lucas Cordeiro de Oliveira, Mateus Araújo da Luz, Antônio Gilson Barbosa de Lima, Suédina Maria de Lima Silva, Marcus Vinícius Lia Fook (2025). \textit{Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds}. ACS Omega. [published; OpenAlex]. \href{https://doi.org/10.1021/acsomega.5c05606}{doi:10.1021/acsomega.5c05606}.
\item Zhifan He, Rui Tang, Min Feng, Xiaohui Li, Changhong Zhang, Jing Li (2025). \textit{Dynamic myocardial injury and variable hallucination latency in Psilocybe keralensis poisoning: a molecularly confirmed case series from China}. Clinical Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1080/15563650.2025.2552438}{doi:10.1080/15563650.2025.2552438}.
\item Sonda S, Pendin D, Comai S, De Martin S, Manfredi P, Mattarei A. (2025). \textit{Emerging mechanisms of psilocybin-induced neuroplasticity.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.tips.2025.08.012}{doi:10.1016/j.tips.2025.08.012}.
\item Sabbah SG, Li S, Wong S, Le GH, Badulescu S, Hawco C, Rosenblat JD, McIntyre RS. (2025). \textit{Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2025.120335}{doi:10.1016/j.jad.2025.120335}.
\item Emma M. Bonniwell (14267047), Rana Alabdali (22241286), Joseph J. Hennessey (22241289), John L. McKee (22179170), Natalie G. Cavalco (20388684), Josie C. Lammers (22241292), Ethan J. Moore (22241295), Luca Franchini (10578054), Cesare Orlandi (204175), John D. McCorvy (1416910) (2025). \textit{Serotonin 5-HT2C Receptor SignalingAnalysis Reveals Psychedelic Biased Agonism}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.5c00647.s001}{doi:10.1021/acschemneuro.5c00647.s001}.
\item Bonniwell EM, Alabdali R, Hennessey JJ, McKee JL, Cavalco NG, Lammers JC, Moore EJ, Franchini L, Orlandi C, McCorvy JD. (2025). \textit{Serotonin 5-HT2C Receptor Signaling Analysis Reveals Psychedelic Biased Agonism.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.5c00647}{doi:10.1021/acschemneuro.5c00647}.
\item Ariane Bélanger, Sue-Ling Chang, Jean-François Stephan, Florence Moureaux, Diane Tapp, Robert Foxman, Pierre Gagnon, Johanne Hébert, Houman Farzin, Michel Dorval (2025). \textit{Supporting Meaningful Choices: A Decision Aid for Individuals Facing Existential Distress and Considering Psilocybin-Assisted Therapy}. Healthcare. [published; OpenAlex]. \href{https://doi.org/10.3390/healthcare13182290}{doi:10.3390/healthcare13182290}.
\item Tap SC, Thomas K, Páleníček T, Stenbæk DS, Oliveira-Maia AJ, van Dalfsen JH, Schoevers RA. (2025). \textit{Concomitant use of antidepressants and classic psychedelics: A scoping review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811251368360}{doi:10.1177/02698811251368360}.
\item Tereza Dleštíková (2025). \textit{The Legal Perspective on Psilocybin for Medical Use in Czechia: A Key Milestone and the Case for Broader Consideration Beyond the Clinical Setting}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030034}{doi:10.3390/psychoactives4030034}.
\item King's College London (2025). \textit{Measurement of Serum Cytokine Levels in Samples Collected as Part of a Clinical Trial of Psilocybin for Treatment-resistant Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT07164755}{source link}.
\item Rachel Yehuda (2025). \textit{Processing Intergenerational Trauma With Psilocybin-Assisted Therapy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06899165}{source link}.
\item Wong S, Meckling G, Fabiano N, Lee S, Jones BDM, Shorr R, Dargel A, Davis AK, Fiedorowicz JG, Solmi M, Rosenblat JD, Mulsant BH, Blumberger DM, Husain MI. (2025). \textit{Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/20451253251372449}{doi:10.1177/20451253251372449}.
\item Alan K. Davis, Meghan DellaCrosse, Nathan D. Sepeda, Adam W. Levin, Mary P Cosimano, Hillary Shaub, Washington Taylor, Peter M. Gooch, Shoval Gilead, Skylar J. Gaughan, Stacey B. Armstrong, Frederick S. Barrett (2025). \textit{Five-year outcomes of psilocybin-assisted therapy for Major Depressive Disorder}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00461}{doi:10.1556/2054.2025.00461}.
\item Aday JS, Carhart-Harris R, Boehnke KF. (2025). \textit{Blunted psychedelic drug effects in older adults}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/yz4cd\_v2}{doi:10.31234/osf.io/yz4cd\_v2}.
\item Unknown authors (2025). \textit{Blunted psychedelic drug effects in older adults}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/yz4cd\_v2}{source link}.
\item Andrade FRT, Buchborn T, Thalheimer G, Meinhardt MW, Joca S, de Almeida RMM. (2025). \textit{Therapeutic Use of Psilocybin in Depression: a Systematic Review of Clinical Evidence.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/neu.2025.10039}{doi:10.1017/neu.2025.10039}.
\item Georgios Mikellides, Marios Kyriazis (2025). \textit{Psychedelics and mental health: reimagining care through science, insight, and compassion}. Frontiers in Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.3389/fphar.2025.1649929}{doi:10.3389/fphar.2025.1649929}.
\item Gregor Hasler (2025). \textit{Gregor Hasler: Three Guiding Questions - How do psychedelics shape the brain? How can they heal psychiatric disorders such as depression and PTSD? How can we ensure their safe and responsible use?}. Psychedelics.. [published; OpenAlex]. \href{https://doi.org/10.61373/pp025k.0032}{doi:10.61373/pp025k.0032}.
\item Kerem Kemal Soylemez, Emma Marie de Boo, Aysil Susuzlu, Joanne Lusher (2025). \textit{Neuroplasticity and Neuro-Generation: The Promise of Psychedelics in Dementia Care}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030031}{doi:10.3390/psychoactives4030031}.
\item M Mercier, Cédric Mabilais, Vasileios Chytas, Leonice Furtado, Federico Seragnoli, Albert Buchard, Tatiana Aboulafia Brakha, Gabriel Thorens, Daniele Zullino, Louise Penzenstadler (2025). \textit{Psilocybin-Assisted Psychotherapy for Chronic Somatoform Pain Disorder: A Case Report}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030030}{doi:10.3390/psychoactives4030030}.
\item David Nutt, David Erritzøe, Anne Katrin Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, Matthew X. Lowe, Oliver Davis, Plinio Ferreira, Rayyan Zafar, Robin Carhart-Harris, Tadeusz Hawrot, Joanna C. Neill (2025). \textit{A lexicon for psychedelic research and treatment}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245251380511}{doi:10.1177/20503245251380511}.
\item Sally Meikle, Olivia Carter, Paul Liknaitzky, Lauren Johansen, Ravi Iyer, Nigel Strauss, M.L. Williams, David Castle, Susan L. Rossell (2025). \textit{Psilocybin with psychotherapeutic support for treatment-resistant depression: a pilot clinical trial}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253251377187}{doi:10.1177/20451253251377187}.
\item Juan Carlos C. Montoy, Ralph C. Wang, Allison R. Coker, Craig G. Smollin, B. Anderson (2025). \textit{US Poison Center Encounters for Psilocybin-Related Exposures: 2013-2022}. Journal of the American College of Emergency Physicians Open. [published; OpenAlex]. \href{https://doi.org/10.1016/j.acepjo.2025.100231}{doi:10.1016/j.acepjo.2025.100231}.
\item Anton L.V. Avanceña, Linh N. Vuong, James G. Kahn, Elliot Marseille (2025). \textit{Psilocybin-assisted therapy for treatment-resistant depression in the US: a model-based cost-effectiveness analysis}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-025-03556-4}{doi:10.1038/s41398-025-03556-4}.
\item Niall M. McGowan, James Rucker, Rachel Yehuda, Manish Agrawal, Nadav Liam Modlin, Hollie Simmons, Agata Tofil-Kaluza, Shriya Das, Guy M. Goodwin (2025). \textit{Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251362390}{doi:10.1177/02698811251362390}.
\item Nathan Brashares Sackett (2025). \textit{A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06853912}{source link}.
\item Samir A Nader (2025). \textit{Psychedelic minimalism: the case against music in psychedelic therapy settings}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1652568}{doi:10.3389/fpsyt.2025.1652568}.
\item Elise C. Tarbi, Skye A. Miner, Kabir Nigam, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Kimberly Roddy, James A. Tulsky, Manish Agrawal, Yvan Beaussant (2025). \textit{“To Have the Encounter with Our Own Finiteness in that Existential Way”: Descriptions of Existential Experience in Patients with Cancer and Major Depression Participating in Psilocybin-Assisted Group Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/28314425251370303}{doi:10.1177/28314425251370303}.
\item Bilenker D, Avena NM. (2025). \textit{Psychedelics and the Serotonin Hypothesis of Eating Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/brainsci15080893}{doi:10.3390/brainsci15080893}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression: a Pilot Clinical Neuroimaging Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06650800}{source link}.
\item Koenig HG. (2025). \textit{Psilocybin-assisted psychotherapy, combined antipsychotic and antidepressant treatment for bipolar depression, duration of birth control pill use and risk of depression, handgrip strength and cognitive function, mood disorders in epilepsy, and mental health issues among physicians.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/00912174251369880}{doi:10.1177/00912174251369880}.
\item COMPASS Pathways (2025). \textit{A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05733546}{source link}.
\item Schuman HD, Deleemans JM, Nguyen T, Savard C, Mina R, Carlson LE. (2025). \textit{Attitudes Toward Psychedelic-Assisted Therapies for Cancer-Related Psychosocial Symptoms: A Multi- Stakeholder Analysis}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-6941009/v1}{doi:10.21203/rs.3.rs-6941009/v1}.
\item Li Y, Li H, Wang H, Wang X. (2025). \textit{Exploring the therapeutic potential of psychedelics in treating substance use disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-025-03168-w}{doi:10.1038/s41380-025-03168-w}.
\item Singleton SP, Sevchik BL, Lahey A, Cuijpers P, Harrer M, Jones MT, Nayak SM, Strain EC, Vandekar SN, Dworkin RH, Scott JC, Satterthwaite TD. (2025). \textit{Psilocybin treatment for symptoms of depression: a living systematic review, meta-analysis, and data resource}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2025.08.13.25333530}{doi:10.1101/2025.08.13.25333530}.
\item Kargbo RB. (2025). \textit{Therapeutic Divergence in 5-HT2A Agonism: Psilocybin and Phenalkylamines for Demoralization Syndrome.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsmedchemlett.5c00475}{doi:10.1021/acsmedchemlett.5c00475}.
\item Nadav Liam Modlin, Jessica L. Maples-Keller, Maria Sarang, Lucie Siebenaler, Carolina Maggio, Susannah Pick, Victoria Williamson, Anthony J. Cleare, James Rucker (2025). \textit{Perspectives on Trauma Treatment, Self-Management Strategies, and Attitudes Toward Psychedelic Therapies in Individuals with Psychological Trauma Symptoms}. Psychiatry and Clinical Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.5152/pcp.2025.24934}{doi:10.5152/pcp.2025.24934}.
\item Margaret Ross, Ravi Iyer, M.L. Williams, Mark Boughey, Clare O’Callaghan, Richard Hiscock, Justin Dwyer (2025). \textit{Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial}. General Hospital Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.genhosppsych.2025.08.001}{doi:10.1016/j.genhosppsych.2025.08.001}.
\item Silczuk A, Madejek RJ, Koweszko T, Mularczyk-Tomczewska P, Adamska E, Gujski M, Szulc A. (2025). \textit{Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.12659/msm.948302}{doi:10.12659/msm.948302}.
\item Im JJH, Sandoe CH (2025). \textit{Psychedelics and Headache Disorders: an Update.}. Current neurology and neuroscience reports. [published; PubMed]. \href{https://doi.org/10.1007/s11910-025-01446-2}{doi:10.1007/s11910-025-01446-2}.
\item Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC. (2025). \textit{Between enhancement and risk: A critical review of psychedelic microdosing.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.copsyc.2025.102129}{doi:10.1016/j.copsyc.2025.102129}.
\item Dotun Adeleye Adeyinka, Dayna Forsyth, Suzanne Currie, Nicoletta Faraone (2025). \textit{Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models}. Frontiers in Systems Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.3389/fnsys.2025.1585367}{doi:10.3389/fnsys.2025.1585367}.
\item Bernard Lerer, Peretz Golding, Michal Brownstien, Adam Kozikowski, Tzuri Lifschytz (2025). \textit{204. A NOVEL, NON-HALLUCINOGENIC PSYCHEDELIC FOR THE TREATMENT OF OCD AND TIC DISORDER}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.019}{doi:10.1093/ijnp/pyaf052.019}.
\item Hiroe Tani (2025). \textit{577. CLINICAL EVIDENCE AND APPLICATIONS OF PSYCHEDELICS FOR MENTAL ILLNESSES}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.377}{doi:10.1093/ijnp/pyaf052.377}.
\item Guy M. Goodwin (2025). \textit{670. CAN WE RE-MEDICALISE THE PSYCHEDELIC EXPERIENCE?}. The International Journal of Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1093/ijnp/pyaf052.159}{doi:10.1093/ijnp/pyaf052.159}.
\item Unknown authors (2025). \textit{631. PSILOCYBIN AND KETANSERIN VS RTMS IN TREATMENT-RESISTANT DEPRESSION: ENHANCING TOLERABILITY BY MITIGATING PSYCHEDELIC EFFECTS}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC12359594}{source link}.
\item Sulstarova A, Scheuerlein L, Monari S, Seragnoli F, Gabriel T, Preller K, Böge K, Sentissi O, Kaiser S, Solmi M, Kirschner M, Sabé M (2025). \textit{Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.}. Asian journal of psychiatry. [published; PubMed]. \href{https://doi.org/10.1016/j.ajp.2025.104604}{doi:10.1016/j.ajp.2025.104604}.
\item Bevione F, Lacidogna MC, Lavalle R, Abbate Daga G, Preti A. (2025). \textit{Psilocybin in the treatment of eating disorders: a systematic review of the literature and registered clinical trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40519-025-01771-y}{doi:10.1007/s40519-025-01771-y}.
\item Amandine Luquiens, Dahbia Belahda, Carine Graux, Noe Igounenc, Chris Serrand, Paul A. Rochefort, Thibault Mura, Felix Sergent (2025). \textit{Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.70152}{doi:10.1111/add.70152}.
\item Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz, Miguel A. Bedoya-Pérez, Anastasia Suraev, Natasha Sommer, Kayla Greenstien, Sarah Maguire, Iain S. McGregor (2025). \textit{Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey}. Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1186/s40337-025-01328-5}{doi:10.1186/s40337-025-01328-5}.
\item Emory University (2025). \textit{The Safety, Feasibility, and Acceptability of Psilocybin Combined With Multidisciplinary Palliative Care in Demoralized Cancer Survivors With Chronic Pain (P-PC)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05506982}{source link}.
\item Patricia A. Cioe, Garrett S Stang, Danish Azam, Sarah Dugal (2025). \textit{“I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke}. Addiction Science \& Clinical Practice. [published; OpenAlex]. \href{https://doi.org/10.1186/s13722-025-00563-0}{doi:10.1186/s13722-025-00563-0}.
\item The University of Texas Health Science Center, Houston (2025). \textit{Acceptability \& Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06706232}{source link}.
\item Ashutosh Bhave (2025). \textit{Rise of the Mushrooms: Effects of Psilocybin Reforms on Psychedelic Usage Patterns}. Journal of Public Policy \& Marketing. [published; OpenAlex]. \href{https://doi.org/10.1177/07439156251360774}{doi:10.1177/07439156251360774}.
\item Katherine Cheung, Caleigh Propes, Marianna Graziosi, Kyle Patch, David B. Yaden (2025). \textit{Informed Consent Documents from Psychedelic Clinical Trials: A Descriptive Ethical Analysis}. AJOB Empirical Bioethics. [published; OpenAlex]. \href{https://doi.org/10.1080/23294515.2025.2526339}{doi:10.1080/23294515.2025.2526339}.
\item Zohaib Nadeem, Stephen Parker, Hugh McGovern, Bianca Sebben, Lena Oestreich (2025). \textit{Attitudes toward psychedelics and psychedelic-assisted psychotherapy among Australian mental healthcare providers}. Australian \& New Zealand Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/00048674251346679}{doi:10.1177/00048674251346679}.
\item Plummer Z, Allen J, Brand J, Mayo LM, Shultz SR, Christie BR. (2025). \textit{Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111448}{doi:10.1016/j.pnpbp.2025.111448}.
\item Damian Świeczkowski, Aleksander Kwaśny, Patrycja Ciurkowska, Michał Pruc, Łukasz Szarpak, Wiesław Jerzy Cubała (2025). \textit{Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811251353250}{doi:10.1177/02698811251353250}.
\item Glenn DL, Choi SH, Zimmerman RS. (2025). \textit{A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811251353251}{doi:10.1177/02698811251353251}.
\item Miyuan Zhang (21677016), Haojiang Zhai (21677019), Longwei Yang (21677022), Haohong Li (5164970), Xiaohui Wang (19899) (2025). \textit{The Medial PrefrontalCortex Modulates Psychedelic-likeEffects of Psilocin}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00324.s001}{doi:10.1021/acsptsci.5c00324.s001}.
\item Miyuan Zhang, Haiyan Zhai, Longwei Yang, Haohong Li, Xiaohui Wang (2025). \textit{The Medial Prefrontal Cortex Modulates Psychedelic-like Effects of Psilocin}. ACS Pharmacology \& Translational Science. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.5c00324}{doi:10.1021/acsptsci.5c00324}.
\item Szigeti B. (2025). \textit{An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/97cqx\_v1}{doi:10.31234/osf.io/97cqx\_v1}.
\item Unknown authors (2025). \textit{An open-label, dose-escalation trial of psilocybin-assisted therapy for bipolar 2 depression}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/97cqx\_v1}{source link}.
\item Yutong Song (2025). \textit{Explore the effect of psilocybin on depression and anxiety}. Arts Culture and Language. [published; OpenAlex]. \href{https://doi.org/10.61173/rcg8me57}{doi:10.61173/rcg8me57}.
\item Khalid Ahmed, Dima Abu Nasrieh, Haneen A. Banihani, Mohammed Fadi Obaidat, Toni Mazzawi, Azzah Khalid Al-Tarawneh, Radwan Bani Mustafa, Zaid Al Kayed (2025). \textit{Exploring Jordanian Physicians’ and Medical Students’ Perspectives on Ketamine and Psychedelic-Assisted Therapies: An Insight from the Middle East}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2526403}{doi:10.1080/02791072.2025.2526403}.
\item Mark Haden, Sarah A. Paschall, Birgitta Woods (2025). \textit{Beyond prohibition: A public health analysis of naturalistic psychedelic use}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00450}{doi:10.1556/2054.2025.00450}.
\item David W. Lawrence, Alex P. Di Battista, Michael G. Hutchison (2025). \textit{Psilocybin Use in an Intercollegiate Athlete with Persisting Symptoms After Concussion: A Case Report}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4030022}{doi:10.3390/psychoactives4030022}.
\item Atiq MA, Baker MR, Voort JLV, Vargas MV, Choi DS (2025). \textit{Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06599-5}{doi:10.1007/s00213-024-06599-5}.
\item Carrithers BM, Roberts DE, Weiss BM, King JD, Carhart-Harris RL, Gordon AR, Pagni BA, Moreau M, Ross S, Zeifman RJ (2025). \textit{Exploring serotonergic psychedelics as a treatment for personality disorders.}. Neuropharmacology. [published; PubMed]. \href{https://doi.org/10.1016/j.neuropharm.2025.110413}{doi:10.1016/j.neuropharm.2025.110413}.
\item Megan Calnan, Grace Blest-Hopley, Chris Busch, Milly Adams, Simon Ruffell, Theodore Piper, Leor Roseman, Hannes Kettner, Robin Carhart-Harris (2025). \textit{Exploring the Therapeutic Effects of Psychedelics Administered to Military Veterans in Naturalistic Retreat Settings}. Brain and Behavior. [published; OpenAlex]. \href{https://doi.org/10.1002/brb3.70660}{doi:10.1002/brb3.70660}.
\item Samuel E Christen, Elias Bekka, Yasmin Schmid, Neal L. Benowitz, Evangelia Liakoni (2025). \textit{Caffeine, nicotine, cannabis, and psilocybin: Pharmacology, toxicology, and potential therapeutic uses of four naturally occurring psychoactive substances}. Swiss Medical Weekly. [published; OpenAlex]. \href{https://doi.org/10.57187/s.4346}{doi:10.57187/s.4346}.
\item Ciszowski K, Ziaja A, Niedzielska-Andres E, Pomierny-Chamioło L. (2025). \textit{Natural hallucinogens of fungal and animal origin: action and potentialapplications - a narrative review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.24425/fmc.2025.156119}{doi:10.24425/fmc.2025.156119}.
\item Schuman HDM, Savard C, Mina R, Barkova S, Conradi HSW, Deleemans JM, Carlson LE. (2025). \textit{Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/curroncol32070380}{doi:10.3390/curroncol32070380}.
\item Nayiri Barton (2025). \textit{Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease}. Global Journal of Medical Research. [published; OpenAlex]. \href{https://doi.org/10.34257/gjmravol25is1pg1}{doi:10.34257/gjmravol25is1pg1}.
\item Adam Bayes (2025). \textit{Australia’s psychedelic experiment: reflections from a psychiatrist clinical researcher}. Australasian Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/10398562251347890}{doi:10.1177/10398562251347890}.
\item Vinarcsik L, Smoller C, Grossberg G. (2025). \textit{Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40266-025-01221-5}{doi:10.1007/s40266-025-01221-5}.
\item Martijn H.B. Koolen, Annika Wirsching, Erwin Krediet, Michiel van Elk (2025). \textit{Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2508156}{doi:10.1080/02791072.2025.2508156}.
\item Daroui D, Mastrostefano A, Davini F, Giuseppe G, Terracina S. (2025). \textit{The Emerging Use of Psilocybin in Adult Populations with Alcohol Use Disorder: A Scoping Review}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202506.1536.v1}{doi:10.20944/preprints202506.1536.v1}.
\item Manish Agrawal, Kim Roddy, Betsy Jenkins, Celia Leeks, Ezekiel Emanuel (2025). \textit{Long-term benefits of single-dose psilocybin in depressed patients with cancer}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35889}{doi:10.1002/cncr.35889}.
\item Ines Erkizia-Santamaría, Igor Horrillo, Nerea Martínez-Álvarez, Daniel Pérez-Martínez, Guadalupe Rivero, Amaia M. Erdozain, J. Javier Meana, Jorge E. Ortega (2025). \textit{Evaluation of behavioural and neurochemical effects of psilocybin in mice subjected to chronic unpredictable mild stress}. Translational Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1038/s41398-025-03421-4}{doi:10.1038/s41398-025-03421-4}.
\item COMPASS Pathways (2025). \textit{The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05312151}{source link}.
\item MycoMedica Life Sciences PBC (2025). \textit{A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06643637}{source link}.
\item Agin-Liebes G, Petridis P, Zeifman R, Link M, Cordova MJ, Bogenschutz M. (2025). \textit{Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/f27jm\_v1}{doi:10.31234/osf.io/f27jm\_v1}.
\item University of California, San Francisco (2025). \textit{Comparison of the Effects of PEX20 (Oral Psilocin), PEX30 (Sublingual Psilocin), and PEX10 (Oral Psilocybin) in Healthy Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05317689}{source link}.
\item Unknown authors (2025). \textit{Psilocybin-Assisted Therapy Increases Self-Compassion in Patients with Alcohol Use Disorder}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/f27jm\_v1}{source link}.
\item Modlin NL, Williamson V, Maggio C, Stubley J, Kirlic N, Cleare A, Rucker J. (2025). \textit{Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/20451253251342319}{doi:10.1177/20451253251342319}.
\item Czopek A, Jończyk J, Fryc M, Kluzik D, Zagórska A. (2025). \textit{Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.5c00152}{doi:10.1021/acschemneuro.5c00152}.
\item Matthew Hicks (2025). \textit{Low-Income Group Psilocybin Assisted Therapy for Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06372197}{source link}.
\item National University of Natural Medicine (2025). \textit{Optimizing Microdosing and Meditation}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06560658}{source link}.
\item Brian M. Ross (2025). \textit{Leveraging psychedelic neuroscience to boost human creativity using artificial intelligence}. Frontiers in Artificial Intelligence. [published; OpenAlex]. \href{https://doi.org/10.3389/frai.2025.1589086}{doi:10.3389/frai.2025.1589086}.
\item Abigail M. Blanton, Pooja Parikh, Scott Zhou, Mohamed Mohamed, Rafael Ufret-Vincenty, Ronald Mancini (2025). \textit{Self-inflicted transorbital intracranial foreign body following ingestion of hallucinogenic psilocybin mushrooms}. American Journal of Ophthalmology Case Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.ajoc.2025.102359}{doi:10.1016/j.ajoc.2025.102359}.
\item Weleff J, Pulido-Saavedra A, Aghaei AM, Ing K, Arakelian M, Fontenele R, Nero N, Barnett BS, Anand A, Bassir Nia A, Angarita GA (2025). \textit{The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2025.116446}{doi:10.1016/j.psychres.2025.116446}.
\item Klim C, VanDreese B, Meyerhoefer T, Breitinger S (2025). \textit{Innovation and inequity in psychedelic research at the Mayo Clinic.}. History of psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/0957154x251318489}{doi:10.1177/0957154x251318489}.
\item Sara Prostko, Alexander Wu, Samuel Maddams, Veronica Szpak, Naomi Rosenblum, Lori M. Hilt, Joji Suzuki (2025). \textit{Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study}. Journal of Addiction Medicine. [published; OpenAlex]. \href{https://doi.org/10.1097/adm.0000000000001517}{doi:10.1097/adm.0000000000001517}.
\item Stéphanie Knatz Peck, Timothy D. Brewerton, Hannah M. Fisher, Julie Trim, Samantha Shao, Nadav Liam Modlin, Jessie Kim, Daphna M. Finn, Walter H. Kaye (2025). \textit{Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa}. Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1186/s40337-025-01274-2}{doi:10.1186/s40337-025-01274-2}.
\item Vogt SB, Liechti ME. (2025). \textit{Clinical pharmacology.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.02.003}{doi:10.1016/bs.irn.2025.02.003}.
\item Swieczkowski D, Kwaśny A, Sadko K, Pruc M, Gaca Z, Szarpak L, Cubała WJ. (2025). \textit{Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2025.116559}{doi:10.1016/j.psychres.2025.116559}.
\item Basedow LA, Lottes L, Falkenberg I, Vogelbacher C, Yildiz C. (2025). \textit{Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/6hjkm\_v1}{doi:10.31234/osf.io/6hjkm\_v1}.
\item Unknown authors (2025). \textit{Under Pressure: Stronger depressive symptoms are associated with more positive expectations towards experimental treatments}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/6hjkm\_v1}{source link}.
\item Roland R. Griffiths, Robert L. Jesse, William A. Richards, Matthew W. Johnson, Nathan D. Sepeda, Anthony P. Bossis, Stephen Ross (2025). \textit{Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0044}{doi:10.1089/psymed.2023.0044}.
\item Wingert AM, Agnorelli C, Peill J, Reed S, Nutt DJ, Erritzoe D. (2025). \textit{Serotonergic psychedelics for depression: A comprehensive overview.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.04.009}{doi:10.1016/bs.irn.2025.04.009}.
\item Morris R, Keeler J, Treasure J, Himmerich H. (2025). \textit{The pharmacological treatment of anxiety in people with eating disorders: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.phrs.2025.107782}{doi:10.1016/j.phrs.2025.107782}.
\item Queen's University (2025). \textit{A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06969170}{source link}.
\item Syed OA, Petranker R, Tsang B. (2025). \textit{The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2025.106204}{doi:10.1016/j.neubiorev.2025.106204}.
\item Kratina S, Strike C, Schwartz R, Nayfeh A, Jopling S, Lo C, Rush B. (2025). \textit{A protocol for a scoping review of variations among psychedelic interventions for psychological suffering associated with the end-of-life.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0318343}{doi:10.1371/journal.pone.0318343}.
\item Logan Neitzke-Spruill, Caroline Beit, Jill O. Robinson, Nikita Singh, Srijith Kambala, Rishi Ramesh, Amy L. McGuire (2025). \textit{A landscape analysis of psychedelic retreat organizations advertising online}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0321648}{doi:10.1371/journal.pone.0321648}.
\item Kim Hoffman, Todd P. Korthuis, Kellie Pertl, David Morgan (2025). \textit{Improving Best Practice Indicators for Psilocybin Assisted Therapy Using a Mul-tiphase Mixed Methods Delphi Study}. International Journal of Multiple Research Approaches. [published; OpenAlex]. \href{https://doi.org/10.29034/ijmra.v17n1a1}{doi:10.29034/ijmra.v17n1a1}.
\item Unknown authors (2025). \textit{Psilocybin-assisted therapy shows range of benefits in cancer patients}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31316}{doi:10.1002/pu.31316}.
\item Centre for Addiction and Mental Health (2025). \textit{Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06518720}{source link}.
\item Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, Zuzanna Gaca, Łukasz Szarpak, Wiesław Jerzy Cubała (2025). \textit{Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis}. The International Journal of Psychiatry in Medicine. [published; OpenAlex]. \href{https://doi.org/10.1177/00912174251337572}{doi:10.1177/00912174251337572}.
\item Louise Penzenstadler, Sandra Baudois, Alma Lingenberg, Sabina Catalano Chiuvé, Emilie Tomkova, Vanessa Fleury (2025). \textit{[Treatment with psychedelics: potential benefits in Parkinson's disease].}. PubMed. [published; OpenAlex]. \href{https://doi.org/10.53738/revmed.2025.21.915.47180}{doi:10.53738/revmed.2025.21.915.47180}.
\item Borgogna NC, Owen T, Petrovitch D, Vaughn J, Johnson DAL, Pagano LA, Aita SL, Hill BD. (2025). \textit{Incremental efficacy systematic review and meta-analysis of psilocybin-for-depression RCTs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-025-06788-w}{doi:10.1007/s00213-025-06788-w}.
\item Lapid MI, Pagali SR, Randall AL, Donovan KA, Bronars CA, Gauthier TA, Bock J, Lim SD, Carey EC, Sokolowski E, Ulrich AM, Hassett LC, Kung S, Whitford KJ, Olivier KR, D'Andre SD. (2025). \textit{Evaluating the effectiveness of psilocybin in alleviating distress among cancer patients: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s147895152500032x}{doi:10.1017/s147895152500032x}.
\item Falchi-Carvalho M, Palhano-Fontes F, Wießner I, Barros H, Bolcont R, Laborde S, Ruschi B Silva S, Montanini D, C Barbosa D, Teixeira E, Florence-Vilela R, Almeida R, K A de Macedo R, Arichelle F, J Pantrigo É, V Costa-Macedo J, da Cruz Nunes JA, de Araújo Costa Neto LA, Nunes Ferreira LF, Dantas Corrêa L, da Costa Bezerra RB, Arcoverde E, Galvão-Coelho N, B Araujo D. (2025). \textit{Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41386-025-02091-6}{doi:10.1038/s41386-025-02091-6}.
\item DuPont CM, Johnson MW. (2025). \textit{Psychedelics and substance use disorder treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.03.005}{doi:10.1016/bs.irn.2025.03.005}.
\item Mimms C, Sotelo K, Khaliq AS. (2025). \textit{Comparative Efficacy and Functional Outcomes of Psychedelic-Assisted Therapies in Treatment-Resistant Depression: A Systematic Review of Recent Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.82532}{doi:10.7759/cureus.82532}.
\item Michel Dorval, Sue-Ling Chang, Houman Farzin, Olivia Nguyen, Jean-François Stephan, Diane Tapp, P. Deschamps, Yann Joly, Florence Moureaux, Robert Foxman, Marianne Masse-Grenier, Jean-Sébastien Fallu (2025). \textit{Roadmap for Equitable Access and Responsible Use of Psilocybin-Assisted Psychotherapy in Palliative Care}. Palliative Medicine Reports. [published; OpenAlex]. \href{https://doi.org/10.1089/pmr.2024.0108}{doi:10.1089/pmr.2024.0108}.
\item Damian Świeczkowski, Aleksander Kwaśny, Michał Pruc, Zuzanna Gaca, Łukasz Szarpak, Wiesław Jerzy Cubała (2025). \textit{Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis}. Pharmacopsychiatry. [published; OpenAlex]. \href{https://doi.org/10.1055/a-2529-7029}{doi:10.1055/a-2529-7029}.
\item Kevin Boehnke (2025). \textit{A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Psilocybin Administration in Concert With Psychotherapy Among Adult Patients With Fibromyalgia}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05128162}{source link}.
\item Meshkat S, Malik G, Zeifman RJ, Swainson J, Balachandra K, Reichelt AC, Zhang Y, Burback L, Winkler O, Greenshaw A, Vermetten E, Mayo LM, Tanguay R, Jetly R, Bhat V. (2025). \textit{Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2025.106163}{doi:10.1016/j.neubiorev.2025.106163}.
\item Felix Mueller (2025). \textit{The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05570708}{source link}.
\item Effinger DP, Schalk SS, King JL, Strong JR, O’Connell CK, Calderon JR, McCorvy JD, Thompson SM. (2025). \textit{Assessing the potential cardiovascular risk of microdosing the psychedelic LSD in mice}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.04.08.647757}{doi:10.1101/2025.04.08.647757}.
\item Danielle Bukovsky, Aron Amaev, Jianmeng Song, Edgardo Torres Carmona, S. Lauren Kyte, Fumihiko Ueno, Vincenzo De Luca, Christopher R. Bowie, Alastair J. Flint, Muhammad Ishrat Husain, Ariel Graff-Guerrero, Philip Gerretsen (2025). \textit{13. Safety, Feasibility, and Tolerability of Psilocybin in Older Adults With Amnestic MCI: Preliminary Data From a SV2a PET Imaging Study}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2025.02.250}{doi:10.1016/j.biopsych.2025.02.250}.
\item Omidian H, Omidian A. (2025). \textit{The Emergence of Psilocybin in Psychiatry and Neuroscience.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph18040555}{doi:10.3390/ph18040555}.
\item Ellen Bradley, Kimberly Sakai, Gisele Fernandes-Osterhold, Balázs Szigeti, Connie Ludwig, Jill L. Ostrem, Caroline M. Tanner, Meredith Bock, Katiah Llerena, Patrick R. Finley, Aoife O’Donovan, José Rafael P. Zuzuárregui, Zachary Busby, Amber McKernan, Andrew Penn, Aliss C.C. Wang, Raymond C. Rosen, Joshua Woolley (2025). \textit{Psilocybin therapy for mood dysfunction in Parkinson’s disease: an open-label pilot trial}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-025-02097-0}{doi:10.1038/s41386-025-02097-0}.
\item Jennifer Jones (2025). \textit{Harnessing neuroplasticity with psychoplastogens: the essential role of psychotherapy in psychedelic treatment optimization}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2025.1565852}{doi:10.3389/fpsyt.2025.1565852}.
\item Totomanova I, Haijen ECHM, Hurks PPM, Ramaekers JG, Kuypers KPC. (2025). \textit{Potential therapeutic effects of psychedelics in small doses: Is there a role for microdosing in psychiatry?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/bs.irn.2025.03.002}{doi:10.1016/bs.irn.2025.03.002}.
\item Ioana A. Cristea, G Tomei, Jazmín Freddi, A. Bonessio (2025). \textit{Selective outcome reporting and non-reporting in trials of psychedelic drugs for mental disorders}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2025.393}{doi:10.1192/j.eurpsy.2025.393}.
\item A. Oliveira-Maia (2025). \textit{Reporting of psychotherapeutic methods in psychedelic treatments: on the road to ethical, professional and regulatory oversight}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2025.64}{doi:10.1192/j.eurpsy.2025.64}.
\item Miller M, Meyers M, Martin A, Napolitano S, Dorsen C, Penn A, Rosa WE (2025). \textit{A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.}. Journal of hospice and palliative nursing: JHPN: the official journal of the Hospice and Palliative Nurses Association. [published; PubMed]. \href{https://doi.org/10.1097/njh.0000000000001113}{doi:10.1097/njh.0000000000001113}.
\item Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum, Margaret Ross, Renee Harvey, Susan L. Rossell, Jerome Sarris, Daniel Perkins, Rachel Ε. Neale, James Bennett-Levy, Shevaugn Johnson, Hanna Beebe, Natalie Roset, Jörg Strobel, Stephen Parker (2025). \textit{Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement}. BMJ Open. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjopen-2024-095992}{doi:10.1136/bmjopen-2024-095992}.
\item Unity Health Toronto (2025). \textit{Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06731335}{source link}.
\item Unknown authors (2025). \textit{Psilocybin-assisted therapy leads to personality shifts in patients with alcohol use disorder}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31300}{doi:10.1002/pu.31300}.
\item M. Cirillo (2025). \textit{Current U.S. Approaches to Studying Psychedelic Medicines Compared to Psychedelics Use Among Indigenous Groups: What Are We Missing?}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678251321040}{doi:10.1177/00221678251321040}.
\item McMaster University (2025). \textit{An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06225232}{source link}.
\item Centre Hospitalier Universitaire de Nīmes (2025). \textit{Psilocybin in Alcohol Use Disorder With Comorbid Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06235411}{source link}.
\item Dino F. (2025). \textit{A Modern Overview of the Potential Therapeutic Effects of Psilocybin in the Treatment of Depressive Disorders, Treatment-Resistant Depression, and End-of-Life Distress.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.80707}{doi:10.7759/cureus.80707}.
\item Eda Köşeli, Belle Buzzi, Torin Honaker, Yogesh Rakholia, Melissa J. Lewis, Maya Gaines-Smith, Alaina M. Jaster, Javier González-Maeso, M. Imad Damaj (2025). \textit{IUPHAR Article: Psilocybin induces long-lasting effects via 5-HT2A receptors in mouse models of chronic pain}. Pharmacological Research. [published; OpenAlex]. \href{https://doi.org/10.1016/j.phrs.2025.107699}{doi:10.1016/j.phrs.2025.107699}.
\item Repple J, Bayas M, Möser C, Kobayashi NF, Reif A. (2025). \textit{Current Evidence for the Role of Rapid-Acting Antidepressants in Bipolar Depression: A Perspective and Plan for Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.biopsych.2025.02.903}{doi:10.1016/j.biopsych.2025.02.903}.
\item Hu S, Lin C, Wang H, Wang X. (2025). \textit{Psychedelics and Eating Disorders: Exploring the Therapeutic Potential for Anorexia Nervosa and Beyond.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.5c00094}{doi:10.1021/acsptsci.5c00094}.
\item Lauren Wilseck, Preet Chatha, Lawrence Canale, Dhvanit Raval, Jeremy Weleff (2025). \textit{Psychedelics for Substance Use Disorders: Updates for the Psychiatric Trainee}. American Journal of Psychiatry Residents Journal. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp-rj.2025.200301}{doi:10.1176/appi.ajp-rj.2025.200301}.
\item Michał Orzechowski, Joanna Orzechowska, Paulina Fijałek, Jan Karczmarz, Aleksandra Paprocka, Marika Gutowska, Agnieszka Kosińska, Urszula Świrk, Wiktoria Belcarz, Katarzyna Kalinowska (2025). \textit{Risks of using psilocybin in treatment of treatment-resistant depression}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2025.79.58319}{doi:10.12775/jehs.2025.79.58319}.
\item University Hospital, Basel, Switzerland (2025). \textit{Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05523401}{source link}.
\item Josephine Yalovitser, jonah levine, Cole Zweber, Lauren Tien, Mallory Stultz, Henry Mitchell, Elizabeth Cote, Charles D. MacLean (2025). \textit{Vermont Primary Care Provider Perspectives on Psychedelics - A Cross-Sectional Study}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2025.2474246}{doi:10.1080/02791072.2025.2474246}.
\item Craig, Danny R, Blalock, Eric M. (2025). \textit{Could psilocin rescue chronic, stress-accelerated, transcriptional aging in brain?}. UKnowledge (University of Kentucky). [published; OpenAlex]. \href{https://uknowledge.uky.edu/jpns/vol2/iss1/1}{source link}.
\item Belitzky E, Ravani Carvalho LV, Taylor M, Ortiz CN, Baum L, Fiellin DA, Lustberg MB. (2025). \textit{Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/cam4.70586}{doi:10.1002/cam4.70586}.
\item Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P. (2025). \textit{Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/93x5h\_v3}{doi:10.31234/osf.io/93x5h\_v3}.
\item Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P. (2025). \textit{Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/93x5h\_v2}{doi:10.31234/osf.io/93x5h\_v2}.
\item Unknown authors (2025). \textit{Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/93x5h\_v3}{source link}.
\item Yaden DB, Graziosi M, Owen AM, Agin-Liebes G, Aaronson ST, Allen KE, Barrett FS, Bogenschutz MP, Carhart-Harris R, Ching THW, Cosimano MP, Danforth A, Davis AK, Garcia-Romeu A, Griffiths R, Grob CS, Gründer G, Gukasyan N, Heinzerling KG, Hendricks PS, Holze F, Horton DM, Johnson MW, Kelmendi B, Knatz Peck S, Koslowski M, Liechti ME, Mertens LJ, Moreno FA, Nayak SM, Nicholas CR, Preller KH, Rieser NM, Ross S, Sergi K, Sloshower J, Smigielski L, Stenbæk DS, Vollenweider FX, Weiss B, Wolff M, Yaden ME. (2025). \textit{A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2024.0019}{doi:10.1089/psymed.2024.0019}.
\item Silva F, Butlen-Ducuing F, Guizzaro L, Balabanov P. (2025). \textit{A review of psychedelics trials completed in depression, informed by European regulatory perspectives.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nsa.2025.105516}{doi:10.1016/j.nsa.2025.105516}.
\item Hitchins K, Reynolds J. (2025). \textit{The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/48yg7\_v2}{doi:10.31234/osf.io/48yg7\_v2}.
\item Unknown authors (2025). \textit{The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/48yg7\_v2}{source link}.
\item Hitchins K, Reynolds J. (2025). \textit{The Impact of Communicating the Benefits and Safety of Psilocybin on Policy Support: A Survey Based Experiment.}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/48yg7\_v1}{doi:10.31234/osf.io/48yg7\_v1}.
\item Meshkat S, Malik T, Zeifman R, Swainson J, Zhang Y, Burback L, Winkler O, Greenshaw AJ, Claire Reichelt A, Vermetten E, Erritzoe D, Jha MK, Dunn W, Jetly R, Husain MI, Bhat V. (2025). \textit{Psychedelics and Suicide-Related Outcomes: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/jcm14051416}{doi:10.3390/jcm14051416}.
\item Dave M, Shore R, Cupido T, Haley C, Clinkard D. (2025). \textit{Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/eja.0000000000002138}{doi:10.1097/eja.0000000000002138}.
\item Nicolas G. Glynos, Anne Baker, Jacob S. Aday, Daniel J. Kruger, Kevin F. Boehnke, Stephanie Lake, Philippe Lucas (2025). \textit{Psychedelics and chronic pain: self-reported outcomes on changed substance use patterns and health following naturalistic psychedelic use}. British Journal of Pain. [published; OpenAlex]. \href{https://doi.org/10.1177/20494637251319497}{doi:10.1177/20494637251319497}.
\item Bor Luen Tang (2025). \textit{Psychedelics for Moral Bioenhancement in Healthy Individuals-A Violation of the Non-Maleficence Principle?}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives4010005}{doi:10.3390/psychoactives4010005}.
\item Brengel EK, Axe B, Maheswari A, Abeer MI, Ortiz RJ, Woodward TJ, Walhof R, Utama R, Sawada C, Balaji S, Kulkarni PP, Bradshaw HB, Gitcho MA, Ferris CF. (2025). \textit{Psilocybin as a Treatment for Repetitive Mild Head Injury: Evidence from Neuroradiology and Molecular Biology}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.02.03.636248}{doi:10.1101/2025.02.03.636248}.
\item Shannon Hughes, Lucia Terpak, Reilly Capps, Pam Peters, Nicole Lilly, Dylan Rivard (2025). \textit{Psilocybin mushroom stewardship: A qualitative inquiry into practices and priorities of “underground” psilocybin mushroom practitioners}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2025.00375}{doi:10.1556/2054.2025.00375}.
\item Joseph A. Zamaria, Gisele Fernandes-Osterhold, Jonathan Shedler, Rachel Yehuda (2025). \textit{Psychedelics assisting therapy, or therapy assisting psychedelics? The importance of psychotherapy in psychedelic-assisted therapy}. Frontiers in Psychology. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyg.2025.1505894}{doi:10.3389/fpsyg.2025.1505894}.
\item Marazziti D, Weiss F, Gurrieri R, Russomanno G, Gambini M, Magnesa A, Coccoglioniti A, Perugi G (2025). \textit{Evaluating the value and risks of psychedelics for psychiatric medicine: a clinical perspective.}. Expert review of neurotherapeutics. [published; PubMed]. \href{https://doi.org/10.1080/14737175.2024.2445016}{doi:10.1080/14737175.2024.2445016}.
\item Eva Louie, Ellen Towers, Alyssa R. Morse, Joshua Watt, Zachary Bryant, Paul Haber, Kirsten C. Morley (2025). \textit{The Acceptability of Psychedelic-Assisted Therapy Amongst Mental Health Consumers: Utilising the Theory of Planned Behaviour}. International Journal of Mental Health Nursing. [published; OpenAlex]. \href{https://doi.org/10.1111/inm.70010}{doi:10.1111/inm.70010}.
\item Piper T, Small F, Brown S, Kelleher M, Mitcheson L, Rucker J, Young AH, Marsden J. (2025). \textit{Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/add.16762}{doi:10.1111/add.16762}.
\item Louis Plourde, Sue-Ling Chang, Houman Farzin, Jean-François Stephan, Jean-Sébastien Fallu, Michel Dorval (2025). \textit{Experiential dimension of psilocybin-assisted therapy training: Necessity or hindrance to wider accessibility?}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00431}{doi:10.1556/2054.2024.00431}.
\item Central Institute of Mental Health, Mannheim (2025). \textit{A Phase II Randomized, Double-blind, Active Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Psilocybin in Treatment-resistant Major Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04670081}{source link}.
\item Melani A, Bonaso M, Biso L, Zucchini B, Conversano C, Scarselli M. (2025). \textit{Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph18010130}{doi:10.3390/ph18010130}.
\item Shakila Meshkat, Richard J. Zeifman, Kathleen E. Stewart, Reinhard Janssen-Aguilar, Wendy Lou, Rakesh Jetly, Candice M. Monson, Venkat Bhat (2025). \textit{Psilocybin-assisted massed cognitive processing therapy for chronic posttraumatic stress disorder: Protocol for an open-label pilot feasibility trial}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0313741}{doi:10.1371/journal.pone.0313741}.
\item Henderson I, Elsaadany R, Chan G, Bajaj V, Duarte D, Goodman S, Grunstein M, Vadhan NP, Duarte RA. (2025). \textit{Exploring the Potential of Psychedelics in the Treatment of Headache Disorders: Clinical Considerations and Exploratory Insights.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11916-024-01321-8}{doi:10.1007/s11916-024-01321-8}.
\item Krawczyk N, Miller M, Gu EY, Irvine N, Ramirez E, Santaella-Tenorio J, Lippincott T, Bogenschutz M, Bunting AM, Meacham MC (2025). \textit{Self-reported experiences and perspectives on using psychedelics to manage opioid use among participants of two Reddit communities.}. Addiction (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1111/add.16767}{doi:10.1111/add.16767}.
\item Zylko A, Rakoczy R, Roberts B, Wilson M, Powell A, Page A, Heitkamp M, Fiest D, Jones J, McMurray M. (2025). \textit{Age- and estrous-dependent effects of psilocybin in rats}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2025.01.10.632408}{doi:10.1101/2025.01.10.632408}.
\item Valerie A. Canady (2025). \textit{Study finds encouraging results in psilocybin treatment for TRD patients}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.34292}{doi:10.1002/mhw.34292}.
\item Eduardo d’Avila Lins Lacerda, Bianca Medeiros Ferraz da Nóbrega, Yasmin Mesquita Dias Franca Gadelha, Liliane Reis Teixeira, Manolo Altieri Espinar, Bruna Trigueiro Carlini, Gabriel Santa Cruz Lins, Anthonielly Leinat Lima, Isabel Azevedo, Paulo Heinrich Soares Bomtempo (2025). \textit{PSYCHEDELICS IN THE TREATMENT OF MENTAL DISORDERS}. Health and Society. [published; OpenAlex]. \href{https://doi.org/10.51249/hs.v5i01.2377}{doi:10.51249/hs.v5i01.2377}.
\item Strand NH, Whitney M, Johnson B, Dunn T, Attanti S, Maloney J, Misra L, Gomez D, Viswanath O, Emami E, Leathem J. (2025). \textit{Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11916-024-01353-0}{doi:10.1007/s11916-024-01353-0}.
\item Erkizia-Santamaría I, Horrillo I, Meana JJ, Ortega JE. (2025). \textit{Clinical and preclinical evidence of psilocybin as antidepressant. A narrative review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2025.111249}{doi:10.1016/j.pnpbp.2025.111249}.
\item Sutherland I, Ho MF, Croarkin PE. (2025). \textit{Psychedelic Treatments in Adolescent Psychopharmacology: Considering Safety, Ethics, and Scientific Rigor.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/cap.2024.0082}{doi:10.1089/cap.2024.0082}.
\item Y. Tony Yang (2025). \textit{From Safe Touch to Sexual Abuse: Walking the Tightrope of Patient Safety in Psychedelic Therapy}. The American Journal of Bioethics. [published; OpenAlex]. \href{https://doi.org/10.1080/15265161.2024.2433418}{doi:10.1080/15265161.2024.2433418}.
\item Patricia A. Cioe, Garrett S Stang, Danish Azam, Sarah Dugal (2024). \textit{Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke}. Figshare. [published; OpenAlex]. \href{https://doi.org/10.6084/m9.figshare.29615217}{doi:10.6084/m9.figshare.29615217}.
\item Hancock, Mackenzie, Shambhu Prasad Adhikari, Getz, Nicole (2024). \textit{Psilocybin-Assisted Therapy for Trauma-Related Disorders: A Scoping Review of a Depression-Dominated Evidence Base with Implications for Intimate Partner Violence-Related PTSD}. Open Science Framework. [published; OpenAlex]. \href{https://doi.org/10.17605/osf.io/ar2s4}{doi:10.17605/osf.io/ar2s4}.
\item Henrique Tofoli Vieira Machado, GEOVANA MENDES DE SEIXAS, L. Silva, Mariana Duarte Garcia Brito, Gabriella Assink de Castro (2024). \textit{Alternative therapy for neurological and psychiatric disorders using psilocybin}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.5327/1516-3180.cpn.1123}{doi:10.5327/1516-3180.cpn.1123}.
\item Andreia Machado Brito da Costa, Ricardo Jorge Dinis-Oliveira, Áurea Madureira-Carvalho, Diana Dias-da-Silva (2024). \textit{Neurotoxic and Neuroprotective Effects of Psychedelics in a Human Neuroblastoma Cell Model}. RevSALUS - Revista Científica da Rede Académica das Ciências da Saúde da Lusofonia. [published; OpenAlex]. \href{https://doi.org/10.51126/revsalus.v7isup.1031}{doi:10.51126/revsalus.v7isup.1031}.
\item Joshua Woolley, MD, PhD (2024). \textit{Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04932434}{source link}.
\item Scott T. Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Trisha Suppes, Harold A. Sackeïm (2024). \textit{Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20231063}{doi:10.1176/appi.ajp.20231063}.
\item Broc A. Pagni, Richard J. Zeifman, Sarah E. Mennenga, Brennan M. Carrithers, Noam Goldway, Snehal Bhatt, Kelley C. O’Donnell, Stephen Ross, Michael P. Bogenschutz (2024). \textit{Multidimensional Personality Changes Following Psilocybin-Assisted Therapy in Patients With Alcohol Use Disorder: Results From a Double-Blind, Placebo-Controlled Clinical Trial}. American Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.ajp.20230887}{doi:10.1176/appi.ajp.20230887}.
\item Manzano-Nunez R, Gomez DA, Toledo-Mendoza C, Perez-Otero M, Matilla IL, Prats C, Perez-Lopez E, Pardo H, Díaz-Pellicer P, De La Torre-Fornell R, Aldea AM. (2024). \textit{Exploring Psychedelics Pharmacology: A Scoping Review Charting the Course of Psilocybin Pharmacokinetics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/wnf.0000000000000617}{doi:10.1097/wnf.0000000000000617}.
\item Lewis BR, Hendrick J, Byrne K, Odette M, Wu C, Garland EL. (2024). \textit{Psilocybin-Assisted Group Psychotherapy + Mindfulness Based Stress Reduction (MBSR) for Frontline Healthcare Provider COVID-19 Related Depression and Burnout: A Randomized Clinical Trial}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.12.31.24319806}{doi:10.1101/2024.12.31.24319806}.
\item D M Schuman H, Barkova S, Mina R, Deleemans JM, Nguyen T, Carlson LE (2024). \textit{"" A Qualitative Analysis of Patient Perspectives on Psychedelic-Assisted Therapy for Cancer-Related Psychosocial Symptoms.}. Integrative cancer therapies. [published; PubMed]. \href{https://doi.org/10.1177/15347354251370982}{doi:10.1177/15347354251370982}.
\item Katherine Cheung, Maxwell Brodie, Sue-Ling Chang, P. Deschamps, Jean-Sébastien Fallu, Houman Farzin, Johanne Hébert, Jean-François Stephan, Michel Dorval, Yann Joly, for the P3A Study Group (2024). \textit{Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns}. The Journal of Law Medicine \& Ethics. [published; OpenAlex]. \href{https://doi.org/10.1017/jme.2025.10109}{doi:10.1017/jme.2025.10109}.
\item Khalaud Naseeb Alhajry, Zahra Mohammed Sukairi, Hamidah Abdullah Lajami, Safiah Anber Bin Ali Ibrahim, Nawal Obaid Alanazi, Eman Ali Alsafwani, Ashwag Saad Hnif Albishi, Nada Naser Alomi, Zahrh Ahmed Ali Al-Hamadah, Anwar Mehdaf Akash Alrowaly (2024). \textit{Psychedelic-Assisted Therapy: The Emerging Role of the Psychiatric-Mental Health Nurse}. Saudi Journal of Medicine and Public Health. [published; OpenAlex]. \href{https://doi.org/10.64483/20251153}{doi:10.64483/20251153}.
\item Koning E, Chaves C, Kirkpatrick RH, Brietzke E. (2024). \textit{Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s40337-024-01185-8}{doi:10.1186/s40337-024-01185-8}.
\item Swieczkowski D, Kwaśny A, Pruc M, Gaca Z, Szarpak L, Cubała WJ. (2024). \textit{Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2024.116337}{doi:10.1016/j.psychres.2024.116337}.
\item Bakshi B, Yerraguntla S, Armon C, Barkhaus P, Bertorini T, Bowser R, Breevoort S, Bromberg M, Brown A, Carter GT, Chang V, Crayle J, Fullam T, Greene M, Heiman-Patterson T, Jackson C, Jhooty S, Mallon E, Cadavid JM, Mcdermott CJ, Pattee G, Pierce K, Ratner D, Sun Y, Wang O, Wicks P, Wiedau M, Bedlack R. (2024). \textit{ALSUntangled \#77: Psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/21678421.2024.2441274}{doi:10.1080/21678421.2024.2441274}.
\item Geller J, Whitney E. (2024). \textit{Therapeutic Potential of MDMA- and Psychedelic-Assisted Psychotherapy for Adolescent Depression and Trauma.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-024-01577-2}{doi:10.1007/s11920-024-01577-2}.
\item Miller M, Meyers M, Martin A, Napolitano S, Dorsen C, Penn A, Rosa WE. (2024). \textit{A Rapid Review of Psychedelic-Assisted Therapy in the Context of Palliative Care.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/njh.0000000000001096}{doi:10.1097/njh.0000000000001096}.
\item Croarkin PE, Sutherland I, Ho MF. (2024). \textit{Psychedelic Therapeutics for Adolescents: Ethics, Safety, Opportunities, and Equipoise.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jaac.2024.12.003}{doi:10.1016/j.jaac.2024.12.003}.
\item Ferreira AE, Reis-Pina P. (2024). \textit{Exploring the role of psychedelic-assisted therapy in enhancing spirituality and mystical experiences in patients with life-threatening illnesses: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpsychores.2024.112020}{doi:10.1016/j.jpsychores.2024.112020}.
\item Christina M. Andrews, Wayne Hall, Keith Humphreys, John Marsden (2024). \textit{Disentangling debate about therapeutic and recreational use of psychedelics}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16744}{doi:10.1111/add.16744}.
\item Freitas RR, Gotsis ES, Gallo AT, Fitzgibbon BM, Bailey NW, Fitzgerald PB. (2024). \textit{The safety of psilocybin-assisted psychotherapy: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/00048674241289024}{doi:10.1177/00048674241289024}.
\item Christopher L. Robinson, Pawan Solanki, S Snyder, Adam Amir, Antje M. Barreveld, Rory Vu Mather, Ivo H. Cerda, Michael Motoc, Harman Chopra, R. Jason Yong, Joel Castellanos, Timothy Furnish, Alan D. Kaye, Vwaire Orhurhu, Trent Emerick (2024). \textit{Chronic pain education: past, present, and future of psychedelics for the management of chronic pain}. Pain Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/pm/pnae124}{doi:10.1093/pm/pnae124}.
\item Scala M, Fabbri C, Fusar-Poli P, Di Lorenzo G, Ferrara M, Amerio A, Fusar-Poli L, Pichiecchio A, Asteggiano C, Menchetti M, De Ronchi D, MNESYS - Mood and Psychosis Sub-Project (Spoke 5), Fanelli G, Serretti A. (2024). \textit{The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s1092852924002268}{doi:10.1017/s1092852924002268}.
\item Marchi M, Farina R, Rachedi K, Laonigro F, Žuljević MF, Pingani L, Ferrari S, Somers M, Boks MPM, Galeazzi GM. (2024). \textit{Psychedelics as an intervention for psychological, existential distress in terminally ill patients: A systematic review and network meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811241303594}{doi:10.1177/02698811241303594}.
\item Seybert C, Schimmers N, Silva L, Breeksema JJ, Veraart J, Bessa BS, d'Orsi D, Schoevers RA, Oliveira-Maia AJ. (2024). \textit{Quality of reporting on psychological interventions in psychedelic treatments: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/s2215-0366(24)00333-x}{doi:10.1016/s2215-0366(24)00333-x}.
\item Jonathan Brett, Elizabeth Knock, Kathy Watson, Steven M. Albert, Krista J. Siefried, Jeffrey Guss (2024). \textit{Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1490907}{doi:10.3389/fpsyt.2024.1490907}.
\item COMPASS Pathways (2024). \textit{Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05481736}{source link}.
\item Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML. (2024). \textit{Synergistic, multi-level understanding of psychedelics: three systematic reviews and meta-analyses of their pharmacology, neuroimaging and phenomenology.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41398-024-03187-1}{doi:10.1038/s41398-024-03187-1}.
\item Terao I, Kodama W. (2024). \textit{Comparative antidepressant effects and safety of intravenous racemic ketamine, psilocybin and theta burst stimulation for major depressive disorder: A systematic review and network meta-analyses of randomized controlled trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/pcn5.70042}{doi:10.1002/pcn5.70042}.
\item Humphreys K, Todd Korthuis P, Stjepanović D, Hall W. (2024). \textit{Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1146/annurev-psych-020124-023532}{doi:10.1146/annurev-psych-020124-023532}.
\item Menon V, Ramamurthy P, Venu S, Andrade C. (2024). \textit{Randomized Controlled Trials of Psilocybin-Assisted Therapy in the Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/acps.13778}{doi:10.1111/acps.13778}.
\item Shabir Kanwal (2024). \textit{Psilocybin Microdosing for Anxiety Relief in Young Adults: A Comparative Review of Emerging Evidence}. Premier Journal of Science. [published; Crossref]. \href{https://doi.org/10.70389/pjs.100036}{doi:10.70389/pjs.100036}.
\item Piercey CJ, Gray B, Sung A, Henry D, Karoly HC. (2024). \textit{Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2023.0052}{doi:10.1089/psymed.2023.0052}.
\item Jitendra Kumar Sinha, Shampa Ghosh, Krishna Kumar Singh, M. P. Singh, Manchala Raghunath (2024). \textit{Exploring Therapeutic Potentials and Pathways of Psychedelics in Alzheimer’s Disease-Related Dementia}. Alzheimer s \& Dementia. [published; OpenAlex]. \href{https://doi.org/10.1002/alz.084413}{doi:10.1002/alz.084413}.
\item Hinkle JT, Graziosi M, Nayak SM, Yaden DB. (2024). \textit{Adverse Events in Studies of Classic Psychedelics: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2024.2546}{doi:10.1001/jamapsychiatry.2024.2546}.
\item Fradet M, Kelly CM, Donnelly AJ, Suppes T. (2024). \textit{Psilocybin and hallucinogenic mushrooms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s1092852924002487}{doi:10.1017/s1092852924002487}.
\item Calder AE, Hase A, Hasler G. (2024). \textit{Effects of psychoplastogens on blood levels of brain-derived neurotrophic factor (BDNF) in humans: a systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-024-02830-z}{doi:10.1038/s41380-024-02830-z}.
\item Ben-Tal T, Pogodin I, Botvinnik A, Lifschytz T, Heresco-Levy U, Lerer B. (2024). \textit{Synergistic Behavioral and Neuroplastic Effects of Psilocybin-NMDAR Modulator Administration}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.11.28.625811}{doi:10.1101/2024.11.28.625811}.
\item Sabé M, Sulstarova A, Glangetas A, De Pieri M, Mallet L, Curtis L, Richard-Lepouriel H, Penzenstadler L, Seragnoli F, Thorens G, Zullino D, Preller K, Böge K, Leucht S, Correll CU, Solmi M, Kaiser S, Kirschner M. (2024). \textit{Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-024-02800-5}{doi:10.1038/s41380-024-02800-5}.
\item Nadav Liam Modlin, Tyler McPhee, Nira Zazon, Maria Sarang, Rebecca Hignett, Susannah Pick, Anthony J. Cleare, Victoria Williamson, James Rucker (2024). \textit{Participants’ Experience of Psychedelic Integration Groups and Processes: A Qualitative Thematic Analysis}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2024.0027}{doi:10.1089/psymed.2024.0027}.
\item Jaime Rojas-Hernández, Lucas F. Borkel, Domingo Jesús Quintana Hernández, Ángelo Santana del Pino, Luis Alberto Henríquez-Hernández (2024). \textit{Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)}. Current Psychology. [published; OpenAlex]. \href{https://doi.org/10.1007/s12144-024-07017-x}{doi:10.1007/s12144-024-07017-x}.
\item Maximillian J. Wood, Rosalind McAlpine, Sunjeev K. Kamboj (2024). \textit{Strategies for resolving challenging psychedelic experiences: insights from a mixed-methods study}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-79931-w}{doi:10.1038/s41598-024-79931-w}.
\item TRYP Therapeutics (2024). \textit{A Phase 2a Safety and Feasibility Study Evaluating Psilocybin (TRP-8802) Administration in Concert With Psychotherapy in the Treatment of Binge Eating Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05035927}{source link}.
\item Shakila Meshkat, Erica Kaczmarek, Zoe Doyle, Ryan M. Brudner, Fabiano A. Gomes, Marc G. Blainey, Geneva Weiglein, Roger S McIntyre, Rodrigo B. Mansur, Joshua D. Rosenblat (2024). \textit{Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2024.0032}{doi:10.1089/psymed.2024.0032}.
\item Erin Y. Wang, David S. Mathai, Natalie Gukasyan, Sandeep M. Nayak, Albert Garcia-Romeu (2024). \textit{Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-78736-1}{doi:10.1038/s41598-024-78736-1}.
\item Zech JM, Yaden DB, Jones GM. (2024). \textit{Associations between psychedelic use and cannabis use disorder in a nationally representative sample.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugalcdep.2024.112502}{doi:10.1016/j.drugalcdep.2024.112502}.
\item Jiwon Lee, Kaylyssa Philip, Duminda N. Wijeysundera, Hance Clarke, Cheryl Pritlove, Joel Katz, Paul Ritvo, Akash Goel, Muhammad Ishrat Husain, Karim S. Ladha (2024). \textit{Prospective Preference Assessment for the Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN (PEACE-PAIN) Trial}. Canadian Journal of Pain. [published; OpenAlex]. \href{https://doi.org/10.1080/24740527.2024.2406285}{doi:10.1080/24740527.2024.2406285}.
\item Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P. (2024). \textit{Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/93x5h}{doi:10.31234/osf.io/93x5h}.
\item Hodge A, Forsyth A, Noorani T, Muthukumaraswamy S, Rolleston A, McHugh P. (2024). \textit{Tū Wairua: Development of an Indigenous Rongoā Māori Approach to Healing with Psilocybin Containing Mushrooms}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/93x5h\_v1}{doi:10.31234/osf.io/93x5h\_v1}.
\item Cristiano Chaves, Rafael G. dos Santos, Serdar Dursun, Massimo Tusconi, Mauro Giovanni Carta, Elisa Brietzke, Jaime E. C. Hallak (2024). \textit{Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1485337}{doi:10.3389/fpsyt.2024.1485337}.
\item Imperial College London (2024). \textit{PsilOCD: Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity (A Pharmacological-Challenge Feasibility Study)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06258031}{source link}.
\item Jordan J. Negrine, Cheneal Puljević, Jason Ferris, Paul Liknaitzky, Christopher M. Perlman, Timothy Piatkowski (2024). \textit{Australian psychologists' attitudes towards psychedelic-assisted therapy and training following a world-first drug down-scheduling}. Drug and Alcohol Review. [published; OpenAlex]. \href{https://doi.org/10.1111/dar.13973}{doi:10.1111/dar.13973}.
\item Marcel Nogueira, Solimary García-Hernández, Gleicy Sotéro Roberto, Leonardo Zanella Marques (2024). \textit{Psilocybin Mushrooms and Public Health in Brazil: Insights from a Retrospective Analysis of Adverse Events and Their Implications for Regulatory Discussions}. International journal of medicinal mushrooms. [published; OpenAlex]. \href{https://doi.org/10.1615/intjmedmushrooms.2024057053}{doi:10.1615/intjmedmushrooms.2024057053}.
\item Aday JS, McAfee J, Conroy DA, Hosanagar A, Tarnal V, Weston C, Scott K, Horowitz D, Harte SE, Pouyan N, Glynos NG, Baker AK, Guss J, Davis AK, Burgess HJ, Mashour GA, Clauw DJ, Boehnke KF. (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/j8zb5}{doi:10.31234/osf.io/j8zb5}.
\item Unknown authors (2024). \textit{Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: An open-label, pilot clinical trial}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/j8zb5\_v1}{source link}.
\item Luoma JB, Wilson-Poe A, Pertl K, Hoffman K, Bazinet A, Stauffer C, McCarty D, Korthuis P. (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/dwhcu\_v1}{doi:10.31234/osf.io/dwhcu\_v1}.
\item Unknown authors (2024). \textit{Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/dwhcu\_v1}{source link}.
\item Filament Health Corp. (2024). \textit{A Registered Clinical Trial of PEX010-Assisted Therapy for Stimulant Use Disorder: A Safety, Feasibility and Efficacy Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06666010}{source link}.
\item Min H, Park SY, Park J, Na S, Lee HS, Kim T, Ham J, Park YT. (2024). \textit{A narrative exploration of psilocybin's potential in mental health.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1429373}{doi:10.3389/fpsyt.2024.1429373}.
\item K S Kim, Abban Yusuf, Abhimanyu Sud, Nav Persaud, Abirami Kirubarajan, Monique Moller, Taryn Lloyd, Braden O’Neill (2024). \textit{Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0309911}{doi:10.1371/journal.pone.0309911}.
\item Emma I Kopra, Jenni Penttinen, James Rucker, Caroline S. Copeland (2024). \textit{Psychedelic-related deaths in England, Wales and Northern Ireland (1997-2022)}. Progress in Neuro-Psychopharmacology and Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.pnpbp.2024.111177}{doi:10.1016/j.pnpbp.2024.111177}.
\item Danielle R. Adams, Heidi Allen, Ginger E. Nicol, Leopoldo J. Cabassa (2024). \textit{Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science}. Translational Behavioral Medicine. [published; OpenAlex]. \href{https://doi.org/10.1093/tbm/ibae053}{doi:10.1093/tbm/ibae053}.
\item Hannah Douglass (2024). \textit{The therapeutic potential and mechanisms of action of psilocybin-assisted therapy in anorexia nervosa treatment}. Open MIND. [published; OpenAlex]. \href{https://doi.org/10.25560/118978}{doi:10.25560/118978}.
\item MycoMedica Life Sciences PBC (2024). \textit{A Phase 1 Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLS101 (psilocybin) in Healthy Participants}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06326606}{source link}.
\item Dimy Fluyau, Vasanth Kattalai Kailasam, Neelambika Revadigar (2024). \textit{Rapid and Prolonged Antidepressant and Antianxiety Effects of Psychedelics and 3,4-Methylenedioxy-methamphetamine-A Systematic Review and Meta-Analysis}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives3040029}{doi:10.3390/psychoactives3040029}.
\item Meshkat S, Tello-Gerez TJ, Gholaminezhad F, Dunkley BT, Reichelt AC, Erritzoe D, Vermetten E, Zhang Y, Greenshaw A, Burback L, Winkler O, Jetly R, Mayo LM, Bhat V. (2024). \textit{Impact of psilocybin on cognitive function: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/pcn.13741}{doi:10.1111/pcn.13741}.
\item Lafrance A, Spriggs MJ, Gukasyan N, Peck SK (2024). \textit{Beyond the numbers: reimagining healing with psychedelics for eating disorders.}. Journal of eating disorders. [published; PubMed]. \href{https://doi.org/10.1186/s40337-024-01111-y}{doi:10.1186/s40337-024-01111-y}.
\item Halman A, Conyers R, Moore C, Khatri D, Sarris J, Perkins D. (2024). \textit{Harnessing Pharmacogenomics in Clinical Research on Psychedelic-Assisted Therapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/cpt.3459}{doi:10.1002/cpt.3459}.
\item University of California, San Francisco (2024). \textit{An Open-Label Pilot Study Examining the Feasibility, Safety, and Effectiveness of Psilocybin Therapy for Depression in Bipolar II Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05065294}{source link}.
\item Li LJ, Mo Y, Shi ZM, Huang XB, Ning YP, Wu HW, Yang XH, Zheng W. (2024). \textit{Psilocybin for major depressive disorder: a systematic review of randomized controlled studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1416420}{doi:10.3389/fpsyt.2024.1416420}.
\item David Erritzøe, Tommaso Barba, Kyle T. Greenway, Roberta Murphy, Jonny Martell, Bruna Giribaldi, Christopher Timmermann, Ashleigh Murphy-Beiner, Michelle Baker Jones, David Nutt, Brandon Weiss, Robin Carhart-Harris (2024). \textit{Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2024.102799}{doi:10.1016/j.eclinm.2024.102799}.
\item James Rucker, Matthew Butler, Sadie Hambleton, Catherine Bird, Mathieu Seynaeve, Sanjay Cheema, Kete Campbell-Coker, Carolina Maggio, Fiona Dunbar, Giorgio Lambru, Manjit Matharu (2024). \textit{Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: results from an open-label phase Ib ascending dose study}. Headache The Journal of Head and Face Pain. [published; OpenAlex]. \href{https://doi.org/10.1111/head.14837}{doi:10.1111/head.14837}.
\item University Hospital, Ghent (2024). \textit{Psilocybin-assisted Psychotherapy in the Treatment of Patients Hospitalized for Treatment-resistant Depression: an Open-label Feasibility Study with an Experiential and Systemic Focus}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06378229}{source link}.
\item Armstrong SB, Davis AK. (2024). \textit{Psychedelic research at a crossroads.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1126/science.adt1024}{doi:10.1126/science.adt1024}.
\item Nicolas G. Glynos, Anne Baker, Jacob S. Aday, Niloufar Pouyan, Julie Barron, Moss Herberholz, Daniel J. Kruger, Kevin F. Boehnke (2024). \textit{Going Underground: Demographics, Services, and Best Practices Endorsed by Practitioners Providing Support for Naturalistic Psychedelic Use}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2024.2405685}{doi:10.1080/02791072.2024.2405685}.
\item Mageean S, Daniel A, Tai S. (2024). \textit{Exploring U.K. cancer doctors’ attitudes toward psilocybin-assisted psychotherapy for cancer-related distress}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4862438/v1}{doi:10.21203/rs.3.rs-4862438/v1}.
\item Danielle B Rodrigues (2024). \textit{Use of Psilocybin in the Treatment of Mental Disorders: Systematic Review of Clinal Trials}. Journal of Complementary Medicine \& Alternative Healthcare. [published; OpenAlex]. \href{https://doi.org/10.19080/jcmah.2024.13.555852}{doi:10.19080/jcmah.2024.13.555852}.
\item Spoelstra SK, Schoevers RA, Venema SD, Knegtering H. (2024). \textit{Psychedelics as a potential treatment for tobacco use disorder: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s44192-024-00095-0}{doi:10.1007/s44192-024-00095-0}.
\item Behera HK, Joga R, Yerram S, Karnati P, Mergu T, Gandhi K, M S, Nathiya D, Singh RP, Srivastava S, Kumar S. (2024). \textit{Exploring the regulatory framework of psychedelics in the US \& Europe.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.ajp.2024.104242}{doi:10.1016/j.ajp.2024.104242}.
\item Schipper S, Nigam K, Schmid Y, Piechotta V, Ljuslin M, Beaussant Y, Schwarzer G, Boehlke C. (2024). \textit{Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1002/14651858.cd015383.pub2}{doi:10.1002/14651858.cd015383.pub2}.
\item Low ZXB, Ng WS, Lim ESY, Goh BH, Kumari Y. (2024). \textit{The immunomodulatory effects of classical psychedelics: A systematic review of preclinical studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2024.111139}{doi:10.1016/j.pnpbp.2024.111139}.
\item Zhen Z, Sun X, Yuan S, Zhang J. (2024). \textit{Psychoactive substances for the treatment of neuropsychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.ajp.2024.104193}{doi:10.1016/j.ajp.2024.104193}.
\item Amany E. Ayad (2024). \textit{G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.1136/rapm-2024-esra.582}{doi:10.1136/rapm-2024-esra.582}.
\item Albert Garcia-Romeu (2024). \textit{Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Psychedelic Medicine}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2024.65789.rfs2023}{doi:10.1089/psymed.2024.65789.rfs2023}.
\item Loizaga-Velder A, Loizaga Pazzi A. (2024). \textit{Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.15288/jsad.23-00011}{doi:10.15288/jsad.23-00011}.
\item Smith CL, Sackett N, Stark BC, Dinh V, Romesburg EW, Roll J (2024). \textit{Understanding Psychedelic-Assisted Psychotherapy Providers' Perspective and Insights: A Qualitative Analysis.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2023.0074}{doi:10.1089/psymed.2023.0074}.
\item Federico Seragnoli, Martignoni Geo, Martignoni Entela, Silke Bachmann, Elisa Rabitti, Silvio Cavuto, Dubus Zoë, Penzenstadler Louise, Gabriel Thorens, Joël Billieux, Zullino Daniele (2024). \textit{Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report}. Clinical Case Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/ccr3.9305}{doi:10.1002/ccr3.9305}.
\item Jungwirth J, Bavato F, Quednow BB. (2024). \textit{[Psychedelic and dissociative agents in psychiatry: challenges in the treatment].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00115-024-01727-0}{doi:10.1007/s00115-024-01727-0}.
\item Najib J. (2024). \textit{The role of psilocybin in depressive disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/03007995.2024.2396536}{doi:10.1080/03007995.2024.2396536}.
\item Klučková T, Nikolič M, Tylš F, Viktorin V, Vejmola Č, Viktorinová M, Bravermanová A, Androvičová R, Andrashko V, Korčák J, Zach P, Hájková K, Kuchař M, Balíková M, Brunovský M, Horáček J, Páleníček T. (2024). \textit{The phenomenology of psilocybin’s experience mediates subsequent persistent psychological effects independently of sex, previous experience or setting}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.08.26.24311611}{doi:10.1101/2024.08.26.24311611}.
\item Jensen ME, Stenbæk DS, Messell CD, Poulsen ED, Varga TV, Fisher PM, Nielsen MKK, Johansen SS, Volkow ND, Knudsen GM, Fink-Jensen A. (2024). \textit{­­­­Single-Dose Psilocybin Therapy for Alcohol Use Disorder: Pharmacokinetics, Feasibility, Safety, and Efficacy in an Open-Label Study}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4947184/v1}{doi:10.21203/rs.3.rs-4947184/v1}.
\item Jim Weil (2024). \textit{Tripping on Utopia: Margaret Mead, the Cold War, and the troubled birth of psychedelic science By BenjaminBreen. New York: Grand Central Publishing, 2024. 384 pp.}. American Anthropologist. [published; OpenAlex]. \href{https://doi.org/10.1111/aman.28009}{doi:10.1111/aman.28009}.
\item William M. Campo, Ann Marie Yali (2024). \textit{Psychedelic use and psychological flexibility: The role of meaningful intention and decentering}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00350}{doi:10.1556/2054.2024.00350}.
\item Clairvoyant Therapeutics (2024). \textit{A24-Week, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Clinical Trial to Evaluate Efficacy and Safety of Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05646303}{source link}.
\item Michael P. Bogenschutz (2024). \textit{A clinical research perspective on the regulation of medical and non-medical use of psychedelic drugs}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16647}{doi:10.1111/add.16647}.
\item Sheppard Pratt Health System (2024). \textit{An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04433858}{source link}.
\item Brugmann University Hospital (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy \& (Neuro)Cognitive Mechanisms}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06160232}{source link}.
\item Nicky J. Mehtani, Mallory O. Johnson, Peter S. Hendricks, Jennifer Mitchell, B. Anderson (2024). \textit{Psilocybin-assisted therapy and HIV-related shame}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-68908-4}{doi:10.1038/s41598-024-68908-4}.
\item Aday JS, Horton D, Fernandes-Osterhold G, O'Donovan A, Bradley ER, Rosen RC, Woolley JD (2024). \textit{Psychedelic-assisted psychotherapy: where is the psychotherapy research?}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-024-06620-x}{doi:10.1007/s00213-024-06620-x}.
\item Chiranth Bhagavan, Richard Kanaan, Olivia Carter, Glenn Nielsen, David J. Berlowitz, Sara Issak, Sabine Braat, Sophie Zaloumis, Zachary Attard, Georgina Oliver, Deanne Mayne, David McKernon, Greg Roebuck, James Rucker, Matthew Butler, Alexander Bryson (2024). \textit{Psilocybin and Motor Function: A Triple-Blind, Dose-Finding Study in Healthy Participants}. Psychiatric Research and Clinical Practice. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.prcp.20240047}{doi:10.1176/appi.prcp.20240047}.
\item Gomez-Escolar A, Folch-Sanchez D, Stefaniuk J, Swithenbank Z, Nisa A, Braddick F, Idrees Chaudhary N, van der Meer PB, Batalla A. (2024). \textit{Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s40263-024-01101-3}{doi:10.1007/s40263-024-01101-3}.
\item Liam Engel, Sascha Thal, Stephen Bright, Mitchell Low (2024). \textit{Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00377}{doi:10.1556/2054.2024.00377}.
\item André Do, Vanessa Michaud, Jean-François Stephan, Miltiadis Moreau, Élise Benoît, Felix-Antoine Berubé, Antoine Bibaud-De Serres, Alain Taillefer, Philippe Vincent (2024). \textit{Serotoninergic antidepressants combination in psilocybin-assisted psychotherapy: a case report}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1394962}{doi:10.3389/fpsyt.2024.1394962}.
\item Anders Fink-Jensen, MD, DMSci (2024). \textit{Psilocybin for Treatment of Alcohol Use Disorder: a Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04718792}{source link}.
\item Nogueira M, García-Hernández S, Roberto GS, Marques LZ. (2024). \textit{Psilocybin mushrooms and public health in Brazil: a low-risk adverse event profile calls for evidence-based regulatory discussions}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.07.11.24310147}{doi:10.1101/2024.07.11.24310147}.
\item Zheng S, Ma R, Yang Y, Li G. (2024). \textit{Psilocybin for the treatment of Alzheimer's disease.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fnins.2024.1420601}{doi:10.3389/fnins.2024.1420601}.
\item Ashutosh Bhave (2024). \textit{Magic of the Mushrooms: Effects of Psilocybin Decriminalization}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2024.2376755}{doi:10.1080/02791072.2024.2376755}.
\item Amir Khajavinia, Déborah Michel, Udoka C. Ezeaka, Randy W. Purves, Robert B. Laprairie, Anas El-Aneed (2024). \textit{Addressing a major interference in the quantification of psilocin in mouse plasma: Development of a validated liquid chromatography tandem mass spectrometry method}. Journal of Chromatography A. [published; OpenAlex]. \href{https://doi.org/10.1016/j.chroma.2024.465123}{doi:10.1016/j.chroma.2024.465123}.
\item Stéphanie Knatz Peck, Samantha Shao, Tessa Gruen, Kevin H. Yang, Alexandra Babakanian, Julie Trim, Daphna M. Finn, Walter H. Kaye (2024). \textit{Psilocybin Therapy for Females With Anorexia Nervosa: A Phase 1, Open-Label Feasibility Study}. FOCUS The Journal of Lifelong Learning in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.focus.24022013}{doi:10.1176/appi.focus.24022013}.
\item DeBattista C, Schatzberg AF. (2024). \textit{The Black Book of Psychotropic Dosing and Monitoring.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.64719/pb.4493}{doi:10.64719/pb.4493}.
\item Nauman Ashraf (2024). \textit{IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?}. Journal of Pakistan Psychiatric Society. [published; OpenAlex]. \href{https://doi.org/10.63050/jpps.21.02.935}{doi:10.63050/jpps.21.02.935}.
\item Zohaib Nadeem, Stephen Parker, Hugh McGovern, Lena Oestreich (2024). \textit{Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia}. Australian \& New Zealand Journal of Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1177/00048674241261779}{doi:10.1177/00048674241261779}.
\item Fluyau D, Kailasam VK, Revadigar N. (2024). \textit{Rapid and prolonged antidepressant and antianxiety effects of psilocybin, lysergic acid diethylamide, ayahuasca, and 3, 4-methylenedioxy-methamphetamine. A systematic review and meta-analysis of randomized controlled trials}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2024.06.17.24308787}{doi:10.1101/2024.06.17.24308787}.
\item Appiani FJ, Caroff SN. (2024). \textit{The cyclical revival of psychedelics in psychiatric treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/03007995.2024.2368725}{doi:10.1080/03007995.2024.2368725}.
\item Guo Q, Guo L, Wang Y, Shang S. (2024). \textit{Efficacy and safety of eight enhanced therapies for treatment-resistant depression: A systematic review and network meta-analysis of RCTs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2024.116018}{doi:10.1016/j.psychres.2024.116018}.
\item P. Todd Korthuis, Kim Hoffman, Adrianne R. Wilson-Poe, Jason B. Luoma, Alissa Bazinet, Kellie Pertl, David L. Morgan, Ryan Cook, Sarann Bielavitz, Renae Myers, R. Cameron Wolf, Dennis McCarty, Christopher S. Stauffer (2024). \textit{Developing the Open Psychedelic Evaluation Nexus consensus measures for assessment of supervised psilocybin services: An e-Delphi study}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241257839}{doi:10.1177/02698811241257839}.
\item Downey AE, Bradley ER, Lerche AS, O'Donovan A, Krystal AD, Woolley J. (2024). \textit{A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2023.0051}{doi:10.1089/psymed.2023.0051}.
\item P. Todd Korthuis, Adrianne R. Wilson-Poe, Joshua C. Black, Andrew A. Monte (2024). \textit{Commentary on Darkeet al.: Expanded psychedelic access requires new safety monitoring systems}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16589}{doi:10.1111/add.16589}.
\item Polito V, Liknaitzky P. (2024). \textit{Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811241254831}{doi:10.1177/02698811241254831}.
\item Linda M. Richmond (2024). \textit{Psychedelics’ Use as Medicine Hits Significant Roadblock}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.07.7.54}{doi:10.1176/appi.pn.2024.07.7.54}.
\item Sandra Szafoni, Piotr Gręblowski, Klaudia Grabowska, Gniewko Więckiewicz (2024). \textit{Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1406888}{doi:10.3389/fpsyt.2024.1406888}.
\item Petrovitch D, Mitchell SM, Van Allen J, Littlefield AK. (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/adnpg}{doi:10.31234/osf.io/adnpg}.
\item University of Sydney (2024). \textit{A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06444243}{source link}.
\item Unknown authors (2024). \textit{Who believes psychedelic-assisted therapies work? Risky cannabis use and other factors are associated with positive treatment-outcome expectancies}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/adnpg\_v1}{source link}.
\item Calder A, Hasler G. (2024). \textit{Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/um2cy}{doi:10.31234/osf.io/um2cy}.
\item Unknown authors (2024). \textit{Validation of the Swiss Psychedelic Side Effects Inventory: Standardized assessment of adverse effects in studies of psychedelics and MDMA}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/um2cy\_v1}{source link}.
\item Ryan J. Rakoczy, Grace N. Runge, Abhishek K. Sen, Oscar Sandoval, Hunter G. Wells, Quynh Nguyen, B. Roberts, Jon H. Sciortino, William J. Gibbons, Lucas M. Friedberg, J. Andrew Jones, Matthew S. McMurray (2024). \textit{Pharmacological and behavioural effects of tryptamines present in psilocybin-containing mushrooms}. British Journal of Pharmacology. [published; OpenAlex]. \href{https://doi.org/10.1111/bph.16466}{doi:10.1111/bph.16466}.
\item Nikola Lash, George Tadros, Eman Tadros (2024). \textit{Therapeutic Implications of Psilocybin in the Wake of Decriminalization}. Integrative and Complementary Therapies. [published; OpenAlex]. \href{https://doi.org/10.1089/ict.2024.27206.nl}{doi:10.1089/ict.2024.27206.nl}.
\item Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T. (2024). \textit{Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2023.4685}{doi:10.1001/jamapsychiatry.2023.4685}.
\item Aaronson ST, van der Vaart A, Sackeim HA. (2024). \textit{Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety-Reply.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamapsychiatry.2024.0423}{doi:10.1001/jamapsychiatry.2024.0423}.
\item Chisamore N, Johnson D, Chen MJQ, Offman H, Chen-Li D, Kaczmarek ES, Doyle Z, McIntyre RS, Rosenblat JD. (2024). \textit{Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpsychires.2024.05.051}{doi:10.1016/j.jpsychires.2024.05.051}.
\item Harman Chopra, Timothy Furnish, Monica Verduzco-Gutierrez, David S. Jevotovsky, Joel Castellanos (2024). \textit{Long-COVID symptoms improved after MDMA and psilocybin therapy: A case report}. Clinical Case Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/ccr3.8791}{doi:10.1002/ccr3.8791}.
\item Ehrenkranz R, Agrawal M, Penberthy JK, Yaden DB. (2024). \textit{Narrative review of the potential for psychedelics to treat Prolonged Grief Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/09540261.2024.2357668}{doi:10.1080/09540261.2024.2357668}.
\item Fang Q, Chan VKY, Chan SSM, Jiao Y, Wang J, Li X. (2024). \textit{Efficacy and safety of psilocybin on treatment-resistant depression: A systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2024.115960}{doi:10.1016/j.psychres.2024.115960}.
\item S Morris (2024). \textit{A Case Report of Psilocybin-induced Psychosis in a Predisposed Patient}. Clinical Psychopharmacology and Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.9758/cpn.24.1180}{doi:10.9758/cpn.24.1180}.
\item Shunichiro Ikeda, Toshihiko Kinoshita (2024). \textit{Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens}. Psychiatry and Clinical Neurosciences Reports. [published; OpenAlex]. \href{https://doi.org/10.1002/pcn5.196}{doi:10.1002/pcn5.196}.
\item Mateusz Pawlicki, Aleksandra Kłos, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Gregułą, Aleksandra Mazurek, Wiktoria Wilanowska (2024). \textit{Psilocybin as a new way for depression treatment}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2024.68.50168}{doi:10.12775/jehs.2024.68.50168}.
\item Viña S. (2024). \textit{Psychedelics Use and the Risk of Reduced Formal Mental Health Care}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-4378944/v1}{doi:10.21203/rs.3.rs-4378944/v1}.
\item Terri D’Arrigo (2024). \textit{Calls to Poison Centers Involving Psilocybin Rising in Youth}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.06.6.2}{doi:10.1176/appi.pn.2024.06.6.2}.
\item Jeffrey JK, Weintraub MJ, Grob CS. (2024). \textit{Clinical Research Trials of Psychedelic-Assisted Therapy in Adolescents Aged 16 to 17 Years: Rationale Balanced With Caution.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jaac.2024.03.021}{doi:10.1016/j.jaac.2024.03.021}.
\item Anthony L. Back, Susanna Myers, John Guy, Juliana Pérez, Leslie Lazar Thorn, Bonnie A. McGregor (2024). \textit{Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0069}{doi:10.1089/psymed.2023.0069}.
\item Nicholas A Kerna, Kevin D. Pruitt, N.D. Victor Carsrud, Kyle Kadivi, Dabeluchi C. Ngwu, Hilary M. Holets, John V. Flores, Ijeoma Nnake, Cornelius I. Azi, Joseph Anderson, Fatimah A. Olunlade, Uzoamaka Nwokorie (2024). \textit{From Venerable Cultural Practices to Modern Psychological Solutions: Enter Entheogens into Mainstream Medicine}. European Journal of Arts Humanities and Social Sciences. [published; OpenAlex]. \href{https://doi.org/10.59324/ejahss.2024.1(3).10}{doi:10.59324/ejahss.2024.1(3).10}.
\item Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Verroust V, Piolino P, Benyamina A (2024). \textit{Safety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review.}. Psychiatry research. [published; PubMed]. \href{https://doi.org/10.1016/j.psychres.2024.115880}{doi:10.1016/j.psychres.2024.115880}.
\item Metaxa AM, Clarke M. (2024). \textit{Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1136/bmj-2023-078084}{doi:10.1136/bmj-2023-078084}.
\item Petrovitch D, Van Allen J, Mitchell SM, Littlefield AK. (2024). \textit{Do undergraduates’ views of psychedelics relate to the context for psychedelic use?}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/xnu5c}{doi:10.31234/osf.io/xnu5c}.
\item Downey AE, Chaphekar AV, Woolley J, Raymond-Flesch M. (2024). \textit{Psilocybin therapy and anorexia nervosa: a narrative review of safety considerations for researchers and clinicians.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s40337-024-01005-z}{doi:10.1186/s40337-024-01005-z}.
\item Unknown authors (2024). \textit{Do undergraduates’ views of psychedelics relate to the context for psychedelic use?}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/xnu5c\_v1}{source link}.
\item Terri D’Arrigo (2024). \textit{MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.05.5.1}{doi:10.1176/appi.pn.2024.05.5.1}.
\item Section for Affective Disorders; Northern Stockholm Psychiatry (2024). \textit{The Effect of Psilocybin on MDD Symptom Severity and Synaptic Density - A Single Dose Randomized, Double Blind, Placebo- Controlled Phase 2 Positron Emission Tomography Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04630964}{source link}.
\item Julia R. Wang, Samuel J. Mendez Araque, Gina Micciche, Andrew McMillan, Emily Coughlin, Rosalie Mattiola, Diana P. English, Kristopher Kaliebe (2024). \textit{Palliative care patients’ attitudes and openness towards psilocybin-assisted psychotherapy for existential distress}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2024.1301960}{doi:10.3389/fpsyt.2024.1301960}.
\item Daniel Meling, Rebecca Ehrenkranz, Sandeep M. Nayak, Helena Aicher, Xaver Funk, Michiel van Elk, Marianna Graziosi, Prisca R. Bauer, Milan Scheidegger, David B. Yaden (2024). \textit{Mind the Psychedelic Hype: Characterizing the Risks and Benefits of Psychedelics for Depression}. Psychoactives. [published; OpenAlex]. \href{https://doi.org/10.3390/psychoactives3020014}{doi:10.3390/psychoactives3020014}.
\item Eiko I. Fried, Ioana A. Cristea, Florian Naudet (2024). \textit{Treating Bipolar Depression Using Psilocybin-Validity Threats Regarding Efficacy and Safety}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2024.0420}{doi:10.1001/jamapsychiatry.2024.0420}.
\item Haniff ZR, Bocharova M, Mantingh T, Rucker JJ, Velayudhan L, Taylor DM, Young AH, Aarsland D, Vernon AC, Thuret S. (2024). \textit{Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pharmthera.2024.108641}{doi:10.1016/j.pharmthera.2024.108641}.
\item M. Nordin, Jón Ingi Hlynsson, Jakob Håkansson Eklund, Per Carlbring (2024). \textit{A double-edged sword: Insights from practitioners on the short and long-term negative effects of psilocybin-assisted psychological interventions}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2024.00337}{doi:10.1556/2054.2024.00337}.
\item Rachael Wilkes, Darren M. Roberts, Paul Liknaitzky, Jonathan Brett (2024). \textit{The psychedelic call: analysis of Australian Poisons Information Centre calls associated with classic psychedelics}. Clinical Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1080/15563650.2024.2346612}{doi:10.1080/15563650.2024.2346612}.
\item J. S. Seo (2024). \textit{Current situation regarding psychedelics and magic mushroom in Korea}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1192/j.eurpsy.2024.1695}{doi:10.1192/j.eurpsy.2024.1695}.
\item Yerubandi A, Thomas JE, Bhuiya NMMA, Harrington C, Villa Zapata L, Caballero J. (2024). \textit{Acute Adverse Effects of Therapeutic Doses of Psilocybin: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1001/jamanetworkopen.2024.5960}{doi:10.1001/jamanetworkopen.2024.5960}.
\item Yao Y, Guo D, Lu TS, Liu FL, Huang SH, Diao MQ, Li SX, Zhang XJ, Kosten TR, Shi J, Bao YP, Lu L, Han Y. (2024). \textit{Efficacy and safety of psychedelics for the treatment of mental disorders: A systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2024.115886}{doi:10.1016/j.psychres.2024.115886}.
\item Terri D’Arrigo (2024). \textit{MedCheck; Psilocybin, Roluperidone, Latozinemab, Lacosamide}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.1}{doi:10.1176/appi.pn.2024.04.4.1}.
\item David Erritzøe, Tommaso Barba, Meg J. Spriggs, Fernando E. Rosas, David Nutt, Robin Carhart-Harris (2024). \textit{Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811241237870}{doi:10.1177/02698811241237870}.
\item Adrian Preda (2024). \textit{Psychedelic Renaissance: Evidence and Culture}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2024.04.4.39}{doi:10.1176/appi.pn.2024.04.4.39}.
\item University of Utah (2024). \textit{A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04522804}{source link}.
\item Ben Seal (2024). \textit{Psychedelic drugs and the law: What’s next?}. Knowable Magazine. [published; OpenAlex]. \href{https://doi.org/10.1146/knowable-031424-2}{doi:10.1146/knowable-031424-2}.
\item Wood ME, Brown GJ, Karschner EL, Seither JZ, Brown JT, Knittel JL, Walterscheid JP. (2024). \textit{Screening and confirmation of psilocin, mitragynine, phencyclidine, ketamine and ketamine metabolites by liquid chromatography-tandem mass spectrometry.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1093/jat/bkae002}{doi:10.1093/jat/bkae002}.
\item Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, Bryce D. Beutler, Kirsten Cherian, Viviana D. Evans, Chelsey Fasano, Owen S. Muir (2024). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin}. American Journal of Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1097/mjt.0000000000001724}{doi:10.1097/mjt.0000000000001724}.
\item Rosalind McAlpine, Matthew D. Sacchet, Otto Simonsson, Maisha M. Khan, Katarina Krajnović, Larisa Morometescu, Sunjeev K. Kamboj (2024). \textit{Development of a digital intervention for psychedelic preparation (DIPP)}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-54642-4}{doi:10.1038/s41598-024-54642-4}.
\item Ching THW, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk SA, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. (2024). \textit{Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1372373}{doi:10.3389/fpsyt.2024.1372373}.
\item Fang S, Yang X, Zhang W. (2024). \textit{Efficacy and acceptability of psilocybin for primary or secondary depression: A systematic review and meta-analysis of randomized controlled trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2024.1359088}{doi:10.3389/fpsyt.2024.1359088}.
\item Hatzipantelis CJ, Olson DE (2024). \textit{The Effects of Psychedelics on Neuronal Physiology.}. Annual review of physiology. [published; PubMed]. \href{https://doi.org/10.1146/annurev-physiol-042022-020923}{doi:10.1146/annurev-physiol-042022-020923}.
\item Joost J. Breeksema, Alistair Niemeijer, Erwin Krediet, T.L. Karsten, Jeanine Kamphuis, Eric Vermetten, Wim van den Brink, Robert A. Schoevers (2024). \textit{Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-024-53188-9}{doi:10.1038/s41598-024-53188-9}.
\item Borissova A, Rucker JJ. (2024). \textit{The development of psilocybin therapy for treatment-resistant depression: an update.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1192/bjb.2023.25}{doi:10.1192/bjb.2023.25}.
\item Sicignano D, Hernandez AV, Schiff B, Elmahy N, White CM (2024). \textit{The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.}. Current medical research and opinion. [published; PubMed]. \href{https://doi.org/10.1080/03007995.2023.2296968}{doi:10.1080/03007995.2023.2296968}.
\item Jitendra Kumar Sinha, Anchal Trisal, Shampa Ghosh, Saurabh Gupta, Krishna Kumar Singh, Sung Soo Han, Madhumita Mahapatra, Mosleh Mohammad Abomughaid, Ali M. Abomughayedh, Abdulmajeed G. Almutary, Danish Iqbal, Rakesh Bhaskar, Prabhu Chandra Mishra, Saurabh Kumar Jha, Niraj Kumar Jha, Abhishek Kumar Singh (2024). \textit{Psychedelics for alzheimer's disease-related dementia: Unveiling therapeutic possibilities and pathways}. Ageing Research Reviews. [published; OpenAlex]. \href{https://doi.org/10.1016/j.arr.2024.102211}{doi:10.1016/j.arr.2024.102211}.
\item Holze F, Singh N, Liechti ME, D'Souza DC. (2024). \textit{Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.bpsc.2024.01.007}{doi:10.1016/j.bpsc.2024.01.007}.
\item Houman Farzin (2024). \textit{Psilocybin-assisted psychotherapy for cancer patients}. International Journal of Whole Person Care. [published; OpenAlex]. \href{https://doi.org/10.26443/ijwpc.v11i1.390}{doi:10.26443/ijwpc.v11i1.390}.
\item Payal Ghosh, Debjeet Sur (2024). \textit{Pharmacotherapy of Psychological Disorders Using Psychedelic Drugs: A Treatise for Psychiatrists}. Current Psychiatry Research and Reviews. [published; OpenAlex]. \href{https://doi.org/10.2174/0126660822258502231120074036}{doi:10.2174/0126660822258502231120074036}.
\item Modlin NL, Creed M, Sarang M, Maggio C, Rucker JJ, Williamson V. (2024). \textit{Trauma-Informed Care in Psychedelic Therapy Research: A Qualitative Literature Review of Evidence-Based Psychotherapy Interventions in PTSD and Psychedelic Therapy Across Conditions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2147/ndt.s432537}{doi:10.2147/ndt.s432537}.
\item Bouchet L, Sager Z, Yrondi A, Nigam KB, Anderson BT, Ross S, Petridis PD, Beaussant Y. (2024). \textit{Older adults in psychedelic-assisted therapy trials: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231215420}{doi:10.1177/02698811231215420}.
\item Kelsey Klute, Lou Lukas, Soonjo Hwang, Yeongjin Gwon, Mridula Krishnan, Jean L. Grem, Sunil R. Hingorani, Jody Koenig Kellas (2024). \textit{Abstract C001: A pilot study of palliadelic treatment with psilocybin to reduce psychological distress and improve quality of life in patients with advanced pancreatic adenocarcinoma}. Cancer Research. [published; OpenAlex]. \href{https://doi.org/10.1158/1538-7445.panca2023-c001}{doi:10.1158/1538-7445.panca2023-c001}.
\item David F. Lo, Hasan Zia, Pranetha Rajkumar, Adarsh Thakur, Heather O’Donnell (2024). \textit{Modern Psychedelic Microdosing Research on Mental Health}. The Primary Care Companion For CNS Disorders. [published; OpenAlex]. \href{https://doi.org/10.4088/pcc.23r03581}{doi:10.4088/pcc.23r03581}.
\item Rouaud A, Calder AE, Hasler G. (2024). \textit{Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231225609}{doi:10.1177/02698811231225609}.
\item Terence H. W. Ching, Lucia Amoroso, Calvin Bohner, Elizabeth J. D’Amico, Jeffrey Eilbott, Tara Entezar, Madison Fitzpatrick, Geena Fram, Rachael Grazioplene, Jamila Hokanson, Anastasia Jankovsky, Stephen A. Kichuk, Bradford Martins, Prerana Patel, Henry Schaer, Sarah Shnayder, Chelsea Witherow, Christopher Pittenger, Benjamin Kelmendi (2024). \textit{Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1278823}{doi:10.3389/fpsyt.2023.1278823}.
\item Johns Hopkins University (2024). \textit{Safety and Tolerability of Psilocybin in Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05562973}{source link}.
\item Shore R, Dobson K, Thomson N, Barnim N, Bergman H, Rideout K, McKeown S, Olmstead MC, Goldie C, Dumont E. (2024). \textit{Behavioural Investigations of Psilocybin in Animals 1962-2021: A Scoping Review}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2024.01.04.574146}{doi:10.1101/2024.01.04.574146}.
\item Vanderijst L, Hever F, Buot A, Dauré C, Benoit J, Hanak C, Veeser J, Morgiève M, Campanella S, Kornreich C, Mallet L, Leys C, Noël X. (2024). \textit{Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3829237/v1}{doi:10.21203/rs.3.rs-3829237/v1}.
\item Barajas, Carlos (2023). \textit{Psilocybin’s Role in Major Depressive Disorder: A Scoping Review}. Digital Commons - George Fox University (George Fox University). [published; OpenAlex]. \href{https://digitalcommons.georgefox.edu/dmsc/31}{source link}.
\item Unknown authors (2023). \textit{Government-funded trial will test psilocybin as treatment for opioid use disorder}. Pharmaceutical journal/The pharmaceutical journal. [published; OpenAlex]. \href{https://doi.org/10.1211/pj.2024.1.335169}{doi:10.1211/pj.2024.1.335169}.
\item Dominic Sisti (2023). \textit{Introduction to the Special Section on Psychedelics Research and Treatment}. Perspectives in biology and medicine. [published; OpenAlex]. \href{https://doi.org/10.1353/pbm.2024.a919714}{doi:10.1353/pbm.2024.a919714}.
\item Correa RMS (2023). \textit{Psychedelic Mushrooms: The Use of Psilocybin in the Treatment of Mental Disorders}. Annals of Bioethics \& Clinical Applications. [published; OpenAlex]. \href{https://doi.org/10.23880/abca-16000266}{doi:10.23880/abca-16000266}.
\item Rakesh Khanna (2023). \textit{Psilocybin for the treatment of posttraumatic stress disorder: A magic to treat a harmony of illusions?}. Journal of Indira Gandhi Institute Of Medical Sciences. [published; OpenAlex]. \href{https://doi.org/10.4103/jigims.jigims\_60\_23}{doi:10.4103/jigims.jigims\_60\_23}.
\item Simonsson O, Hendricks PS, Stenfors CU, Goldberg SB, Honk L, Osika W (2023). \textit{Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811231218931}{doi:10.1177/02698811231218931}.
\item Schenberg EE, King F, da Fonseca JE, Roseman L. (2023). \textit{Is Poorly Assisted Psilocybin Treatment an Increasing Risk?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.20230664}{doi:10.1176/appi.ajp.20230664}.
\item Smith WR, Sisti DA, Appelbaum PS. (2023). \textit{The safety of supported psilocybin use in Oregon.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41591-023-02727-4}{doi:10.1038/s41591-023-02727-4}.
\item Zaretsky TG, Jagodnik KM, Barsic R, Antonio JH, Bonanno PA, MacLeod C, Pierce C, Carney H, Morrison MT, Saylor C, Danias G, Lepow L, Yehuda R. (2023). \textit{The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2174/1570159x22666231027111147}{doi:10.2174/1570159x22666231027111147}.
\item Olivier B, Olivier JDA. (2023). \textit{Efficacy, Safety, and Tolerability of Psychedelics in Treatment-Resistant Depression (TRD).}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/978-981-97-4402-2\_3}{doi:10.1007/978-981-97-4402-2\_3}.
\item Petranker R, Anderson T, Fewster EC, Aberman Y, Hazan M, Gaffrey M, Seli P (2023). \textit{Keeping the promise: a critique of the current state of microdosing research.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2024.1217102}{doi:10.3389/fpsyt.2024.1217102}.
\item Isabelle Straumann, Friederike Holze, A. Becker, Laura Ley, Nepomuk Halter, Matthias E. Liechti (2023). \textit{Safety pharmacology of acute psilocybin administration in healthy participants}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2024.104060}{doi:10.1016/j.nsa.2024.104060}.
\item Baeleigh VanderZwaag, Albert Garcia-Romeu, Mauricio A. García-Barrera (2023). \textit{Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery}. Therapeutic Advances in Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/20451253241264812}{doi:10.1177/20451253241264812}.
\item Verheijen Marcha C.T. (2023). \textit{Psilocybin Therapy for Depression: A Review of Current Molecular Knowledge}. Journal of the Netherlands Society of Toxicology. [published; Crossref]. \href{https://doi.org/10.61833/jnst.2024.0002}{doi:10.61833/jnst.2024.0002}.
\item Karolina Wąsik, Sebastian Tomaszuk, Magda Wojtuś (2023). \textit{Psilocybin - new remedy for patients with psychiatric disorders? Critical analysis of the current state of knowledge}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.50.01.005}{doi:10.12775/jehs.2023.50.01.005}.
\item Tabaac BJ, Shinozuka K, Arenas A, Beutler BD, Cherian K, Evans VD, Fasano C, Muir OS. (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/a8xwk}{doi:10.31234/osf.io/a8xwk}.
\item Multidisciplinary Association for Psychedelic Studies (2023). \textit{Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00979693}{source link}.
\item Unknown authors (2023). \textit{Psychedelic Therapy: A Primer for Primary Care Clinicians - Part IV. Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/a8xwk\_v1}{source link}.
\item Śladowska K, Kawalec P, Brzostek T, Pilc A. (2023). \textit{Potential use of psilocybin drugs in the treatment of depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14728214.2023.2264180}{doi:10.1080/14728214.2023.2264180}.
\item Yvan Beaussant, Elise C. Tarbi, Kabir Nigam, Skye A. Miner, Zachary Sager, Justin J. Sanders, Michael Ljuslin, Benjamin Guérin, Paul Thambi, James A. Tulsky, Manish Agrawal (2023). \textit{Acceptability of psilocybin-assisted group therapy in patients with cancer and major depressive disorder: Qualitative analysis}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35024}{doi:10.1002/cncr.35024}.
\item Manish Agrawal, William A. Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli, Kimberly Roddy, Norma Stevens, Brian D. Richards, Nick Schor, Heather Honstein, Betsy Jenkins, Mark Bates, Paul Thambi (2023). \textit{Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder}. Cancer. [published; OpenAlex]. \href{https://doi.org/10.1002/cncr.35010}{doi:10.1002/cncr.35010}.
\item Yale University (2023). \textit{Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02981173}{source link}.
\item Brennan W, Kelman AR, Belser AB. (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/psymed.2023.0007}{doi:10.1089/psymed.2023.0007}.
\item Unknown authors (2023). \textit{Drugs for depressionr.}. The Medical letter on drugs and therapeutics. [published; PubMed]. \href{https://doi.org/10.58347/tml.2023.1691a}{doi:10.58347/tml.2023.1691a}.
\item David B. Yaden, Natalie Gukasyan, Sandeep M. Nayak (2023). \textit{Psilocybin in Bipolar II Study Provides Preliminary Data on Safety}. JAMA Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1001/jamapsychiatry.2023.4680}{doi:10.1001/jamapsychiatry.2023.4680}.
\item Emmanuelle A. D. Schindler, Jason J. Sico (2023). \textit{Studying classic psychedelics for the management of headache disorders: Considerations for Veterans}. Journal of Military Veteran and Family Health. [published; OpenAlex]. \href{https://doi.org/10.3138/jmvfh-2023-0006}{doi:10.3138/jmvfh-2023-0006}.
\item Christopher R. Nicholas, David Horton, Julia Malicki, Amelia Baltes, Paul R. Hutson, Randall Brown (2023). \textit{Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0012}{doi:10.1089/psymed.2023.0012}.
\item Wang SM, Kim S, Choi WS, Lim HK, Woo YS, Pae CU, Bahk WM. (2023). \textit{Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.9758/cpn.23.1134}{doi:10.9758/cpn.23.1134}.
\item Apex Labs Ltd. (2023). \textit{A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-Assisted Psychotherapy in Treating Severe Depression Among Adults With Post-Traumatic Stress Disorder (PTSD).}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06141876}{source link}.
\item McAlpine R, Krajnović K, Khan M, Morometescu L, Simonsson O, Sacchet M, Kamboj S. (2023). \textit{Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/9ev27}{doi:10.31234/osf.io/9ev27}.
\item Unknown authors (2023). \textit{Development of a Digital Intervention for Psychedelic Preparation (DIPP): a theory- and person-centred approach}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/9ev27\_v1}{source link}.
\item Tahlia R. Harrison (2023). \textit{Altered stakes: Identifying gaps in the informed consent process for psychedelic-assisted therapy trials}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00267}{doi:10.1556/2054.2023.00267}.
\item Danelle Jones (2023). \textit{Psychedelic Integration: Psychotherapy for non-ordinary states of consciousness}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00306}{doi:10.1556/2054.2023.00306}.
\item Bahji A, Lunsky I, Gutierrez G, Vazquez G. (2023). \textit{Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2023.2278586}{doi:10.1080/02791072.2023.2278586}.
\item Schoeller F, Jain A, Adrien V, Maes P, Reggente N. (2023). \textit{Aesthetic Chills Mitigate Maladaptive Cognition In Depression}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3582420/v1}{doi:10.21203/rs.3.rs-3582420/v1}.
\item Tor-Morten Kvam, Malin V. Uthaug, Kristoffer Andreas Aamodt Andersen, Birk Berggrav Refsum, Paula Aarseth Tunstad, Lowan H. Stewart, Henrik Børsting Jacobsen, Cato Grønnerød (2023). \textit{Epidemiology of classic psychedelic substances: results from a Norwegian internet convenience sample}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1287196}{doi:10.3389/fpsyt.2023.1287196}.
\item COMPASS Pathways (2023). \textit{The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04739865}{source link}.
\item Heresco-Levy U, Lerer B. (2023). \textit{Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1038/s41380-023-02312-8}{doi:10.1038/s41380-023-02312-8}.
\item Rhee TG, Davoudian PA, Sanacora G, Wilkinson ST. (2023). \textit{Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drudis.2023.103818}{doi:10.1016/j.drudis.2023.103818}.
\item Leiqi LIU, Jing-Ze Chen, Wusheng Fu, Cui-Ying Tang (2023). \textit{Determination of amanita peptide and tryptamine toxins in wild mushrooms by high performance liquid chromatography-tandem mass spectrometry}. Chinese Journal of Chromatography. [published; OpenAlex]. \href{https://doi.org/10.3724/sp.j.1123.2023.07013}{doi:10.3724/sp.j.1123.2023.07013}.
\item Cameron LP, Benetatos J, Lewis V, Bonniwell EM, Jaster AM, Moliner R, Castrén E, McCorvy JD, Palner M, Aguilar-Valles A. (2023). \textit{Beyond the 5-HT2A Receptor: Classic and Nonclassic Targets in Psychedelic Drug Action.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1523/jneurosci.1384-23.2023}{doi:10.1523/jneurosci.1384-23.2023}.
\item Kaminski D, Reinert JP. (2023). \textit{The Tolerability and Safety of Psilocybin in Psychiatric and Substance-Dependence Conditions: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/10600280231205645}{doi:10.1177/10600280231205645}.
\item Kratina S, Lo C, Schwartz R, Strike C, Jopling S, Nayfeh A, Rush B. (2023). \textit{A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/4gfyd}{doi:10.31234/osf.io/4gfyd}.
\item Unknown authors (2023). \textit{A protocol for a scoping review of psychedelic interventions to alleviate psychological suffering in populations coping with end-of-life issues}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/4gfyd\_v1}{source link}.
\item Jules Evans, Oliver Robinson, Eirini K. Argyri, Shayam Suseelan, Ashleigh Murphy-Beiner, Rosalind McAlpine, David Luke, Katrina Michelle, Ed Prideaux (2023). \textit{Extended difficulties following the use of psychedelic drugs: A mixed methods study}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0293349}{doi:10.1371/journal.pone.0293349}.
\item Wsół A. (2023). \textit{Cardiovascular safety of psychedelic medicine: current status and future directions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s43440-023-00539-4}{doi:10.1007/s43440-023-00539-4}.
\item Rakoczy RJ, Runge GN, Sen AK, Sandoval O, Nguyen Q, Roberts BR, Sciortino JH, Gibbons WJ, Friedberg LM, Andrew Jones J, McMurray MS. (2023). \textit{Pharmacological and behavioral effects of tryptamines present in psilocybin-containing mushrooms}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.10.19.563138}{doi:10.1101/2023.10.19.563138}.
\item Watford T, Masood N. (2023). \textit{Psilocybin, an Effective Treatment for Major Depressive Disorder in Adults - A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.9758/cpn.23.1120}{doi:10.9758/cpn.23.1120}.
\item Yale University (2023). \textit{Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03806985}{source link}.
\item Yale University (2023). \textit{Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03341689}{source link}.
\item Kiffer G. Card, Ashmita Grewal, Kalysha Closson, Gina Martin, Laura Baracaldo, Sandra Allison, Daniel J. Kruger, Zach Walsh (2023). \textit{Therapeutic Potential of Psilocybin for Treating Psychological Distress among Survivors of Adverse Childhood Experiences: Evidence on Acceptability and Potential Efficacy of Psilocybin Use}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2023.2268640}{doi:10.1080/02791072.2023.2268640}.
\item Shinozuka K, Jerotic K, Mediano P, Zhao AT, Preller KH, Carhart-Harris R, Kringelbach ML. (2023). \textit{Synergistic, Multi-level Understanding of Psychedelics: Three Systematic Reviews and Meta-analyses of Their Pharmacology, Neuroimaging and Phenomenology}. bioRxiv. [preprint; bioRxiv]. \href{https://doi.org/10.1101/2023.10.06.561183}{doi:10.1101/2023.10.06.561183}.
\item Robert H. Dworkin, Michael McDermott, Sandeep M. Nayak, Eric C. Strain (2023). \textit{Psychedelics and Psychotherapy: Is the Whole Greater than the Sum of its Parts?}. Clinical Pharmacology \& Therapeutics. [published; OpenAlex]. \href{https://doi.org/10.1002/cpt.3050}{doi:10.1002/cpt.3050}.
\item C Donegan, Dimitri Daldegan-Bueno, Rachael L. Sumner, David B Menkes, William J. Evans, Nicholas Hoeh, Frederick Sundram, Lisa Reynolds, Rhys Ponton, Alana Cavadino, Todd Smith, Partha S. Roop, Nathan Allen, Binu Abeysinghe, Darren Svirskis, Anna Forsyth, Mahima Bansal, Suresh Muthukumaraswamy (2023). \textit{An open-label pilot trial assessing tolerability and feasibility of LSD microdosing in patients with major depressive disorder (LSDDEP1)}. Pilot and Feasibility Studies. [published; OpenAlex]. \href{https://doi.org/10.1186/s40814-023-01399-8}{doi:10.1186/s40814-023-01399-8}.
\item Unknown authors (2023). \textit{Psilocybin shows promising results in subjects continuing to use an antidepressant}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.31089}{doi:10.1002/pu.31089}.
\item Gold ND, Mallard AJ, Hermann JC, Zeifman RJ, Pagni BA, Bogenschutz MP, Ross S (2023). \textit{Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2022.0604}{doi:10.1089/jpm.2022.0604}.
\item University of New Mexico (2023). \textit{Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT01534494}{source link}.
\item Haniya J. Halim, Bradley G. Burk, Rachel E. Fargason, Badari Birur (2023). \textit{Manic episode following psilocybin use in a man with bipolar II disorder: a case report}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1221131}{doi:10.3389/fpsyt.2023.1221131}.
\item University of Zurich (2023). \textit{Phase II, Randomized, Double Blind, Placebo Controlled, Parallel Group, Single Center Study of Psilocybin Efficacy and Mechanism in Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04141501}{source link}.
\item Taylor Black (2023). \textit{Lifeboat ethics, risk, and therapeutic opportunity: an appeal for equitable psychedelic therapy access in the “high-risk” addiction patient}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1159843}{doi:10.3389/fpsyt.2023.1159843}.
\item Keith G. Heinzerling, Karina Sergi, Micah Linton, Rhianna Rich, Brittany Youssef, Inez Bentancourt, Jennifer E. Bramen, Prabha Siddarth, L. Schwartzberg, Daniel F. Kelly (2023). \textit{Nature-themed video intervention may improve cardiovascular safety of psilocybin-assisted therapy for alcohol use disorder}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1215972}{doi:10.3389/fpsyt.2023.1215972}.
\item Brian S. Barnett, Miranda Arakelian, David S. Beebe, Jared Ontko, Connor Riegal, Willie O. Siu, Jeremy Weleff, Harrison G. Pope (2023). \textit{American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A7-Year Follow-Up Survey}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0036}{doi:10.1089/psymed.2023.0036}.
\item Guy M. Goodwin (2023). \textit{The psychedelic experience and treatment-resistant depression}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.21140}{doi:10.1002/wps.21140}.
\item Lobe Sciences Ltd. (2023). \textit{Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT06035900}{source link}.
\item NM Mahmudul Alam Bhuiya, Robin J. Jacobs, Karina Wang, Yiqun Sun, Brenda Nava, Luke Sampiere, Akhila Yerubandi, Joshua Caballero (2023). \textit{Predictors of Pharmacy Students' Attitudes About the Therapeutic Use of Psilocybin}. Cureus. [published; OpenAlex]. \href{https://doi.org/10.7759/cureus.45169}{doi:10.7759/cureus.45169}.
\item Wolfgang AS, Hoge CW. (2023). \textit{Psychedelic-Assisted Therapy in Military and Veterans Healthcare Systems: Clinical, Legal, and Implementation Considerations.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11920-023-01446-4}{doi:10.1007/s11920-023-01446-4}.
\item Syed OA, Tsang B, Gerlai R. (2023). \textit{The zebrafish for preclinical psilocybin research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2023.105381}{doi:10.1016/j.neubiorev.2023.105381}.
\item Marc J. Weintraub, Jessica Jeffrey, Charles S. Grob, Megan Ichinose, R. Lindsey Bergman, Ziva D. Cooper, David J. Miklowitz (2023). \textit{Psilocybin-Assisted Cognitive Behavioral Therapy for Adults with Major Depressive Disorder: Rationale and Treatment Development}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0018}{doi:10.1089/psymed.2023.0018}.
\item David W. Lawrence (2023). \textit{Self-administration of Psilocybin for the Acute Treatment of Migraine: A Case Report.}. PubMed. [published; OpenAlex]. \href{https://pubmed.ncbi.nlm.nih.gov/37817818}{source link}.
\item Kalfas M, Taylor RH, Tsapekos D, Young AH. (2023). \textit{Psychedelics for treatment resistant depression: are they game changers?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14656566.2023.2281582}{doi:10.1080/14656566.2023.2281582}.
\item Evelyn Attia, Joanna Steinglass (2023). \textit{Psilocybin for anorexia nervosa: If it helps, let’s learn how}. Med. [published; OpenAlex]. \href{https://doi.org/10.1016/j.medj.2023.08.003}{doi:10.1016/j.medj.2023.08.003}.
\item Emmanuelle A. D. Schindler, Peter S. Hendricks (2023). \textit{Adapting psychedelic medicine for headache and chronic pain disorders}. Expert Review of Neurotherapeutics. [published; OpenAlex]. \href{https://doi.org/10.1080/14737175.2023.2246655}{doi:10.1080/14737175.2023.2246655}.
\item Sharma P, Nguyen QA, Matthews SJ, Carpenter E, Mathews DB, Patten CA, Hammond CJ. (2023). \textit{Psilocybin history, action and reaction: A narrative clinical review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231190858}{doi:10.1177/02698811231190858}.
\item Charles L. Raison, Gerard Sanacora, Joshua Woolley, Keith G. Heinzerling, Boadie W. Dunlop, Randall Brown, Rishi Kakar, Michael Hassman, Rupal Trivedi, Reid Robison, Natalie Gukasyan, Sandeep M. Nayak, Xiaojue Hu, Kelley C. O’Donnell, Benjamin Kelmendi, Jordan Sloshower, Andrew Penn, Ellen Bradley, Daniel F. Kelly, Tanja Mletzko, Christopher R. Nicholas, Paul R. Hutson, Gary Tarpley, Malynn Utzinger, Kelsey Lenoch, Kasia Warchol, Theraysa Gapasin, Mike C. Davis, Courtney Nelson-Douthit, Steffanie H Wilson, Carrie Brown, William Linton, Matthew W. Johnson, Stephen Ross, Roland R. Griffiths (2023). \textit{Single-Dose Psilocybin Treatment for Major Depressive Disorder}. JAMA. [published; OpenAlex]. \href{https://doi.org/10.1001/jama.2023.14530}{doi:10.1001/jama.2023.14530}.
\item David S. Mathai, Samantha Hilbert, Nathan D. Sepeda, Justin C. Strickland, Roland R. Griffiths, Albert Garcia-Romeu (2023). \textit{Double-Blind Comparison of the Two Hallucinogens Dextromethorphan and Psilocybin: Experience-Dependent and Enduring Psychological Effects in Healthy Volunteers}. Psychedelic Medicine. [published; OpenAlex]. \href{https://doi.org/10.1089/psymed.2023.0035}{doi:10.1089/psymed.2023.0035}.
\item Natália Bernardi Videira, Vijayalekshmi Nair, Valérie Paquet, Dean Calhoun (2023). \textit{The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits}. Journal of Applied Toxicology. [published; OpenAlex]. \href{https://doi.org/10.1002/jat.4533}{doi:10.1002/jat.4533}.
\item Grant Jones, Maha Al-Suwaidi, Franchesca Castro-Ramirez, Taylor C. McGuire, Patrick Mair, Matthew K. Nock (2023). \textit{Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1169692}{doi:10.3389/fpsyt.2023.1169692}.
\item Wong S, Yu AY, Fabiano N, Finkelstein O, Pasricha A, Jones BDM, Rosenblat JD, Blumberger DM, Mulsant BH, Husain MI. (2023). \textit{Beyond Psilocybin: Reviewing the Therapeutic Potential of Other Serotonergic Psychedelics in Mental and Substance Use Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2023.2251133}{doi:10.1080/02791072.2023.2251133}.
\item Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin J. Mallard, Daniel E. Roberts, David Erritzøe, Stephen Ross, Robin Carhart-Harris (2023). \textit{Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-023-40856-5}{doi:10.1038/s41598-023-40856-5}.
\item Benjamin M. Ross, James T. Neill (2023). \textit{Exploring the relationship between mental health, drug use, personality, and attitudes towards psilocybin-assisted therapy}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2023.00264}{doi:10.1556/2054.2023.00264}.
\item Joseph J. Palamar, Caroline Rutherford, Austin Le, Katherine M. Keyes (2023). \textit{Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2023.2240322}{doi:10.1080/02791072.2023.2240322}.
\item Mauro Cavarra, Natasha L. Mason, Kim P. C. Kuypers, Valérie Bonnelle, William Smith, Amanda Feilding, Pamela Kryskow, Johannes G. Ramaekers (2023). \textit{Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study}. European Journal of Pain. [published; OpenAlex]. \href{https://doi.org/10.1002/ejp.2171}{doi:10.1002/ejp.2171}.
\item Raúl Escamilla, María Eva González-Trujano, Jesús M. González Mariscal, J. Martı́n Torres-Valencia, Héctor Guzmán-González, José Luis Vega, Anja Loizaga-Velder (2023). \textit{A Proposal to Study the Safety and Efficacy of Psilocybe cubensis in Preclinical and Clinical Studies as a Therapeutic Alternative for Major Depressive Disorder}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2023.2246459}{doi:10.1080/02791072.2023.2246459}.
\item Nick Zagorski (2023). \textit{Australia Legalizes Psychedelics for Use in Depression, PTSD Therapy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.09.9.20}{doi:10.1176/appi.pn.2023.09.9.20}.
\item Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R. (2023). \textit{The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231190865}{doi:10.1177/02698811231190865}.
\item Grant Jones, Felipe Herrmann, Erica Wang (2023). \textit{Associations between individual hallucinogens and hallucinogen misuse among U.S. Adults who recently initiated hallucinogen use}. Addictive Behaviors Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.abrep.2023.100513}{doi:10.1016/j.abrep.2023.100513}.
\item Anna Jaremek, Joanna Kępa, Norbert Kandefer, Michał Wyszkowski, Aleksandra Grabarczyk, Anna Pawlak, Sylwia Grad, Małgorzata Gregorek, Paweł Gregorek (2023). \textit{Psilocybin's Emerging Role in Combating Depressive Disorder}. Journal of Education Health and Sport. [published; OpenAlex]. \href{https://doi.org/10.12775/jehs.2023.40.01.011}{doi:10.12775/jehs.2023.40.01.011}.
\item Amanda E. Downey, Maxine Boyd, Anita V. Chaphekar, Joshua Woolley, Marissa Raymond-Flesch (2023). \textit{“But the reality is it's happening”: A qualitative study of eating disorder providers about psilocybin-assisted psychotherapy}. International Journal of Eating Disorders. [published; OpenAlex]. \href{https://doi.org/10.1002/eat.24041}{doi:10.1002/eat.24041}.
\item Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, Seragnoli F, Zullino D, Kirschner M, Kaiser S, Solmi M, Sabé M. (2023). \textit{Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2023.07.011}{doi:10.1016/j.euroneuro.2023.07.011}.
\item Kevin F. Boehnke, Kasey Cox, Cody Weston, Moss Herberholz, Nicolas Glynos, Nicholas Kolbman, Christopher W. Fields, Julie Barron, Daniel J. Kruger (2023). \textit{Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1224551}{doi:10.3389/fpsyt.2023.1224551}.
\item Schindler EAD. (2023). \textit{The Potential of Psychedelics for the Treatment of Episodic Migraine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11916-023-01145-y}{doi:10.1007/s11916-023-01145-y}.
\item Ruzmayuddin Mamat, Rusdi Abd Rashid, Maw Shin Sim, Baharudin Ibrahim, Suzaily Wahab, Azmir Ahmad (2023). \textit{Prevalence of psilocybin use in vaping and associated factors: a study among amphetamine-type stimulants (ATS) use disorder in Malaysia}. Journal of Addictive Diseases. [published; OpenAlex]. \href{https://doi.org/10.1080/10550887.2023.2240932}{doi:10.1080/10550887.2023.2240932}.
\item Jing X, Hoeh NR, Menkes DB. (2023). \textit{Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s147895152300069x}{doi:10.1017/s147895152300069x}.
\item Ibrahim IB, Videbech P, Straszek SPV. (2023). \textit{Psychedelic drugs in the treatment of psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/37615227}{source link}.
\item Terri D’Arrigo (2023). \textit{Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.08.8.3}{doi:10.1176/appi.pn.2023.08.8.3}.
\item Brain and Cognition Discovery Foundation (2023). \textit{The Efficacy and Tolerability of Psilocybin in Participants With Treatment-Resistant Depression: a Phase 2, Randomized Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05029466}{source link}.
\item Finkelstein C, Soha O, Roy A, Phillipou A, Rossell S. (2023). \textit{“Why would you open someone’s brain up?” Lived experience insights inform a psilocybin-assisted psychotherapy treatment manual for body image disturbance}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3189970/v1}{doi:10.21203/rs.3.rs-3189970/v1}.
\item The Roots to Thrive Society for Psychedelic Therapy (2023). \textit{An Open Label Pragmatic Feasibility Study on a Resilience Focused Community of Practice Program With Psilocybin-assisted Therapy (PaT) for End-of-Life Patients.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05958758}{source link}.
\item Simonsson O, Carlbring P, Carhart-Harris R, Davis AK, Nutt DJ, Griffiths RR, Erritzoe D, Goldberg SB. (2023). \textit{Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2023.115349}{doi:10.1016/j.psychres.2023.115349}.
\item Zeiss R. (2023). \textit{Psilocybin as an antidepressant strategy - a review of safety aspects}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC10405689}{source link}.
\item Вікторія Шаповалова, Alina Osyntseva, Валерій Шаповалов, Serhii Nehretskii (2023). \textit{Pharmacognostic, Forensic and Pharmaceutical, Organizational and Legal, Clinical and Pharmacological Multidisciplinary Study with an Assessment of Peculiarities of Circulation (Use) of Smoking Mixtures of Spices and Entheogens of Amanita Muscaria Mushroom}. SSP Modern Pharmacy and Medicine. [published; OpenAlex]. \href{https://doi.org/10.53933/sspmpm.v3i3.105}{doi:10.53933/sspmpm.v3i3.105}.
\item Unknown authors (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.1089/psymed.2023.00071}{doi:10.1089/psymed.2023.00071}.
\item Brennan B, Kelman A, Belser AB. (2023). \textit{A Systematic Review of Reporting Practices in Psychedelic Clinical Trials: Psychological Support, Therapy, and Psychosocial Interventions}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/2ab59}{doi:10.31234/osf.io/2ab59}.
\item Nkadimeng SM, Hay L, Steinmann CM, Eloff JN. (2023). \textit{Administration effects of four psilocybin mushroom extracts on serotonin levels and endothelial nitric oxide synthase activity levels in vivo and in vitro after one hour}. Research Square. [preprint; Europe PMC]. \href{https://doi.org/10.21203/rs.3.rs-3088850/v1}{doi:10.21203/rs.3.rs-3088850/v1}.
\item Guy M. Goodwin, Megan Croal, David Feifel, John R. Kelly, Lindsey Marwood, Sunil Mistry, Veronica O’Keane, Stéphanie Knatz Peck, Hollie Simmons, Claudia Sisa, S. C. Stansfield, Joyce Tsai, Sam Williams, Ekaterina Malievskaia (2023). \textit{Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-023-01648-7}{doi:10.1038/s41386-023-01648-7}.
\item Jim Gilligan (2023). \textit{Leveraging psychedelic therapies for binge eating disorder}. Open Access Government. [published; OpenAlex]. \href{https://doi.org/10.56367/oag-039-10936}{doi:10.56367/oag-039-10936}.
\item Tetem J, Fischmann T, Möller TJ. (2023). \textit{Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/ztyxh}{doi:10.31234/osf.io/ztyxh}.
\item Unknown authors (2023). \textit{Psychoactive substances in psychotherapy - A vision for the future? - A systematic review on Psilocybin}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/ztyxh\_v1}{source link}.
\item Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ. (2023). \textit{Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231180276}{doi:10.1177/02698811231180276}.
\item Bonnieux JN, VanderZwaag B, Premji Z, Garcia-Romeu A, Garcia-Barrera MA. (2023). \textit{Psilocybin's effects on cognition and creativity: A scoping review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811231179801}{doi:10.1177/02698811231179801}.
\item Kozak Z, Johnson MW, Aaronson ST. (2023). \textit{Assessing potential of psilocybin for depressive disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/13543784.2023.2273493}{doi:10.1080/13543784.2023.2273493}.
\item Muhammad Ishrat Husain, Daniel M. Blumberger, David Castle, Nicole Ledwos, Elise Fellows, Brett D. M. Jones, Abigail Ortiz, Stefan Kloiber, Wei Wang, Joshua D. Rosenblat, Benoit H. Mulsant (2023). \textit{Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2023.535}{doi:10.1192/bjo.2023.535}.
\item Valerie A. Canady (2023). \textit{FDA issues first draft guidance on psychedelic research}. Mental Health Weekly. [published; OpenAlex]. \href{https://doi.org/10.1002/mhw.33697}{doi:10.1002/mhw.33697}.
\item Scala M, Fanelli G, De Ronchi D, Serretti A, Fabbri C. (2023). \textit{Clinical specificity profile for novel rapid acting antidepressant drugs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/yic.0000000000000488}{doi:10.1097/yic.0000000000000488}.
\item Halucenex Life Sciences Inc. (2023). \textit{Investigating the Therapeutic Effects of Psilocybin in Treatment-Resistant Post-Traumatic Stress Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05243329}{source link}.
\item Terri D’Arrigo (2023). \textit{Experts Offer Tips on Talking With Patients About Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.07.7.51}{doi:10.1176/appi.pn.2023.07.7.51}.
\item Nick Zagorski (2023). \textit{Psychedelic Therapy Requires Enhanced Consent Discussions}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.07.7.46}{doi:10.1176/appi.pn.2023.07.7.46}.
\item Calder A, Mock S, Friedli N, Pasi P, Hasler G. (2023). \textit{Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.euroneuro.2023.05.008}{doi:10.1016/j.euroneuro.2023.05.008}.
\item Kevin Herkenham (2023). \textit{A regulatory framework review of Schedule I psychedelics in the United States}. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. [published; OpenAlex]. \href{https://doi.org/10.1002/jac5.1841}{doi:10.1002/jac5.1841}.
\item Katherine M. Keyes, Megan E. Patrick (2023). \textit{Hallucinogen use among young adults ages 19-30 in the United States: Changes from 2018 to 2021}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.16259}{doi:10.1111/add.16259}.
\item Nkadimeng SM, Steinmann CM, Eloff JN. (2023). \textit{Cardioprotective Potential of the Ethanol and Water Extracts of Four Psilocybin Mushrooms on Angiotensin II-Induced Hypertrophy and Oxidative Stress on H9C2 Cardiomyocytes}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202306.0362.v1}{doi:10.20944/preprints202306.0362.v1}.
\item Tooba Noor, Areej Shakil, Aimen Waqar Khan, Syeda Mahrukh Fatima Zaidi, Hussain Sohail Rangwala, Burhanuddin Sohail Rangwala (2023). \textit{Psilocybin therapy: A novel approach to treating depression}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000175}{doi:10.1097/gh9.0000000000000175}.
\item Gold ND, Podrebarac SK, White LA, Marini C, Simon NM, Mittelman MS, Ross S, Bogenschutz MP, Petridis PD (2023). \textit{Examining the Rationale for Studying Psychedelic-Assisted Psychotherapy for the Treatment of Caregiver Distress.}. Psychedelic medicine (New Rochelle, N.Y.). [published; PubMed]. \href{https://doi.org/10.1089/psymed.2022.0011}{doi:10.1089/psymed.2022.0011}.
\item Scott Hoener, Aaron Wolfgang, David A. Nissan, Edmund G. Howe (2023). \textit{Ethical considerations for psychedelic-assisted therapy in military clinical settings}. Journal of Medical Ethics. [published; OpenAlex]. \href{https://doi.org/10.1136/jme-2023-108943}{doi:10.1136/jme-2023-108943}.
\item Combat Stress (2023). \textit{Evaluation of the Acceptability, Safety, Feasibility, and Efficacy of Psilocybin-assisted Psychotherapy (PaP) for the Treatment of Post-traumatic Stress Disorder (PTSD) in Military Veterans}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05876481}{source link}.
\item Laura Ley, Friederike Holze, Denis Arikci, A. Becker, Isabelle Straumann, Aaron Klaiber, Fabio Coviello, Sophie Dierbach, Jan Thomann, Urs Duthaler, Dino Luethi, Nimmy Varghese, Anne Eckert, Matthias E. Liechti (2023). \textit{Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants}. Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1038/s41386-023-01607-2}{doi:10.1038/s41386-023-01607-2}.
\item Qasim S, Zaheer Z, Jawad MY, Shad MU. (2023). \textit{Neurobiological Correlates of Psilocybin Response in Depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.4088/pcc.22r03419}{doi:10.4088/pcc.22r03419}.
\item University of Wisconsin, Madison (2023). \textit{Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04842045}{source link}.
\item University of Wisconsin, Madison (2023). \textit{A Phase 1 Study Comparing the Pharmacokinetics and Safety of Intravenous and Oral Psilocybin}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05467761}{source link}.
\item Johns Hopkins University (2023). \textit{Effects of Psilocybin in Anorexia Nervosa}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04052568}{source link}.
\item Alan K. Davis, Adam W. Levin, Paul Nagib, Stacey B. Armstrong, Rafael Lancelotta (2023). \textit{Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD}. BMJ Open. [published; OpenAlex]. \href{https://doi.org/10.1136/bmjopen-2022-068884}{doi:10.1136/bmjopen-2022-068884}.
\item Eric N. Kramer, Kalyn Reddy, Bryan Shapiro (2023). \textit{A suicide attempt following psilocybin ingestion in a patient with no prior psychiatric history}. Psychiatry Research Case Reports. [published; OpenAlex]. \href{https://doi.org/10.1016/j.psycr.2023.100118}{doi:10.1016/j.psycr.2023.100118}.
\item Terence H. W. Ching, Rachael Grazioplene, Calvin Bohner, Stephen A. Kichuk, Giuliana DePalmer, Elizabeth J. D’Amico, Jeffrey Eilbott, Anastasia Jankovsky, Michelle Burke, Jamila Hokanson, Brad Martins, Chelsea Witherow, Prerana Patel, Lucia Amoroso, Henry Schaer, Christopher Pittenger, Benjamin Kelmendi (2023). \textit{Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1178529}{doi:10.3389/fpsyt.2023.1178529}.
\item COMPASS Pathways (2023). \textit{The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03775200}{source link}.
\item Bennett JN, Blough MD, Mitchell I, Galloway L, Bains R. (2023). \textit{A Phase I trial to inform clinical protocols for the safe administration of psilocybin-assisted psychotherapy}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2023.04.12.23288325}{doi:10.1101/2023.04.12.23288325}.
\item Whinkin E, Opalka M, Watters C, Jaffe A, Aggarwal S. (2023). \textit{Psilocybin in Palliative Care: An Update.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s13670-023-00383-7}{doi:10.1007/s13670-023-00383-7}.
\item Khan I, Jaura TA, Tukruna A, Arif A, Tebha SS, Nasir S, Mukherjee D, Masroor N, Yosufi A. (2023). \textit{Use of Selective Alternative Therapies for Treatment of OCD.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2147/ndt.s403997}{doi:10.2147/ndt.s403997}.
\item Zia FZ, Baumann MH, Belouin SJ, Dworkin RH, Ghauri MH, Hendricks PS, Henningfield JE, Lanier RK, Ross S, Berger A. (2023). \textit{Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2023.109528}{doi:10.1016/j.neuropharm.2023.109528}.
\item Simonsson O, Hendricks PS, Chambers R, Osika W, Goldberg SB (2023). \textit{Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.}. Journal of affective disorders. [published; PubMed]. \href{https://doi.org/10.1016/j.jad.2023.01.073}{doi:10.1016/j.jad.2023.01.073}.
\item Feduccia A, Agin-Liebes G, Price CM, Grinsell N, Paradise S, Rabin DM. (2023). \textit{The need for establishing best practices and gold standards in psychedelic medicine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2023.03.083}{doi:10.1016/j.jad.2023.03.083}.
\item Domanegg K, Sommer WH, Meinhardt MW. (2023). \textit{Psychedelic Targeting of Metabotropic Glutamate Receptor 2 and Its Implications for the Treatment of Alcoholism.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/cells12060963}{doi:10.3390/cells12060963}.
\item Optimi Health Corporation (2023). \textit{Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05252598}{source link}.
\item Ching THW, Grazioplene R, Pittenger C, Kelmendi B. (2023). \textit{Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/ba42z}{doi:10.31234/osf.io/ba42z}.
\item Unknown authors (2023). \textit{Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/ba42z\_v1}{source link}.
\item New York State Psychiatric Institute (2023). \textit{Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04656301}{source link}.
\item Turkia M. (2023). \textit{Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/wupvy}{doi:10.31234/osf.io/wupvy}.
\item Unknown authors (2023). \textit{Self-treatment of depression and complex post-traumatic stress disorder with psilocybin and LSD-A retrospective case study}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/wupvy\_v1}{source link}.
\item Steven W. Cotten, Frederick G. Strathmann, Frederick S. Barrett, Laura Labay, James Mullally, Alexander M. Sherwood, Frank Wiegand (2023). \textit{Psychedelics for Medicinal Use: How Will This Alter the Collective Laboratory Consciousness?}. Clinical Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1093/clinchem/hvad016}{doi:10.1093/clinchem/hvad016}.
\item Kalkman HO (2023). \textit{Inhibition of Microglial GSK3β Activity Is Common to Different Kinds of Antidepressants: A Proposal for an In Vitro Screen to Detect Novel Antidepressant Principles.}. Biomedicines. [published; PubMed]. \href{https://doi.org/10.3390/biomedicines11030806}{doi:10.3390/biomedicines11030806}.
\item Otterman LS (2023). \textit{Research into Psychedelic-Assisted Psychotherapy for Anorexia Nervosa Should be Funded.}. Journal of bioethical inquiry. [published; PubMed]. \href{https://doi.org/10.1007/s11673-022-10220-9}{doi:10.1007/s11673-022-10220-9}.
\item Jha MK, Mathew SJ. (2023). \textit{Pharmacotherapies for Treatment-Resistant Depression: How Antipsychotics Fit in the Rapidly Evolving Therapeutic Landscape.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1176/appi.ajp.20230025}{doi:10.1176/appi.ajp.20230025}.
\item 飯倉 洋治, 馬場 實, 三河 春樹, 西間 三馨, 前田 和一, 赤坂 徹, 正木 拓朗, 有田 昌彦 (2023). \textit{Effect of psilocybin on decision-making and motivation in the healthy rat.}. PubMed. [published; OpenAlex]. \href{https://doi.org/10.1016/j.bbr.2022.114262}{doi:10.1016/j.bbr.2022.114262}.
\item Jacques Ambrose, J.S. Zabinski (2023). \textit{Psychedelic Renaissance: Clinical Health Justice, Patient Safety, and Equity Need to Be Put First}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.03.3.43}{doi:10.1176/appi.pn.2023.03.3.43}.
\item Terri D’Arrigo (2023). \textit{Psychedelics Legislation Gains Momentum}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2023.03.3.4}{doi:10.1176/appi.pn.2023.03.3.4}.
\item Henríquez-Hernández LA, Rojas-Hernández J, Quintana-Hernández DJ, Borkel LF. (2023). \textit{Hofmann vs. Paracelsus: Do Psychedelics Defy the Basics of Toxicology?-A Systematic Review of the Main Ergolamines, Simple Tryptamines, and Phenylethylamines.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/toxics11020148}{doi:10.3390/toxics11020148}.
\item Sellers EM, Romach MK. (2023). \textit{Psychedelics: Science sabotaged by Social Media.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2023.109426}{doi:10.1016/j.neuropharm.2023.109426}.
\item Deborah Rudin, Alexander Areesanan, Matthias E. Liechti, Carsten Gründemann (2023). \textit{Classic psychedelics do not affect T cell and monocyte immune responses}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2023.1042440}{doi:10.3389/fpsyt.2023.1042440}.
\item Benjamin R. Lewis, Kevin Byrne, John Hendrick, Eric L. Garland, Paul Thielking, Anna C. Beck (2023). \textit{Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00222}{doi:10.1556/2054.2022.00222}.
\item Dragana Marković, Eleonora Čapelja (2023). \textit{Therapeutic potential of psilocybin: a promising agent in treating major depressive disorder}. AIDASCO Reviews. [published; OpenAlex]. \href{https://doi.org/10.59783/aire.2023.15}{doi:10.59783/aire.2023.15}.
\item Keith Heinzerling (2023). \textit{Pilot Trial of Visual Healing®, a Nature-themed Virtual Immersive Experience, to Optimize Set and Setting in Psilocybin-assisted Therapy for Alcohol Use Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04410913}{source link}.
\item Benjamin A. Korman (2023). \textit{Recruitment discrimination of lifetime classic psychedelic users is unjustified: Evidence from employees' motivation-based workplace absenteeism}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00240}{doi:10.1556/2054.2022.00240}.
\item Lindsay P. Cameron, Seona D. Patel, Maxemiliano V. Vargas, Eden V. Barragan, Hannah N. Saeger, Hunter T. Warren, Winston L. Chow, J.A. Gray, David E. Olson (2023). \textit{5-HT2ARs Mediate Therapeutic Behavioral Effects of Psychedelic Tryptamines}. ACS Chemical Neuroscience. [published; OpenAlex]. \href{https://doi.org/10.1021/acschemneuro.2c00718}{doi:10.1021/acschemneuro.2c00718}.
\item Kooijman NI, Willegers T, Reuser A, Mulleners WM, Kramers C, Vissers KCP, van der Wal SEI. (2023). \textit{Are psychedelics the answer to chronic pain: A review of current literature.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/papr.13203}{doi:10.1111/papr.13203}.
\item Sebastian William Foster (2023). \textit{Cognitive liberty and the constitutionality of criminalising psilocybin mushrooms in South Africa}. South African Journal on Human Rights. [published; OpenAlex]. \href{https://doi.org/10.1080/02587203.2023.2202875}{doi:10.1080/02587203.2023.2202875}.
\item Guy M. Goodwin, Lindsey Marwood, S. Mistry, Anna Nowakowska, Zainib Shabir, H. Clifton Simmons, E.K. Teoh, Jeng-Yu Tsai, E. Malievskaia (2022). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a long-term observational follow-up study}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2023.102906}{doi:10.1016/j.nsa.2023.102906}.
\item Sebastian William Foster (2022). \textit{The right to privacy in the decriminalisation of psilocybin mushrooms in South Africa}. Law Democracy \& Development. [published; OpenAlex]. \href{https://doi.org/10.17159/2077-4907/2023/ldd.v27.1}{doi:10.17159/2077-4907/2023/ldd.v27.1}.
\item Simonsson O, Goldberg SB (2022). \textit{Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2021.2022816}{doi:10.1080/02791072.2021.2022816}.
\item Jack E. Henningfield, Judy Ashworth, David J. Heal, Sharon L. Smith (2022). \textit{Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811221140004}{doi:10.1177/02698811221140004}.
\item Leah Feulner, Thanpicha Sermchaiwong, Nathan Rodland, David Galarneau (2022). \textit{Efficacy and Safety of Psychedelics in Treating Anxiety Disorders}. Ochsner Journal. [published; OpenAlex]. \href{https://doi.org/10.31486/toj.23.0076}{doi:10.31486/toj.23.0076}.
\item Gail A. Edelsohn, Dominic Sisti (2022). \textit{Past Is Prologue: Ethical Issues in Pediatric Psychedelics Research and Treatment}. Perspectives in biology and medicine. [published; OpenAlex]. \href{https://doi.org/10.1353/pbm.2023.0007}{doi:10.1353/pbm.2023.0007}.
\item Natalie Gukasyan (2022). \textit{On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depression}. Med. [published; OpenAlex]. \href{https://doi.org/10.1016/j.medj.2022.12.003}{doi:10.1016/j.medj.2022.12.003}.
\item Mann JJ. (2022). \textit{Is psilocybin an effective antidepressant and what is its Mechanism of action?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.xcrm.2022.100906}{doi:10.1016/j.xcrm.2022.100906}.
\item Shaw L, Rea K, Lachowsky NJ, Roth EA (2022). \textit{Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2022.2054746}{doi:10.1080/02791072.2022.2054746}.
\item IsHak WW, Garcia P, Pearl R, Dang J, William C, Totlani J, Danovitch I. (2022). \textit{The Impact of Psilocybin on Patients Experiencing Psychiatric Symptoms: A Systematic Review of Randomized Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/37387703}{source link}.
\item Blest-Hopley G, Amit BH, O'Neill A, Ruffell SGD (2022). \textit{Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1191970}{doi:10.3389/fpsyt.2023.1191970}.
\item Phan AN, Terry GE (2022). \textit{Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1144276}{doi:10.3389/fpsyt.2023.1144276}.
\item Li I, Fong R, Hagen M, Tabaac B (2022). \textit{Medical student attitudes and perceptions of psychedelic-assisted therapies.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1190507}{doi:10.3389/fpsyt.2023.1190507}.
\item Blond BN, Schindler EAD (2022). \textit{Case report: Psychedelic-induced seizures captured by intracranial electrocorticography.}. Frontiers in neurology. [published; PubMed]. \href{https://doi.org/10.3389/fneur.2023.1214969}{doi:10.3389/fneur.2023.1214969}.
\item Barnett BS, Bassir Nia A, Sackett NB, Weleff J (2022). \textit{Editorial: Psychedelics as treatments for substance use disorders: exploring therapeutic potential, risks, underlying mechanisms of action, and implementation challenges.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2023.1305478}{doi:10.3389/fpsyt.2023.1305478}.
\item Kruger DJ, Enghoff O, Herberholz M, Barron J, Boehnke KF (2022). \textit{"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2023.2201263}{doi:10.1080/02791072.2023.2201263}.
\item Heal DJ, Gosden J, Smith SL, Atterwill CK. (2022). \textit{Experimental strategies to discover and develop the next generation of psychedelics and entactogens as medicines.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2022.109375}{doi:10.1016/j.neuropharm.2022.109375}.
\item Meghan DellaCrosse, Mollie Pleet, Emma Morton, Amir Ashtari, Kimberly Sakai, Josh Woolley, Erin E. Michalak (2022). \textit{“A sense of the bigger picture:” A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0279073}{doi:10.1371/journal.pone.0279073}.
\item Emma Morton, Kimberly Sakai, Amir Ashtari, Mollie Pleet, Erin E. Michalak, Josh Woolley (2022). \textit{Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of ‘magic mushroom’ consumption}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/02698811221131997}{doi:10.1177/02698811221131997}.
\item Unknown authors (2022). \textit{History of epilepsy increases risk of psychedelic-induced seizures}. The Brown University Psychopharmacology Update. [published; OpenAlex]. \href{https://doi.org/10.1002/pu.30967}{doi:10.1002/pu.30967}.
\item Kelly DF, Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. (2022). \textit{Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1227/neu.0000000000002275}{doi:10.1227/neu.0000000000002275}.
\item Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS (2022). \textit{Psychedelic-Assisted Therapy for People with Eating Disorders.}. Current psychiatry reports. [published; PubMed]. \href{https://doi.org/10.1007/s11920-022-01394-5}{doi:10.1007/s11920-022-01394-5}.
\item MacCallum CA, Lo LA, Pistawka CA, Deol JK. (2022). \textit{Therapeutic use of psilocybin: Practical considerations for dosing and administration.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2022.1040217}{doi:10.3389/fpsyt.2022.1040217}.
\item Irizarry R, Winczura A, Dimassi O, Dhillon N, Minhas A, Larice J. (2022). \textit{Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.31796}{doi:10.7759/cureus.31796}.
\item Gotvaldová K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M. (2022). \textit{Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids.}. International Journal of Molecular Sciences. [published; Europe PMC]. \href{https://doi.org/10.3390/ijms232214068}{doi:10.3390/ijms232214068}.
\item NYU Langone Health (2022). \textit{A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT02061293}{source link}.
\item O'Donnell KC, Mennenga SE, Owens LT, Podrebarac SK, Baron T, Rotrosen J, Ross S, Forcehimes AA, Bogenschutz MP. (2022). \textit{Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.}. Contemporary Clinical Trials. [published; Europe PMC]. \href{https://doi.org/10.1016/j.cct.2022.106976}{doi:10.1016/j.cct.2022.106976}.
\item Hamna Raheel, Unaiza Naeem, Asim Shaikh, Omer Ahmed Shaikh (2022). \textit{The psychedelic renaissance: can psilocybin possibly combat depression?}. International Journal of Surgery Global Health. [published; OpenAlex]. \href{https://doi.org/10.1097/gh9.0000000000000089}{doi:10.1097/gh9.0000000000000089}.
\item Paganin W, Signorini S, Signorini S, Leccese V, Sciarretta A. (2022). \textit{[Treatment-resistant depression. From classification to new therapies.]}. Rivista di psichiatria. [published; Europe PMC]. \href{https://doi.org/10.1708/3922.39072}{doi:10.1708/3922.39072}.
\item Sheppard Pratt Health System (2022). \textit{The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04433845}{source link}.
\item Beckley Psytech Limited (2022). \textit{An Exploratory Open-Label, Phase 1b, Ascending Dose Study to Evaluate the Effects of Oral 3-[2-(Dimethylamino)Ethyl]-1h-indol-4-yl Dihydrogen Phosphate (Psilocybin, BPL-PSILO) on Cognition in Patients With Chronic Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04905121}{source link}.
\item Sottile RJ, Vida T. (2022). \textit{A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2022.991753}{doi:10.3389/fpsyt.2022.991753}.
\item Ching THW, Kichuk S, DePalmer G, Pittenger C, Kelmendi B. (2022). \textit{Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/85s9p}{doi:10.31234/osf.io/85s9p}.
\item Unknown authors (2022). \textit{Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/85s9p\_v1}{source link}.
\item Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI. (2022). \textit{A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/jcp.0000000000001608}{doi:10.1097/jcp.0000000000001608}.
\item Timmermann C, Watts R, Dupuis D (2022). \textit{Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations.}. Transcultural psychiatry. [published; PubMed]. \href{https://doi.org/10.1177/13634615221082796}{doi:10.1177/13634615221082796}.
\item Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC (2022). \textit{If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.}. The journal of pain. [published; PubMed]. \href{https://doi.org/10.1016/j.jpain.2022.05.003}{doi:10.1016/j.jpain.2022.05.003}.
\item Simonsson O, Goldberg SB, Chambers R, Osika W, Long DM, Hendricks PS (2022). \textit{Prevalence and associations of classic psychedelic-related seizures in a population-based sample.}. Drug and alcohol dependence. [published; PubMed]. \href{https://doi.org/10.1016/j.drugalcdep.2022.109586}{doi:10.1016/j.drugalcdep.2022.109586}.
\item Dougherty RF, Clarke P, Alti M, Kuc J, Schlosser D, Dunlop BW, Hellerstein DJ, Aaronson ST, Zisook S, Young AH, Carhart-Harris R, Goodwin G, Ryslik GA. (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/kh3cx}{doi:10.31234/osf.io/kh3cx}.
\item Unknown authors (2022). \textit{Psilocybin Therapy for Treatment Resistant Depression: Prediction of Clinical Outcome by Natural Language Processing}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/kh3cx\_v1}{source link}.
\item COMPASS Pathways (2022). \textit{Multicentre Study To Assess Safety And Efficacy Of Psilocybin In Patients With Treatment-Resistant Depression Following Completion Of COMP001 And COMP003 Trials (P-TRD LTFU)}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04519957}{source link}.
\item Mellner C, Dahlen M, Simonsson O (2022). \textit{Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.}. International journal of environmental research and public health. [published; PubMed]. \href{https://doi.org/10.3390/ijerph191811353}{doi:10.3390/ijerph191811353}.
\item Johnston CB, Mangini M, Grob C, Anderson B. (2022). \textit{The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jagp.2022.08.007}{doi:10.1016/j.jagp.2022.08.007}.
\item Rodrigues J, Nombora O, Ribeiro L. (2022). \textit{Therapeutic potential of serotoninergic psychedelic substances in the treatment of Obsessive Compulsive Disorder}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9567436}{source link}.
\item National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders. (2022). \textit{Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop}. National Academies Press (US), Washington (DC). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36049038}{source link}.
\item Christensen JA, Fipps DC, Bostwick JM. (2022). \textit{To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder.}. Experimental and Clinical Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1037/pha0000597}{doi:10.1037/pha0000597}.
\item Kaypak AC, Raz A. (2022). \textit{Macrodosing to microdosing with psychedelics: Clinical, social, and cultural perspectives.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/13634615221119386}{doi:10.1177/13634615221119386}.
\item Brian Peacock (2022). \textit{A-118 Psychedelic Interventions for Neuropsychological Conditions}. Archives of Clinical Neuropsychology. [published; OpenAlex]. \href{https://doi.org/10.1093/arclin/acac060.118}{doi:10.1093/arclin/acac060.118}.
\item Henningfield JE, Coe MA, Griffiths RR, Belouin SJ, Berger A, Coker AR, Comer SD, Heal DJ, Hendricks PS, Nichols CD, Sapienza F, Vocci FJ, Zia FZ. (2022). \textit{Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2022.109220}{doi:10.1016/j.neuropharm.2022.109220}.
\item Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenway KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. (2022). \textit{The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/07067437221111371}{doi:10.1177/07067437221111371}.
\item Levin A, Nagib PB, Deiparine S, Gao T, Mitchell J, Davis AK. (2022). \textit{Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2022.103816}{doi:10.1016/j.drugpo.2022.103816}.
\item Clifton JM, Belcher AM, Greenblatt AD, Welsh CM, Cole TO, Davis AK. (2022). \textit{Psilocybin use patterns and perception of risk among a cohort of Black individuals with Opioid Use Disorder.}. Journal of Psychedelic Studies. [published; Europe PMC]. \href{https://doi.org/10.1556/2054.2022.00214}{doi:10.1556/2054.2022.00214}.
\item Terri D’Arrigo (2022). \textit{Med Check: Psilocybin for OCD, Nuplazid Vote, and More}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.08.8.2}{doi:10.1176/appi.pn.2022.08.8.2}.
\item Rosa WE, Sager Z, Miller M, Bernstein I, Doerner Rinaldi A, Addicott K, Ljuslin M, Adrian C, Back AL, Beachy J, Bossis AP, Breitbart WS, Cosimano MP, Fischer SM, Guss J, Knighton E, Phelps J, Richards BD, Richards WA, Tulsky JA, Williams MT, Beaussant Y (2022). \textit{Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.}. Journal of palliative medicine. [published; PubMed]. \href{https://doi.org/10.1089/jpm.2022.0036}{doi:10.1089/jpm.2022.0036}.
\item Polito V, Liknaitzky P (2022). \textit{The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field.}. Neuroscience and biobehavioral reviews. [published; PubMed]. \href{https://doi.org/10.1016/j.neubiorev.2022.104706}{doi:10.1016/j.neubiorev.2022.104706}.
\item University of California, San Diego (2022). \textit{Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04661514}{source link}.
\item Dodd S, Norman TR, Eyre HA, Stahl SM, Phillips A, Carvalho AF, Berk M. (2022). \textit{Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s1092852922000888}{doi:10.1017/s1092852922000888}.
\item Madsen MK, Petersen AS, Stenbæk DS, Sørensen IM, Schiønning H, Fjeld T, Nykjær CH, Ulv Larsen SM, Grzywacz M, Mathiesen T, Klausen IL, Overgaard-Hansen O, Brendstrup-Brix K, Linnet K, Johansen SS, Fisher PM, Jensen RH, Knudsen GM. (2022). \textit{Psilocybin-induced reduction in chronic cluster headache attack frequency correlates with changes in hypothalamic functional connectivity}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2022.07.10.22277414}{doi:10.1101/2022.07.10.22277414}.
\item Rajkumar RP. (2022). \textit{Pharmacotherapy for the Secondary Prevention of Suicide: Leads from the Social Pain Hypothesis}. Preprints.org. [preprint; Europe PMC]. \href{https://doi.org/10.20944/preprints202207.0064.v1}{doi:10.20944/preprints202207.0064.v1}.
\item Bosch OG, Halm S, Seifritz E. (2022). \textit{Psychedelics in the treatment of unipolar and bipolar depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s40345-022-00265-5}{doi:10.1186/s40345-022-00265-5}.
\item da Costa SC, Oesterle T, Rummans TA, Richelson E, Gold M. (2022). \textit{Psychedelic drugs for psychiatric disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2022.120332}{doi:10.1016/j.jns.2022.120332}.
\item Farley M, Tran H, Towler S, Gevorkyan J, Pearring S, Rodda LN. (2022). \textit{A Single Method for 127 Recommended and Additional DUID Drugs in Blood and Urine by LC-MS-MS.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1093/jat/bkab075}{doi:10.1093/jat/bkab075}.
\item Wake Network, Inc. (2022). \textit{Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04989972}{source link}.
\item Inouye A, Wolfgang A. (2022). \textit{3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Therapy in Hawaii: A Brief Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.26402}{doi:10.7759/cureus.26402}.
\item Schindler EAD. (2022). \textit{Psychedelics as preventive treatment in headache and chronic pain disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2022.109166}{doi:10.1016/j.neuropharm.2022.109166}.
\item Annie M. McCartney, H. T. McGovern, Alexander De Foe (2022). \textit{Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2022.00211}{doi:10.1556/2054.2022.00211}.
\item M Rekatsina, E Moka, A Vadalouca, G Varrassi (2022). \textit{SP56 Psychedelic drugs and pain}. Unknown journal. [published; OpenAlex]. \href{https://doi.org/10.1136/rapm-2022-esra.62}{doi:10.1136/rapm-2022-esra.62}.
\item Manish Agrawal, Paul Thambi, Sarah Shnayder (2022). \textit{The safety and efficacy of psilocybin therapy in patients with cancer and major depressive disorder.}. Journal of Clinical Oncology. [published; OpenAlex]. \href{https://doi.org/10.1200/jco.2022.40.16\_suppl.12097}{doi:10.1200/jco.2022.40.16\_suppl.12097}.
\item Malcolm B, Thomas K (2022). \textit{Serotonin toxicity of serotonergic psychedelics.}. Psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1007/s00213-021-05876-x}{doi:10.1007/s00213-021-05876-x}.
\item Husain MI, Umer M, Mulsant BH (2022). \textit{Can the revival of serotonergic psychedelic drugs as treatments for mental disorders help to characterize their risks and benefits?}. Expert opinion on drug safety. [published; PubMed]. \href{https://doi.org/10.1080/14740338.2022.2063274}{doi:10.1080/14740338.2022.2063274}.
\item Jairaj C, Rucker JJ. (2022). \textit{Postpartum depression: A role for psychedelics?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811221093793}{doi:10.1177/02698811221093793}.
\item Henner RL, Keshavan MS, Hill KP. (2022). \textit{Review of potential psychedelic treatments for PTSD.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2022.120302}{doi:10.1016/j.jns.2022.120302}.
\item Richard Karel (2022). \textit{Psilocybin-Assisted Therapy Found to Improve Depression, Offer Other Benefits}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.06.6.30}{doi:10.1176/appi.pn.2022.06.6.30}.
\item Dominique Strauss, Soumya Ghosh, Zurika Murray, Marieka Gryzenhout (2022). \textit{An Overview on the Taxonomy, Phylogenetics and Ecology of the Psychedelic Genera Psilocybe, Panaeolus, Pluteus and Gymnopilus}. Frontiers in Forests and Global Change. [published; OpenAlex]. \href{https://doi.org/10.3389/ffgc.2022.813998}{doi:10.3389/ffgc.2022.813998}.
\item National Institute of Mental Health, Czech Republic (2022). \textit{Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant Depression}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT05383313}{source link}.
\item Mocanu V, Mackay L, Christie D, Argento E. (2022). \textit{Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.}. Substance Abuse Treatment Prevention and Policy. [published; Europe PMC]. \href{https://doi.org/10.1186/s13011-022-00468-0}{doi:10.1186/s13011-022-00468-0}.
\item Stéphanie Knatz Peck, Samatha Shao, Susan Murray, Walter H. Kaye (2022). \textit{P450. Pilot Study Evaluation of Psilocybin Therapy for Anorexia Nervosa: Safety, Acceptability, and Preliminary Efficacy}. Biological Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.biopsych.2022.02.686}{doi:10.1016/j.biopsych.2022.02.686}.
\item Rossi GN, Hallak JEC, Bouso Saiz JC, Dos Santos RG. (2022). \textit{Safety issues of psilocybin and LSD as potential rapid acting antidepressants and potential challenges.}. Expert Opinion on Drug Safety. [published; Europe PMC]. \href{https://doi.org/10.1080/14740338.2022.2066650}{doi:10.1080/14740338.2022.2066650}.
\item Gill H, Puramat P, Patel P, Gill B, Marks CA, Rodrigues NB, Castle D, Cha DS, Mansur RB, Rosenblat JD, McIntyre RS. (2022). \textit{The Effects of Psilocybin in Adults with Major Depressive Disorder and the General Population: Findings from Neuroimaging Studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2022.114577}{doi:10.1016/j.psychres.2022.114577}.
\item Rudzki S. (2022). \textit{Is PTSD an Evolutionary Survival Adaptation Initiated by Unrestrained Cytokine Signaling and Maintained by Epigenetic Change?}. Military Medicine. [published; Europe PMC]. \href{https://doi.org/10.1093/milmed/usac095}{doi:10.1093/milmed/usac095}.
\item Cátia Esteves, Elena M. M. de Redrojo, José Luis Manjón, Gabriel Moreno, Filipe E. Antunes, Gemma Montalvo, Fernando E. Ortega-Ojeda (2022). \textit{Combining FTIR-ATR and OPLS-DA methods for magic mushrooms discrimination}. Forensic Chemistry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.forc.2022.100421}{doi:10.1016/j.forc.2022.100421}.
\item Kopra EI, Ferris JA, Winstock AR, Young AH, Rucker JJ. (2022). \textit{Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811221084063}{doi:10.1177/02698811221084063}.
\item Hackl B, Todt H, Kubista H, Kubista H, Hilber K, Koenig X. (2022). \textit{Psilocybin Therapy of Psychiatric Disorders Is Not Hampered by hERG Potassium Channel-Mediated Cardiotoxicity.}. The International Journal of Neuropsychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1093/ijnp/pyab085}{doi:10.1093/ijnp/pyab085}.
\item Michael Avissar, Adrian Jacques H. Ambrose (2022). \textit{Demystifying Psychedelic Treatments in Psychiatry: Is Ego Dissolution the Solution?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2022.04.4.35}{doi:10.1176/appi.pn.2022.04.4.35}.
\item Davis AK, Arterberry BJ, Xin Y, Agin-Liebes G, Schwarting C, Williams MT. (2022). \textit{Race, Ethnic, and Sex Differences in Prevalence of and Trends in Hallucinogen Consumption Among Lifetime Users in the United States Between 2015 and 2019.}. Frontiers in Epidemiology. [published; Europe PMC]. \href{https://doi.org/10.3389/fepid.2022.876706}{doi:10.3389/fepid.2022.876706}.
\item Adams AM, Anas NA, Sen AK, Hinegardner-Hendricks JD, O'Dell PJ, Gibbons WJ, Flower JE, McMurray MS, Jones JA. (2022). \textit{Development of an E. coli-based norbaeocystin production platform and evaluation of behavioral effects in rats.}. Metabolic Engineering Communications. [published; Europe PMC]. \href{https://doi.org/10.1016/j.mec.2022.e00196}{doi:10.1016/j.mec.2022.e00196}.
\item Kisely S, Connor M, Somogyi AA, Siskind D. (2022). \textit{A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/00048674221083868}{doi:10.1177/00048674221083868}.
\item Meade E, Hehir S, Rowan N, Garvey M. (2022). \textit{Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/jof8030290}{doi:10.3390/jof8030290}.
\item Bates N, Bello JK, Osazuwa-Peters N, Sullivan MD, Scherrer JF. (2022). \textit{Depression and Long-Term Prescription Opioid Use and Opioid Use Disorder: Implications for Pain Management in Cancer.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11864-022-00954-4}{doi:10.1007/s11864-022-00954-4}.
\item Mertens LJ, Koslowski M, Betzler F, Evens R, Gilles M, Jungaberle A, Jungaberle H, Majić T, Ströhle A, Wolff M, Wellek S, Gründer G. (2022). \textit{Methodological challenges in psychedelic drug trials: Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - Rationale and study design.}. Neuroscience Applied. [published; Europe PMC]. \href{https://doi.org/10.1016/j.nsa.2022.100104}{doi:10.1016/j.nsa.2022.100104}.
\item van Amsterdam J, van den Brink W. (2022). \textit{The therapeutic potential of psilocybin: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14740338.2022.2047929}{doi:10.1080/14740338.2022.2047929}.
\item Jaster AM, Elder H, Marsh SA, de la Fuente Revenga M, Negus SS, González-Maeso J. (2022). \textit{Effects of the 5-HT2A receptor antagonist volinanserin on head-twitch response and intracranial self-stimulation depression induced by different structural classes of psychedelics in rodents.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-022-06092-x}{doi:10.1007/s00213-022-06092-x}.
\item Schlag AK, Aday J, Salam I, Neill JC, Nutt DJ (2022). \textit{Adverse effects of psychedelics: From anecdotes and misinformation to systematic science.}. Journal of psychopharmacology (Oxford, England). [published; PubMed]. \href{https://doi.org/10.1177/02698811211069100}{doi:10.1177/02698811211069100}.
\item Hodge AT, Sukpraprut-Braaten S, Narlesky M, Strayhan RC. (2022). \textit{The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2022.2044096}{doi:10.1080/02791072.2022.2044096}.
\item Yu CL, Liang CS, Yang FC, Tu YK, Hsu CW, Carvalho AF, Stubbs B, Thompson T, Tsai CK, Yeh TC, Yang SN, Shin JI, Chu CS, Tseng PT, Su KP. (2022). \textit{Trajectory of Antidepressant Effects after Single- or Two-Dose Administration of Psilocybin: A Systematic Review and Multivariate Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/jcm11040938}{doi:10.3390/jcm11040938}.
\item Van Court RC, Wiseman MS, Meyer KW, Ballhorn DJ, Amses KR, Slot JC, Dentinger BTM, Garibay-Orijel R, Uehling JK. (2022). \textit{Diversity, biology, and history of psilocybin-containing fungi: Suggestions for research and technological development.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.funbio.2022.01.003}{doi:10.1016/j.funbio.2022.01.003}.
\item Maia LO, Beaussant Y, Garcia ACM. (2022). \textit{The Therapeutic Potential of Psychedelic-assisted Therapies for Symptom Control in Patients Diagnosed With Serious Illness: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jpainsymman.2022.01.024}{doi:10.1016/j.jpainsymman.2022.01.024}.
\item Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR. (2022). \textit{Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.7759/cureus.21944}{doi:10.7759/cureus.21944}.
\item Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. (2022). \textit{Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211073759}{doi:10.1177/02698811211073759}.
\item Markopoulos A, Inserra A, De Gregorio D, Gobbi G. (2022). \textit{Evaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2021.749068}{doi:10.3389/fphar.2021.749068}.
\item Bender D, Hellerstein DJ. (2022). \textit{Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-021-06049-6}{doi:10.1007/s00213-021-06049-6}.
\item Jones GM, Nock MK. (2022). \textit{MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211058923}{doi:10.1177/02698811211058923}.
\item Rucker JJ, Marwood L, Ajantaival RJ, Bird C, Eriksson H, Harrison J, Lennard-Jones M, Mistry S, Saldarini F, Stansfield S, Tai SJ, Williams S, Weston N, Malievskaia E, Young AH. (2022). \textit{The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration and preparation.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211064720}{doi:10.1177/02698811211064720}.
\item Josh Nagra (2021). \textit{Psychedelic Agents as Potential Therapeutics for Obsessive Compulsive Disorder}. DOAJ (DOAJ: Directory of Open Access Journals). [published; OpenAlex]. \href{https://doaj.org/article/7ce75968f7bc41c58d82163435d80b03}{source link}.
\item G.M. Goodwin, Scott T. Aaronson, Boadie W. Dunlop, David Feifel, David J. Hellerstein, N. Hewitt, L. Marwood, S. Mistry, Metten Somers, S.C. Stansfield, J. Tsai, S. Williams, Antony Young, Sidney Zisook, E. Malievskaia (2021). \textit{The safety and efficacy of COMP360 psilocybin therapy in treatment-resistant depression: results from a phase IIb randomised controlled trial}. Neuroscience Applied. [published; OpenAlex]. \href{https://doi.org/10.1016/j.nsa.2022.100511}{doi:10.1016/j.nsa.2022.100511}.
\item F. N. Smith, Joanna C. Neill, Verity Wainwright (2021). \textit{An Interpretative Phenomenological Analysis of the use of psilocybin by veterans with symptoms of trauma}. Drug Science Policy and Law. [published; OpenAlex]. \href{https://doi.org/10.1177/20503245221124117}{doi:10.1177/20503245221124117}.
\item Khaleel Rajwani (2021). \textit{Should Adolescents be Included in Emerging Psychedelic Research?}. Canadian Journal of Bioethics. [published; OpenAlex]. \href{https://doi.org/10.7202/1089784ar}{doi:10.7202/1089784ar}.
\item Schindler EAD. (2021). \textit{Psychedelics in the Treatment of Headache and Chronic Pain Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2022\_365}{doi:10.1007/7854\_2022\_365}.
\item Johnson MW. (2021). \textit{Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2022\_327}{doi:10.1007/7854\_2022\_327}.
\item Khan AJ, Bradley E, O'Donovan A, Woolley J. (2021). \textit{Psilocybin for Trauma-Related Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2022\_366}{doi:10.1007/7854\_2022\_366}.
\item Raison CL, Jain R, Penn AD, Cole SP, Jain S (2021). \textit{Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2022.831092}{doi:10.3389/fpsyt.2022.831092}.
\item Yaden DB, Earp D, Graziosi M, Friedman-Wheeler D, Luoma JB, Johnson MW (2021). \textit{Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.}. Frontiers in psychology. [published; PubMed]. \href{https://doi.org/10.3389/fpsyg.2022.873279}{doi:10.3389/fpsyg.2022.873279}.
\item Davis AK, Agin-Liebes G, España M, Pilecki B, Luoma J (2021). \textit{Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2021.1971343}{doi:10.1080/02791072.2021.1971343}.
\item Victor Chiruta, Paulina K Zemla, Pixie Miller, Nicola Santarossa, John A Hannan (2021). \textit{Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020}. Journal of Medical and Health Studies. [published; OpenAlex]. \href{https://doi.org/10.32996/jmhs.2021.2.2.18}{doi:10.32996/jmhs.2021.2.2.18}.
\item Niles H, Fogg C, Kelmendi B, Lazenby M (2021). \textit{Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.}. BMC palliative care. [published; PubMed]. \href{https://doi.org/10.1186/s12904-021-00889-x}{doi:10.1186/s12904-021-00889-x}.
\item Elman I, Pustilnik A, Borsook D. (2021). \textit{Beating pain with psychedelics: Matter over mind?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2021.12.005}{doi:10.1016/j.neubiorev.2021.12.005}.
\item Pearson C, Siegel J, Gold JA. (2021). \textit{Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2021.120096}{doi:10.1016/j.jns.2021.120096}.
\item Lea J. Mertens, Michael Koslowski, Felix Betzler, Ricarda Evens, Maria Gilles, Andrea Jungaberle, Henrik Jungaberle, Tomislav Majić, Max Wolff, Andreas Ströhle, Stefan Wellek, Gerhard Gründer (2021). \textit{P.0421 Efficacy and safety of psilocybin in treatment-resistant major depression (EPIsoDE) - study design, rationale and current status}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2021.10.394}{doi:10.1016/j.euroneuro.2021.10.394}.
\item A. Andreiev, E. Bucuci, James Chue, Charl Els, Pierre Chue (2021). \textit{P.0623 The clinical relevance of the pharmacokinetics of psilocybin}. European Neuropsychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1016/j.euroneuro.2021.10.588}{doi:10.1016/j.euroneuro.2021.10.588}.
\item Linda M. Richmond (2021). \textit{Marijuana, Hallucinogen Use Reach Historic Levels Among Young Adults}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.11.29}{doi:10.1176/appi.pn.2021.11.29}.
\item David J. Hellerstein, Kevin A. Sabet, Jeffrey A. Lieberman (2021). \textit{Psychedelic Drugs for Mental Disorders and Human Potential: Placebo or Panacea}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.12.14}{doi:10.1176/appi.pn.2021.12.14}.
\item Weleff J, Akiki TJ, Barnett BS. (2021). \textit{Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2021.11.22.21266718}{doi:10.1101/2021.11.22.21266718}.
\item Strumila R, Nobile B, Korsakova L, Lengvenyte A, Olie E, Lopez-Castroman J, Guillaume S, Courtet P. (2021). \textit{Psilocybin, a Naturally Occurring Indoleamine Compound, Could Be Useful to Prevent Suicidal Behaviors.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph14121213}{doi:10.3390/ph14121213}.
\item Schimmers N, Breeksema JJ, Smith-Apeldoorn SY, Veraart J, van den Brink W, Schoevers RA. (2021). \textit{Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-021-06027-y}{doi:10.1007/s00213-021-06027-y}.
\item Maryland Oncology Hematology, PA (2021). \textit{The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04593563}{source link}.
\item Yu CL, Yang FC, Yang SN, Tseng PT, Stubbs B, Yeh TC, Hsu CW, Li DJ, Liang CS. (2021). \textit{Psilocybin for End-of-Life Anxiety Symptoms: A Systematic Review and Meta-Analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.30773/pi.2021.0209}{doi:10.30773/pi.2021.0209}.
\item Barnett BS, Parker SE, Weleff J. (2021). \textit{United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2021.103473}{doi:10.1016/j.drugpo.2021.103473}.
\item Gonda X, Dome P, Neill JC, Tarazi FI. (2021). \textit{Novel antidepressant drugs: Beyond monoamine targets.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s1092852921000791}{doi:10.1017/s1092852921000791}.
\item Zeiss R, Gahr M, Graf H. (2021). \textit{Rediscovering Psilocybin as an Antidepressive Treatment Strategy.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/ph14100985}{doi:10.3390/ph14100985}.
\item Kverno KS, Mangano E. (2021). \textit{Treatment-Resistant Depression: Approaches to Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3928/02793695-20210816-01}{doi:10.3928/02793695-20210816-01}.
\item Figueiredo I, Viegas F, Ferreira F, Santos A, Ramos J, Miranda J. (2021). \textit{Therapeutic interventions for PTSD - current evidence on the the role of psychedelics}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9475922}{source link}.
\item Miranda J, Barbosa M, Figueiredo I, Mota P, Tarelho A. (2021). \textit{Treating addiction with psychedelics - are we waking up?}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC9480123}{source link}.
\item Wayne Hall, Michael Farrell (2021). \textit{What can we learn from the history of research on psychedelic drugs in the addictions?}. Addiction. [published; OpenAlex]. \href{https://doi.org/10.1111/add.15560}{doi:10.1111/add.15560}.
\item Lukačovič M, Masaryk R. (2021). \textit{Use of hallucinogens in Slovakia: Does it differ from global trends?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2021.103385}{doi:10.1016/j.drugpo.2021.103385}.
\item Nayak SM, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. (2021). \textit{Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.}. Pharmacopsychiatry. [published; Europe PMC]. \href{https://doi.org/10.1055/a-1524-2794}{doi:10.1055/a-1524-2794}.
\item van Dongen RM, Alderliefste GJ, Onderwater GLJ, Ferrari MD, Terwindt GM (2021). \textit{Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without.}. European journal of neurology. [published; PubMed]. \href{https://doi.org/10.1111/ene.14914}{doi:10.1111/ene.14914}.
\item Psiuk D, Nowak E, Cholewa K, Łopuszańska U, Samardakiewicz M. (2021). \textit{The Potential Role of Serotonergic Hallucinogens in Depression Treatment.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/life11080765}{doi:10.3390/life11080765}.
\item Tim Hirschfeld, Laura Smit-Rigter, Daan van der Gouwe, Simon Reiche, Heino Stöver, Tomislav Majić (2021). \textit{Safer Tripping: Serotonergic Psychedelics and Drug Checking. Submission and Detection Rates, Potential Harms, and Challenges for Drug Analysis}. Current Addiction Reports. [published; OpenAlex]. \href{https://doi.org/10.1007/s40429-021-00385-5}{doi:10.1007/s40429-021-00385-5}.
\item Nick Zagorski (2021). \textit{Psychedelic Therapy Hits Another Milestone, But Caution Urged}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.7.14}{doi:10.1176/appi.pn.2021.7.14}.
\item King's College London (2021). \textit{A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT04959253}{source link}.
\item Mayer CE, LeBaron VT, Acquaviva KD. (2021). \textit{Exploring the Use of Psilocybin Therapy for Existential Distress: A Qualitative Study of Palliative Care Provider Perceptions.}. Journal of Psychoactive Drugs. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2021.1916659}{doi:10.1080/02791072.2021.1916659}.
\item McCartney A, McGovern H, De Foe A. (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/9kuhs}{doi:10.31234/osf.io/9kuhs}.
\item Unknown authors (2021). \textit{Psychedelic Assisted Therapy for Major Depressive Disorder: A Review}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/9kuhs\_v1}{source link}.
\item Sarah-Catherine Rodan, Phillip Aouad, Iain S. McGregor, Sarah Maguire (2021). \textit{Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa}. OBM Neurobiology. [published; OpenAlex]. \href{https://doi.org/10.21926/obm.neurobiol.2102102}{doi:10.21926/obm.neurobiol.2102102}.
\item Corrigan A, Burchill E, Pelton L, Marrocu A, Mazzoleni A, Shackshaft L. (2021). \textit{Psilocybin: the magic medicine for depression?}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/PMC/PMC8770735}{source link}.
\item Gabrielle Agin-Liebes, Eve Ekman, B. Anderson, Maxx Malloy, Alexandra Haas, Josh Woolley (2021). \textit{Participant Reports of Mindfulness, Posttraumatic Growth, and Social Connectedness in Psilocybin-Assisted Group Therapy: An Interpretive Phenomenological Analysis}. Journal of Humanistic Psychology. [published; OpenAlex]. \href{https://doi.org/10.1177/00221678211022949}{doi:10.1177/00221678211022949}.
\item Fradkin D. (2021). \textit{Psilocybin: A brief overview for psychiatric mental health nurse practitioners.}. Perspectives In Psychiatric Care. [published; Europe PMC]. \href{https://doi.org/10.1111/ppc.12888}{doi:10.1111/ppc.12888}.
\item Fogg C, Michaels TI, de la Salle S, Jahn ZW, Williams MT. (2021). \textit{Ethnoracial health disparities and the ethnopsychopharmacology of psychedelic-assisted psychotherapies.}. Experimental and Clinical Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1037/pha0000490}{doi:10.1037/pha0000490}.
\item Amber Elyse Corrigan, Ella Burchill, Lucy Pelton, Alessia Marrocu, Adele Mazzoleni, Lydia Shackshaft (2021). \textit{Psilocybin: the magic medicine for depression?}. BJPsych Open. [published; OpenAlex]. \href{https://doi.org/10.1192/bjo.2021.456}{doi:10.1192/bjo.2021.456}.
\item Chao YS, Horton J. (2021). \textit{Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders}. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON). [published; Europe PMC]. \href{https://europepmc.org/article/MED/36170470}{source link}.
\item Teixeira PJ, Johnson MW, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris RL. (2021). \textit{Psychedelics and health behaviour change.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/02698811211008554}{doi:10.1177/02698811211008554}.
\item Wayne Hall (2021). \textit{The need for publicly funded research on therapeutic use of psychedelic drugs}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20847}{doi:10.1002/wps.20847}.
\item Gründer G, Jungaberle H. (2021). \textit{The Potential Role of Psychedelic Drugs in Mental Health Care of the Future.}. Pharmacopsychiatry. [published; Europe PMC]. \href{https://doi.org/10.1055/a-1486-7386}{doi:10.1055/a-1486-7386}.
\item Despina Stratidakis (2021). \textit{Addressing the Implicit Impacts of Sexual Trauma: An Exploration of Somatic Experiencing as an Adjunct to Psilocybin-Assisted Therapy}. National University System Repository (National University System). [published; OpenAlex]. \href{http://hdl.handle.net/20.500.11803/1295}{source link}.
\item Rocha JM, Rossi GN, de Lima Osório F, Bouso JC, de Oliveira Silveira G, Yonamine M, Campos AC, Bertozi G, Cecílio Hallak JE, Dos Santos RG. (2021). \textit{Effects of Ayahuasca on the Recognition of Facial Expressions of Emotions in Naive Healthy Volunteers: A Pilot, Proof-of-Concept, Randomized Controlled Trial.}. Journal of Clinical Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1097/jcp.0000000000001396}{doi:10.1097/jcp.0000000000001396}.
\item Rucker JJ, Young AH. (2021). \textit{Psilocybin: From Serendipity to Credibility?}. Frontiers in Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2021.659044}{doi:10.3389/fpsyt.2021.659044}.
\item Gard DE, Pleet MM, Bradley ER, Penn A, Gallenstein ML, Riley LS, DellaCrosse M, Garfinkle E, Michalak EE, Woolley JD. (2021). \textit{Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2021.04.02.21254838}{doi:10.1101/2021.04.02.21254838}.
\item Stanley N. Caroff (2021). \textit{The Return of Psychedelics: Still Time to Prevent Tragedy}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.4.8}{doi:10.1176/appi.pn.2021.4.8}.
\item Teixeira PJ, Johnson M, Timmermann C, Watts R, Erritzoe D, Douglass H, Kettner H, Carhart-Harris R. (2021). \textit{Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/8vks6}{doi:10.31234/osf.io/8vks6}.
\item Unknown authors (2021). \textit{Psychedelics and Health Behavior Change - Journal of Psychopharmacology (in press)}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/8vks6\_v1}{source link}.
\item Perkins D, Sarris J, Rossell S, Bonomo Y, Forbes D, Davey C, Hoyer D, Loo C, Murray G, Hood S, Schubert V, Galvão-Coelho NL, O'Donnell M, Carter O, Liknaitzky P, Williams M, Siskind D, Penington D, Berk M, Castle D. (2021). \textit{Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm.}. Australian \& New Zealand Journal of Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1177/0004867421998785}{doi:10.1177/0004867421998785}.
\item Dos Santos RG, Hallak JE, Baker G, Dursun S. (2021). \textit{Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881120986422}{doi:10.1177/0269881120986422}.
\item Ross S, Agin-Liebes G, Lo S, Zeifman RJ, Ghazal L, Benville J, Franco Corso S, Bjerre Real C, Guss J, Bossis A, Mennenga SE. (2021). \textit{Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.}. ACS Pharmacology \& Translational Science. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.1c00020}{doi:10.1021/acsptsci.1c00020}.
\item Zeifman RJ, Singhal N, Breslow L, Weissman CR. (2021). \textit{On the Relationship between Classic Psychedelics and Suicidality: A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acsptsci.1c00024}{doi:10.1021/acsptsci.1c00024}.
\item Nick Zagorski (2021). \textit{Session on Psychedelics Sure to Be Enlightening}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2021.3.14}{doi:10.1176/appi.pn.2021.3.14}.
\item Nayak S, Gukasyan N, Barrett FS, Erowid E, Erowid F, Griffiths RR. (2021). \textit{Classic psychedelic coadministration with lithium, but not lamotrigine, is associated with seizures: an analysis of online psychedelic experience reports}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/r726d}{doi:10.31234/osf.io/r726d}.
\item Tai SJ, Nielson EM, Lennard-Jones M, Johanna Ajantaival RL, Winzer R, Richards WA, Reinholdt F, Richards BD, Gasser P, Malievskaia E. (2021). \textit{Development and Evaluation of a Therapist Training Program for Psilocybin Therapy for Treatment-Resistant Depression in Clinical Research.}. Frontiers in Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2021.586682}{doi:10.3389/fpsyt.2021.586682}.
\item Bates MLS, Trujillo KA. (2021). \textit{Use and abuse of dissociative and psychedelic drugs in adolescence.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pbb.2021.173129}{doi:10.1016/j.pbb.2021.173129}.
\item Barnett BS, Greer GR. (2021). \textit{Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jaclp.2020.12.011}{doi:10.1016/j.jaclp.2020.12.011}.
\item Mertens LJ, Preller KH. (2021). \textit{Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/a-1341-1907}{doi:10.1055/a-1341-1907}.
\item Ravital LaBua (2020). \textit{The Effect of Psilocybin on Personality}. CUNY Academic Works (City University of New York). [published; OpenAlex]. \href{https://academicworks.cuny.edu/gc\_etds/4460}{source link}.
\item Yogesh Kumar Chahar (2020). \textit{Unmet need in depression: Psilocybin, a breakthrough treatment option}. International Journal of Advanced Research in Medicine. [published; OpenAlex]. \href{https://doi.org/10.22271/27069567.2021.v3.i1f.159}{doi:10.22271/27069567.2021.v3.i1f.159}.
\item Inserra A, De Gregorio D, Gobbi G. (2020). \textit{Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1124/pharmrev.120.000056}{doi:10.1124/pharmrev.120.000056}.
\item Bouso JC, Ona G, Dos Santos RG, Hallak JEC. (2020). \textit{Psychedelic Medicines in Major Depression: Progress and Future Challenges.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/978-981-33-6044-0\_26}{doi:10.1007/978-981-33-6044-0\_26}.
\item Williams ML, Korevaar D, Harvey R, Fitzgerald PB, Liknaitzky P, O'Carroll S, Puspanathan P, Ross M, Strauss N, Bennett-Levy J (2020). \textit{Translating Psychedelic Therapies From Clinical Trials to Community Clinics: Building Bridges and Addressing Potential Challenges Ahead.}. Frontiers in psychiatry. [published; PubMed]. \href{https://doi.org/10.3389/fpsyt.2021.737738}{doi:10.3389/fpsyt.2021.737738}.
\item Sanah Malomile Nkadimeng, Christiaan M.L. Steinmann, J.N. Eloff (2020). \textit{Effects and safety of Psilocybe cubensis and Panaeolus cyanescens magic mushroom extracts on endothelin-1-induced hypertrophy and cell injury in cardiomyocytes}. Scientific Reports. [published; OpenAlex]. \href{https://doi.org/10.1038/s41598-020-79328-5}{doi:10.1038/s41598-020-79328-5}.
\item Christopher S. Stauffer, B. Anderson, Kile Ortigo, Joshua Woolley (2020). \textit{Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience}. ACS Pharmacology \& Translational Science. [published; OpenAlex]. \href{https://doi.org/10.1021/acsptsci.0c00169}{doi:10.1021/acsptsci.0c00169}.
\item University Hospital, Basel, Switzerland (2020). \textit{Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy Subjects}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT03912974}{source link}.
\item Holoyda B (2020). \textit{Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.}. Psychiatric services (Washington, D.C.). [published; PubMed]. \href{https://doi.org/10.1176/appi.ps.202000213}{doi:10.1176/appi.ps.202000213}.
\item Andersen KAA, Carhart-Harris R, Nutt DJ, Erritzoe D. (2020). \textit{Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1111/acps.13249}{doi:10.1111/acps.13249}.
\item Courtney C. Walton, Paul Liknaitzky (2020). \textit{Advancing elite athlete mental health treatment with psychedelic-assisted psychotherapy}. Journal of Applied Sport Psychology. [published; OpenAlex]. \href{https://doi.org/10.1080/10413200.2020.1848941}{doi:10.1080/10413200.2020.1848941}.
\item Goldberg SB, Shechet B, Nicholas CR, Ng CW, Deole G, Chen Z, Raison CL. (2020). \textit{Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1017/s003329172000389x}{doi:10.1017/s003329172000389x}.
\item NYU Langone Health (2020). \textit{Effects of Psilocybin on Anxiety and Psychosocial Distress in Cancer Patients}. ClinicalTrials.gov. [clinical trial; ClinicalTrials.gov]. \href{https://clinicaltrials.gov/study/NCT00957359}{source link}.
\item Ona G, Bouso JC. (2020). \textit{Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neubiorev.2020.09.035}{doi:10.1016/j.neubiorev.2020.09.035}.
\item Peter S. Hendricks (2020). \textit{Psilocybin-assisted group therapy: A new hope for demoralization}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2020.100557}{doi:10.1016/j.eclinm.2020.100557}.
\item Gill H, Gill B, Chen-Li D, El-Halabi S, Rodrigues NB, Cha DS, Lipsitz O, Lee Y, Rosenblat JD, Majeed A, Mansur RB, Nasri F, Ho R, McIntyre RS. (2020). \textit{The emerging role of psilocybin and MDMA in the treatment of mental illness.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14737175.2020.1826931}{doi:10.1080/14737175.2020.1826931}.
\item Nicole Harrington Cirino (2020). \textit{Wait for the Science Before Widespread Use of Psilocybin}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.10a32}{doi:10.1176/appi.pn.2020.10a32}.
\item B. Anderson, Alicia Danforth, Prof Robert Daroff, Christopher S. Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, James Dilley, Jennifer Mitchell, Joshua Woolley (2020). \textit{Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study}. EClinicalMedicine. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eclinm.2020.100538}{doi:10.1016/j.eclinm.2020.100538}.
\item Vargas AS, Luís Â, Barroso M, Gallardo E, Pereira L. (2020). \textit{Psilocybin as a New Approach to Treat Depression and Anxiety in the Context of Life-Threatening Diseases-A Systematic Review and Meta-Analysis of Clinical Trials.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3390/biomedicines8090331}{doi:10.3390/biomedicines8090331}.
\item Greif A, Šurkala M. (2020). \textit{Compassionate use of psychedelics.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s11019-020-09958-z}{doi:10.1007/s11019-020-09958-z}.
\item John R. Kelly, Matthew Crockett, Laith Alexander, Martin Haran, Amanda Baker, Lisa M. Burke, Christine Brennan, Veronica O’Keane (2020). \textit{Psychedelic science in post-COVID-19 psychiatry}. Irish Journal of Psychological Medicine. [published; OpenAlex]. \href{https://doi.org/10.1017/ipm.2020.94}{doi:10.1017/ipm.2020.94}.
\item Edward Jacobs (2020). \textit{A potential role for psilocybin in the treatment of obsessive-compulsive disorder}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2020.00128}{doi:10.1556/2054.2020.00128}.
\item Nick Zagorski (2020). \textit{Journal Digest: Home Environment; Postpartum Mental Illness; Placebo in Psychedelic Study; Single Gene Mutation; Topiramate}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.6a34}{doi:10.1176/appi.pn.2020.6a34}.
\item William Smith, Dominic Sisti (2020). \textit{Ethics and ego dissolution: the case of psilocybin}. Journal of Medical Ethics. [published; OpenAlex]. \href{https://doi.org/10.1136/medethics-2020-106070}{doi:10.1136/medethics-2020-106070}.
\item Ron Shore (2020). \textit{Psychedelics, Safety and Clinical Trial Design}. QSpace (Queen's University Library). [published; OpenAlex]. \href{http://hdl.handle.net/1974/27835}{source link}.
\item Katie O’Connor (2020). \textit{Can Psychedelics Radically Change SUD Treatment?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2020.2a12}{doi:10.1176/appi.pn.2020.2a12}.
\item Robert B. Kargbo (2020). \textit{Psilocybin Therapeutic Research: The Present and Future Paradigm}. ACS Medicinal Chemistry Letters. [published; OpenAlex]. \href{https://doi.org/10.1021/acsmedchemlett.0c00048}{doi:10.1021/acsmedchemlett.0c00048}.
\item Wendy Kline (2020). \textit{Psychedelic Birth: Bodies, Boundaries and the Perception of Pain in the 1970s}. Gender \& History. [published; OpenAlex]. \href{https://doi.org/10.1111/1468-0424.12471}{doi:10.1111/1468-0424.12471}.
\item Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson, Rotem Petranker, Lê-Anh Dinh-Williams, Katrina Hui, Emma Hapke (2020). \textit{Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities}. Journal of Psychopharmacology. [published; OpenAlex]. \href{https://doi.org/10.1177/0269881120908004}{doi:10.1177/0269881120908004}.
\item Bheatrix Bienemann, Nina Stamato Ruschel, Maria Luiza Pesse Campos, Marco Aurélio Negreiros, Daniel C. Mograbi (2020). \textit{Self-reported negative outcomes of psilocybin users: A quantitative textual analysis}. PLoS ONE. [published; OpenAlex]. \href{https://doi.org/10.1371/journal.pone.0229067}{doi:10.1371/journal.pone.0229067}.
\item James Sexton, Charles D. Nichols, Peter S. Hendricks (2020). \textit{Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics}. Frontiers in Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.3389/fpsyt.2019.00896}{doi:10.3389/fpsyt.2019.00896}.
\item Chi T, Gold JA. (2020). \textit{A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jns.2020.116715}{doi:10.1016/j.jns.2020.116715}.
\item Goldberg SB, Pace BT, Nicholas CR, Raison CL, Hutson PR. (2020). \textit{The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.psychres.2020.112749}{doi:10.1016/j.psychres.2020.112749}.
\item Dax Oliver (2019). \textit{Analysis of Newspaper Coverage of Psilocybin from January 1, 1989 to December 31, 2019}. CUNY Academic Works (City University of New York). [published; OpenAlex]. \href{https://academicworks.cuny.edu/gc\_etds/4074}{source link}.
\item Sofia Gyllvik (2019). \textit{The Therapeutic Potential of Psilocybin and 3,4-Methylenedioxymethamphetamine in the Treatment of Depression and Post-Traumatic Stress Disorder}. Diva portal (Dalarna University Library). [published; OpenAlex]. \href{http://urn.kb.se/resolve?urn=urn:nbn:se:his:diva-18729}{source link}.
\item James Rucker, Jessie Schnall, Daniel D’Hotman, David King, Timmy Davis, Joanna C. Neill (2019). \textit{Medicinal use of psilocybin: Reducing restrictions on research and treatment.}. Unknown journal. [published; OpenAlex]. \href{https://www.drugsandalcohol.ie/32599/}{source link}.
\item Lea T, Amada N, Jungaberle H (2019). \textit{Psychedelic Microdosing: A Subreddit Analysis.}. Journal of psychoactive drugs. [published; PubMed]. \href{https://doi.org/10.1080/02791072.2019.1683260}{doi:10.1080/02791072.2019.1683260}.
\item Shore R, Ioudovski P, Goldie C, McKeown S, Dumont E, Queen’s University, Kingston On. (2019). \textit{Mapping Psilocybin-Assisted Therapies: A Scoping Review}. medRxiv. [preprint; medRxiv]. \href{https://doi.org/10.1101/2019.12.04.19013896}{doi:10.1101/2019.12.04.19013896}.
\item Martin Andersson, Anette Kjellgren (2019). \textit{Twenty percent better with 20 micrograms? A qualitative study of psychedelic microdosing self-rapports and discussions on YouTube}. Harm Reduction Journal. [published; OpenAlex]. \href{https://doi.org/10.1186/s12954-019-0333-3}{doi:10.1186/s12954-019-0333-3}.
\item Poulie CBM, Jensen AA, Halberstadt AL, Kristensen JL. (2019). \textit{DARK Classics in Chemical Neuroscience: NBOMes.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1021/acschemneuro.9b00528}{doi:10.1021/acschemneuro.9b00528}.
\item Nick Zagorski (2019). \textit{Johns Hopkins Opens Research Center on Psychedelics}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.10a16}{doi:10.1176/appi.pn.2019.10a16}.
\item Kelley C. O’Donnell, Sarah E. Mennenga, Michael P. Bogenschutz (2019). \textit{Psilocybin for depression: Considerations for clinical trial design}. Journal of Psychedelic Studies. [published; OpenAlex]. \href{https://doi.org/10.1556/2054.2019.026}{doi:10.1556/2054.2019.026}.
\item Begola MJ, Schillerstrom JE. (2019). \textit{Hallucinogens and Their Therapeutic Use: A Literature Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/pra.0000000000000409}{doi:10.1097/pra.0000000000000409}.
\item Muttoni S, Ardissino M, John C. (2019). \textit{Classical psychedelics for the treatment of depression and anxiety: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.jad.2019.07.076}{doi:10.1016/j.jad.2019.07.076}.
\item Kuypers KP, Ng L, Erritzoe D, Knudsen GM, Nichols CD, Nichols DE, Pani L, Soula A, Nutt D. (2019). \textit{Microdosing psychedelics: More questions than answers? An overview and suggestions for future research.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881119857204}{doi:10.1177/0269881119857204}.
\item Richard Simoneaux (2019). \textit{The Potential of Psilocybin Administration in Terminal Cancer Patients}. Oncology Times. [published; OpenAlex]. \href{https://doi.org/10.1097/01.cot.0000574916.46844.cf}{doi:10.1097/01.cot.0000574916.46844.cf}.
\item Paul Summergrad (2019). \textit{Psychedelic Medicine: Careful Studies, Regulations Are the Answer}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.5a25}{doi:10.1176/appi.pn.2019.5a25}.
\item Richard Doblin, Merete Bruun Christiansen, Lisa Jerome, Brad Burge (2019). \textit{The Past and Future of Psychedelic Science: An Introduction to This Issue}. Journal of Psychoactive Drugs. [published; OpenAlex]. \href{https://doi.org/10.1080/02791072.2019.1606472}{doi:10.1080/02791072.2019.1606472}.
\item Nick Zagorski (2019). \textit{Is Psychedelic Medicine on the Horizon?}. Psychiatric News. [published; OpenAlex]. \href{https://doi.org/10.1176/appi.pn.2019.1b1}{doi:10.1176/appi.pn.2019.1b1}.
\item Anderson T, Petranker R, Rosenbaum D, Weissman CR, Dinh-Williams LA, Hui K, Hapke E, Farb NAS. (2019). \textit{Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-018-5106-2}{doi:10.1007/s00213-018-5106-2}.
\item Anderson T, Petranker R, Rosenbaum D, Weissman C, Dinh-Williams L, Hui K, Hapke E, Farb NAS. (2018). \textit{Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers}. PsyArXiv. [preprint; PsyArXiv]. \href{https://doi.org/10.31234/osf.io/gk4jd}{doi:10.31234/osf.io/gk4jd}.
\item Unknown authors (2018). \textit{Microdosing Psychedelics: Personality, mental health, and creativity differences in microdosers}. PsyArXiv. [preprint; PsyArXiv]. \href{https://osf.io/preprints/psyarxiv/gk4jd\_v1}{source link}.
\item Robin Carhart-Harris (2018). \textit{Serotonin, psychedelics and psychiatry}. World Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1002/wps.20555}{doi:10.1002/wps.20555}.
\item Leonard JB, Anderson B, Klein-Schwartz W. (2018). \textit{Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881118793086}{doi:10.1177/0269881118793086}.
\item Dos Santos RG, Bouso JC, Alcázar-Córcoles MÁ, Hallak JEC. (2018). \textit{Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/17512433.2018.1511424}{doi:10.1080/17512433.2018.1511424}.
\item Garcia-Romeu A, Richards WA (2018). \textit{Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.}. International review of psychiatry (Abingdon, England). [published; PubMed]. \href{https://doi.org/10.1080/09540261.2018.1486289}{doi:10.1080/09540261.2018.1486289}.
\item Schenberg EE. (2018). \textit{Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.}. Frontiers in Pharmacology. [published; Europe PMC]. \href{https://doi.org/10.3389/fphar.2018.00733}{doi:10.3389/fphar.2018.00733}.
\item Johnson MW, Griffiths RR, Hendricks PS, Henningfield JE. (2018). \textit{The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2018.05.012}{doi:10.1016/j.neuropharm.2018.05.012}.
\item Dorsen C, Palamar J, Shedlin MG. (2018). \textit{Ceremonial "plant medicine" use and its relationship to recreational drug use: an exploratory study.}. Addiction Research \& Theory. [published; Europe PMC]. \href{https://doi.org/10.1080/16066359.2018.1455187}{doi:10.1080/16066359.2018.1455187}.
\item Kaelen M, Giribaldi B, Raine J, Evans L, Timmerman C, Rodriguez N, Roseman L, Feilding A, Nutt D, Carhart-Harris R. (2018). \textit{The hidden therapist: evidence for a central role of music in psychedelic therapy.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-017-4820-5}{doi:10.1007/s00213-017-4820-5}.
\item Byock I. (2018). \textit{Taking Psychedelics Seriously.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1089/jpm.2017.0684}{doi:10.1089/jpm.2017.0684}.
\item Phil Wolfson (2017). \textit{Psychedelics, the Spiritual and Consciousness-an Evolving Confluence in the Cultural Stream}. Tikkun. [published; OpenAlex]. \href{https://doi.org/10.1215/08879982-4354390}{doi:10.1215/08879982-4354390}.
\item Bogenschutz MP, Ross S. (2017). \textit{Therapeutic Applications of Classic Hallucinogens.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/7854\_2016\_464}{doi:10.1007/7854\_2016\_464}.
\item Rucker JJH, Iliff J, Nutt DJ. (2017). \textit{Psychiatry \& the psychedelic drugs. Past, present \& future.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.neuropharm.2017.12.040}{doi:10.1016/j.neuropharm.2017.12.040}.
\item Joanna Stefaniuk (2017). \textit{„Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku}. CeON Repository (Centre for Evaluation in Education and Science). [published; OpenAlex]. \href{https://depot.ceon.pl/handle/123456789/13483}{source link}.
\item Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR. (2017). \textit{Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults.}. Clinical Pharmacokinetics. [published; Europe PMC]. \href{https://doi.org/10.1007/s40262-017-0540-6}{doi:10.1007/s40262-017-0540-6}.
\item Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. (2017). \textit{The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3389/fpsyt.2017.00240}{doi:10.3389/fpsyt.2017.00240}.
\item Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, Kaelen M, Giribaldi B, Bloomfield M, Pilling S, Rickard JA, Forbes B, Feilding A, Taylor D, Curran HV, Nutt DJ. (2017). \textit{Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.}. Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-017-4771-x}{doi:10.1007/s00213-017-4771-x}.
\item Kyzar EJ, Nichols CD, Gainetdinov RR, Nichols DE, Kalueff AV. (2017). \textit{Psychedelic Drugs in Biomedicine.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.tips.2017.08.003}{doi:10.1016/j.tips.2017.08.003}.
\item Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. (2017). \textit{Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2017.09.012}{doi:10.1016/j.pnpbp.2017.09.012}.
\item Andersson M, Persson M, Kjellgren A. (2017). \textit{Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches.}. Harm Reduction Journal. [published; Europe PMC]. \href{https://doi.org/10.1186/s12954-017-0186-6}{doi:10.1186/s12954-017-0186-6}.
\item Sellers EM, Leiderman DB. (2017). \textit{Psychedelic Drugs as Therapeutics: No Illusions About the Challenges.}. Clinical Pharmacology \& Therapeutics. [published; Europe PMC]. \href{https://doi.org/10.1002/cpt.776}{doi:10.1002/cpt.776}.
\item Sessa B. (2017). \textit{The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s00213-017-4713-7}{doi:10.1007/s00213-017-4713-7}.
\item Larsen JK. (2017). \textit{LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark.}. Nordic Journal of Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1080/08039488.2017.1336251}{doi:10.1080/08039488.2017.1336251}.
\item Johnson MW, Griffiths RR. (2017). \textit{Potential Therapeutic Effects of Psilocybin.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1007/s13311-017-0542-y}{doi:10.1007/s13311-017-0542-y}.
\item Majić T, Jungaberle H, Jungaberle H, Schmidt TT, Zeuch A, Hermle L, Gallinat J. (2017). \textit{[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1055/s-0043-103085}{doi:10.1055/s-0043-103085}.
\item Thomas K, Malcolm B, Lastra D. (2017). \textit{Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2017.1320734}{doi:10.1080/02791072.2017.1320734}.
\item Albert Garcia-Romeu (2016). \textit{Psychedelics as change agents in addiction and mood disorders.}. Unknown journal. [published; OpenAlex]. \href{https://www.drugsandalcohol.ie/29118/}{source link}.
\item Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR. (2016). \textit{The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881116678781}{doi:10.1177/0269881116678781}.
\item Rucker JJ, Jelen LA, Flynn S, Frowde KD, Young AH. (2016). \textit{Psychedelics in the treatment of unipolar mood disorders: a systematic review.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881116679368}{doi:10.1177/0269881116679368}.
\item Jeanne G, Purper-Ouakil D, Rigole H, Franc N. (2016). \textit{[New patterns of substance use and abuse among French adolescents, a knowledge synthesis].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.encep.2016.05.012}{doi:10.1016/j.encep.2016.05.012}.
\item Carbonaro TM, Bradstreet MP, Barrett FS, MacLean KA, Jesse R, Johnson MW, Griffiths RR. (2016). \textit{Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881116662634}{doi:10.1177/0269881116662634}.
\item Patra S. (2016). \textit{Return of the psychedelics: Psilocybin for treatment resistant depression.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.ajp.2016.08.010}{doi:10.1016/j.ajp.2016.08.010}.
\item de Veen BT, Schellekens AF, Verheij MM, Homberg JR. (2016). \textit{Psilocybin for treating substance use disorders?}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1080/14737175.2016.1220834}{doi:10.1080/14737175.2016.1220834}.
\item Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. (2016). \textit{Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.}. The Lancet Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1016/s2215-0366(16)30065-7}{doi:10.1016/s2215-0366(16)30065-7}.
\item Laura Orsolini, Alessandro Valchera, Duccio Papanti, R. Vecchiotti, Domenico De Berardis (2016). \textit{The “Endless Trip”: Psychopathology and psychopharmacology in the Hallucinogen Persisting Perception Disorder (HPPD)}. European Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1016/j.eurpsy.2016.01.1060}{doi:10.1016/j.eurpsy.2016.01.1060}.
\item Di Lorenzo C, Coppola G, Di Lorenzo G, Bracaglia M, Rossi P, Pierelli F. (2015). \textit{The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey.}. Cephalalgia. [published; Europe PMC]. \href{https://doi.org/10.1177/0333102415583145}{doi:10.1177/0333102415583145}.
\item Baumeister D, Tojo LM, Tracy DK. (2015). \textit{Legal highs: staying on top of the flood of novel psychoactive substances.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1177/2045125314559539}{doi:10.1177/2045125314559539}.
\item Bogenschutz MP, Johnson MW. (2015). \textit{Classic hallucinogens in the treatment of addictions.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pnpbp.2015.03.002}{doi:10.1016/j.pnpbp.2015.03.002}.
\item Johansen PØ, Krebs TS. (2015). \textit{Psychedelics not linked to mental health problems or suicidal behavior: a population study.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881114568039}{doi:10.1177/0269881114568039}.
\item Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. (2015). \textit{Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881114565144}{doi:10.1177/0269881114565144}.
\item Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. (2014). \textit{Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881114548296}{doi:10.1177/0269881114548296}.
\item Baumeister D, Barnes G, Giaroli G, Tracy D (2014). \textit{Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles.}. Therapeutic advances in psychopharmacology. [published; PubMed]. \href{https://doi.org/10.1177/2045125314527985}{doi:10.1177/2045125314527985}.
\item Robert L. Jesse, Roland R. Griffi (2013). \textit{PSILOCYBIN RESEARCH AT JOHNS HOPKINS: A2014 REPORT}. Unknown journal. [published; OpenAlex]. \href{http://csp.org/HopkinsPsilocybin2014.pdf}{source link}.
\item Charlesice Hawkins (2013). \textit{Literature review: Considerations for Psychedelic Research}. UC Merced Undergraduate Research Journal. [published; OpenAlex]. \href{https://doi.org/10.5070/m451020759}{doi:10.5070/m451020759}.
\item Burdick BV, Adinoff B. (2013). \textit{A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment.}. The American Journal of Drug and Alcohol Abuse. [published; Europe PMC]. \href{https://doi.org/10.3109/00952990.2013.811513}{doi:10.3109/00952990.2013.811513}.
\item Krebs TS, Johansen PØ. (2013). \textit{Psychedelics and mental health: a population study.}. PLoS ONE. [published; Europe PMC]. \href{https://doi.org/10.1371/journal.pone.0063972}{doi:10.1371/journal.pone.0063972}.
\item Robin Carhart-Harris (2013). \textit{PSYCHEDELIC DRUGS, MAGICAL THINKING AND PSYCHOSIS}. Journal of Neurology Neurosurgery \& Psychiatry. [published; OpenAlex]. \href{https://doi.org/10.1136/jnnp-2013-306103.17}{doi:10.1136/jnnp-2013-306103.17}.
\item Stebelska K. (2013). \textit{Fungal hallucinogens psilocin, ibotenic acid, and muscimol: analytical methods and biologic activities.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/ftd.0b013e31828741a5}{doi:10.1097/ftd.0b013e31828741a5}.
\item Kjellgren A, Jonsson K. (2013). \textit{Methoxetamine (MXE)--a phenomenological study of experiences induced by a "legal high" from the internet.}. Journal of Psychoactive Drugs. [published; Europe PMC]. \href{https://doi.org/10.1080/02791072.2013.803647}{doi:10.1080/02791072.2013.803647}.
\item Helander A, Beck O, Hägerkvist R, Hultén P. (2013). \textit{Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3109/00365513.2013.793817}{doi:10.3109/00365513.2013.793817}.
\item Tennison MN. (2012). \textit{Moral transhumanism: the next step.}. The Journal of Medicine and Philosophy A Forum for Bioethics and Philosophy of Medicine. [published; Europe PMC]. \href{https://doi.org/10.1093/jmp/jhs024}{doi:10.1093/jmp/jhs024}.
\item Olthuis JV, Darredeau C, Barrett SP. (2012). \textit{Substance use initiation: the role of simultaneous polysubstance use.}. Drug and Alcohol Review. [published; Europe PMC]. \href{https://doi.org/10.1111/j.1465-3362.2012.00470.x}{doi:10.1111/j.1465-3362.2012.00470.x}.
\item van Amsterdam J, Opperhuizen A, van den Brink W (2011). \textit{Harm potential of magic mushroom use: a review.}. Regulatory toxicology and pharmacology: RTP. [published; PubMed]. \href{https://doi.org/10.1016/j.yrtph.2011.01.006}{doi:10.1016/j.yrtph.2011.01.006}.
\item Meyer MR, Maurer HH. (2011). \textit{Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.2217/pgs.10.171}{doi:10.2217/pgs.10.171}.
\item Moreno JL, Kurita M, Holloway T, López J, Cadagan R, Martínez-Sobrido L, García-Sastre A, González-Maeso J. (2011). \textit{Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.}. Journal of Neuroscience. [published; Europe PMC]. \href{https://doi.org/10.1523/jneurosci.4230-10.2011}{doi:10.1523/jneurosci.4230-10.2011}.
\item Riley S, Thompson J, Griffin C. (2010). \textit{Turn on, tune in, but don't drop out: The impact of neo-liberalism on magic mushroom users' (in)ability to imagine collectivist social worlds.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.drugpo.2010.07.001}{doi:10.1016/j.drugpo.2010.07.001}.
\item Studerus E, Kometer M, Hasler F, Vollenweider FX. (2010). \textit{Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881110382466}{doi:10.1177/0269881110382466}.
\item Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. (2010). \textit{Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.}. Archives of General Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.1001/archgenpsychiatry.2010.116}{doi:10.1001/archgenpsychiatry.2010.116}.
\item Carhart-Harris RL, Williams TM, Sessa B, Tyacke RJ, Rich AS, Feilding A, Nutt DJ. (2010). \textit{The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: a preliminary investigation of tolerability.}. Journal of Psychopharmacology. [published; Europe PMC]. \href{https://doi.org/10.1177/0269881110367445}{doi:10.1177/0269881110367445}.
\item Matthias Karst, John H. Halpern, Michael Bernateck, Torsten Passie (2010). \textit{The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: An open, non-randomized case series}. Cephalalgia. [published; OpenAlex]. \href{https://doi.org/10.1177/0333102410363490}{doi:10.1177/0333102410363490}.
\item J.C. Ballenger (2007). \textit{Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder}. Yearbook of Psychiatry and Applied Mental Health. [published; OpenAlex]. \href{https://doi.org/10.1016/s0084-3970(08)70820-x}{doi:10.1016/s0084-3970(08)70820-x}.
\item Andy Letcher (2007). \textit{Mad Thoughts on Mushrooms: Discourse and Power in the Study of Psychedelic Consciousness}. Anthropology of Consciousness. [published; OpenAlex]. \href{https://doi.org/10.1525/ac.2007.18.2.74}{doi:10.1525/ac.2007.18.2.74}.
\item Frecska E, Luna LE. (2006). \textit{The adverse effects of hallucinogens from intramural perspective.}. PubMed. [published; Europe PMC]. \href{https://europepmc.org/article/MED/17211054}{source link}.
\item Moreno FA, Wiegand CB, Taitano EK, Delgado PL. (2006). \textit{Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder.}. The Journal of Clinical Psychiatry. [published; Europe PMC]. \href{https://doi.org/10.4088/jcp.v67n1110}{doi:10.4088/jcp.v67n1110}.
\item Halpern JH. (2004). \textit{Hallucinogens and dissociative agents naturally growing in the United States.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1016/j.pharmthera.2004.03.003}{doi:10.1016/j.pharmthera.2004.03.003}.
\item Vollenweider FX, Vollenweider-Scherpenhuyzen MF. (2003). \textit{[Hallucinogens, amphetamines and entactogens].}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1024/0040-5930.60.6.323}{doi:10.1024/0040-5930.60.6.323}.
\item Krzysztof Borowiak, Anna Machoy-Mokrzyńska, Leszek Domański, Sławomir Majdanik, Edward Dutkiewicz, K Safranow, Tomasz Janus, V Mikolajek (2002). \textit{Electrocardiographic examination of heart function in rats exposed to hallucinogens from Psilocybe mushrooms}. Acta Toxicologica. [published; OpenAlex]. \href{http://yadda.icm.edu.pl/yadda/element/bwmeta1.element.agro-article-d607ea49-70b5-4739-b280-7088af5d6e30}{source link}.
\item Moeller MR, Kraemer T. (2002). \textit{Drugs of abuse monitoring in blood for control of driving under the influence of drugs.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1097/00007691-200204000-00003}{doi:10.1097/00007691-200204000-00003}.
\item Riley SC, James C, Gregory D, Dingle H, Cadger M. (2001). \textit{Patterns of recreational drug use at dance events in Edinburgh, Scotland.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.1046/j.1360-0443.2001.967103513.x}{doi:10.1046/j.1360-0443.2001.967103513.x}.
\item Ho E, Karimi-Tabesh L, Koren G (2000). \textit{Characteristics of pregnant women who use ecstasy (3, 4-methylenedioxymethamphetamine).}. Neurotoxicology and teratology. [published; PubMed]. \href{https://doi.org/10.1016/s0892-0362(01)00178-7}{doi:10.1016/s0892-0362(01)00178-7}.
\item Adlaf EM, Paglia A, Ivis FJ, Ialomiteanu A. (2000). \textit{Nonmedical drug use among adolescent students: highlights from the 1999 Ontario Student Drug Use Survey.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/10870495}{source link}.
\item Adlaf EM, Ivis FJ. (1998). \textit{Recent findings from the Ontario Student Drug Use Survey.}. Unknown journal. [published; Europe PMC]. \href{https://europepmc.org/article/MED/9757168}{source link}.
\item Borowiak KS, Ciechanowski K, Waloszczyk P. (1997). \textit{Psilocybin mushroom (Psilocybe semilanceata) intoxication with myocardial infarction.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3109/15563659809162584}{doi:10.3109/15563659809162584}.
\item Gable RS. (1992). \textit{Toward a comparative overview of dependence potential and acute toxicity of psychoactive substances used nonmedically.}. Unknown journal. [published; Europe PMC]. \href{https://doi.org/10.3109/00952999309001618}{doi:10.3109/00952999309001618}.
\end{enumerate}
\end{document}
